Mitch Report
Antony Kaspi & Mark Ziemann
date generated: 2026-05-06
Background
Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch
Input profiles
Here is the first few lines of the input profile.
| x | |
|---|---|
| 5_8S_rRNA | -1.6789077 |
| A1BG | 0.4773455 |
| A1BG-AS1 | -0.3881907 |
| A1CF | 0.3059609 |
| A2M | -0.6340972 |
| A2M-AS1 | 1.0223691 |
Here are some metrics about the input data profile:
| Profile metrics | |
|---|---|
| num_genesets | 2725 |
| num_genes_in_profile | 21253 |
| duplicated_genes_present | 0 |
| num_profile_genes_in_sets | 8700 |
| num_profile_genes_not_in_sets | 12553 |
Here is a plot of the input profiles. Note the dynamic ranges.
Here is the contour plot of the profile including all detected genes.
Input genesets
Here are some metrics about the gene sets used:
GMT file of genesets:| Gene sets metrics | |
|---|---|
| num_genesets | 2725 |
| num_genesets_excluded | 1198 |
| num_genesets_included | 1527 |
Differential pathway expression
Interactive enrichment scatterplot
Significance is calculated by -log10(p-value). All points shown are
FDR<0.05.
Significance is calculated by -log10(p-value). Top N sets shown
irrespective of FDR.
Results table
Top N= 50 gene sets| set | setSize | pANOVA | s.dist | p.adjustANOVA |
|---|---|---|---|---|
| Activation of caspases through apoptosome-mediated cleavage | 6 | 9.26e-04 | -0.781 | 0.007500 |
| Neurotransmitter clearance | 6 | 1.96e-03 | 0.730 | 0.013600 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | 7 | 1.17e-03 | -0.708 | 0.008910 |
| Fructose metabolism | 7 | 1.27e-03 | 0.703 | 0.009620 |
| Establishment of Sister Chromatid Cohesion | 11 | 7.48e-05 | -0.690 | 0.000921 |
| Regulation of IFNA/IFNB signaling | 12 | 4.63e-05 | -0.679 | 0.000630 |
| ARMS-mediated activation | 6 | 4.15e-03 | -0.676 | 0.025600 |
| G2/M DNA replication checkpoint | 5 | 8.99e-03 | -0.675 | 0.047900 |
| Fructose catabolism | 5 | 9.65e-03 | 0.668 | 0.050400 |
| Interleukin-21 signaling | 9 | 6.45e-04 | -0.657 | 0.005510 |
| Response to metal ions | 6 | 5.35e-03 | -0.657 | 0.032000 |
| Protein repair | 6 | 6.10e-03 | -0.646 | 0.035200 |
| SMAC (DIABLO) binds to IAPs | 7 | 3.31e-03 | -0.641 | 0.021300 |
| SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes | 7 | 3.31e-03 | -0.641 | 0.021300 |
| SMAC, XIAP-regulated apoptotic response | 7 | 3.31e-03 | -0.641 | 0.021300 |
| Butyrophilin (BTN) family interactions | 10 | 6.21e-04 | 0.625 | 0.005350 |
| NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake | 5 | 1.57e-02 | 0.624 | 0.072600 |
| Maturation of protein 3a 9683673 | 9 | 1.46e-03 | -0.612 | 0.010800 |
| Maturation of protein 3a 9694719 | 9 | 1.46e-03 | -0.612 | 0.010800 |
| Wax and plasmalogen biosynthesis | 5 | 1.79e-02 | -0.611 | 0.080500 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | 6 | 9.64e-03 | -0.610 | 0.050400 |
| ROBO receptors bind AKAP5 | 7 | 6.19e-03 | -0.597 | 0.035500 |
| Interleukin-6 signaling | 10 | 1.08e-03 | -0.597 | 0.008450 |
| Regulation of TP53 Activity through Association with Co-factors | 11 | 6.61e-04 | 0.593 | 0.005620 |
| Type I hemidesmosome assembly | 8 | 4.92e-03 | -0.574 | 0.029600 |
| RUNX3 regulates CDKN1A transcription | 7 | 9.30e-03 | 0.568 | 0.049100 |
| Condensation of Prometaphase Chromosomes | 11 | 1.16e-03 | -0.566 | 0.008880 |
| Mitotic Telophase/Cytokinesis | 13 | 4.21e-04 | -0.565 | 0.003780 |
| Diseases of Mismatch Repair (MMR) | 5 | 3.19e-02 | -0.554 | 0.123000 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | 9 | 4.03e-03 | -0.554 | 0.025200 |
| Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus | 5 | 3.45e-02 | -0.546 | 0.130000 |
| OAS antiviral response | 8 | 8.02e-03 | -0.541 | 0.043900 |
| Metabolism of ingested SeMet, Sec, MeSec into H2Se | 7 | 1.33e-02 | 0.540 | 0.063900 |
| Cohesin Loading onto Chromatin | 10 | 3.59e-03 | -0.532 | 0.022800 |
| Negative regulation of TCF-dependent signaling by WNT ligand antagonists | 6 | 2.50e-02 | -0.528 | 0.102000 |
| Platelet sensitization by LDL | 16 | 2.59e-04 | -0.527 | 0.002500 |
| Ca2+ activated K+ channels | 6 | 2.67e-02 | 0.522 | 0.108000 |
| Cytosolic iron-sulfur cluster assembly | 13 | 1.31e-03 | 0.515 | 0.009860 |
| Cobalamin (Cbl) metabolism | 7 | 1.91e-02 | -0.511 | 0.083400 |
| Regulation of NPAS4 gene expression | 11 | 4.31e-03 | -0.497 | 0.026500 |
| Regulation of RUNX1 Expression and Activity | 18 | 2.79e-04 | -0.495 | 0.002680 |
| Regulation of IFNG signaling | 14 | 1.41e-03 | -0.493 | 0.010500 |
| Transcriptional regulation of testis differentiation | 5 | 5.65e-02 | 0.492 | 0.188000 |
| NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose | 5 | 5.68e-02 | 0.492 | 0.189000 |
| Interleukin-20 family signaling | 17 | 4.75e-04 | -0.489 | 0.004220 |
| Signaling by PDGFRA extracellular domain mutants | 12 | 3.41e-03 | -0.488 | 0.021800 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | 12 | 3.41e-03 | -0.488 | 0.021800 |
| MASTL Facilitates Mitotic Progression | 10 | 7.86e-03 | -0.485 | 0.043500 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | 10 | 7.98e-03 | -0.484 | 0.043800 |
| RUNX1 regulates transcription of genes involved in differentiation of keratinocytes | 7 | 2.68e-02 | -0.483 | 0.108000 |
Results (complete table)
Click HERE to show results for all gene sets
| set | setSize | pANOVA | s.dist | p.adjustANOVA |
|---|---|---|---|---|
| Activation of caspases through apoptosome-mediated cleavage | 6 | 9.26e-04 | -7.81e-01 | 7.50e-03 |
| Neurotransmitter clearance | 6 | 1.96e-03 | 7.30e-01 | 1.36e-02 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | 7 | 1.17e-03 | -7.08e-01 | 8.91e-03 |
| Fructose metabolism | 7 | 1.27e-03 | 7.03e-01 | 9.62e-03 |
| Establishment of Sister Chromatid Cohesion | 11 | 7.48e-05 | -6.90e-01 | 9.21e-04 |
| Regulation of IFNA/IFNB signaling | 12 | 4.63e-05 | -6.79e-01 | 6.30e-04 |
| ARMS-mediated activation | 6 | 4.15e-03 | -6.76e-01 | 2.56e-02 |
| G2/M DNA replication checkpoint | 5 | 8.99e-03 | -6.75e-01 | 4.79e-02 |
| Fructose catabolism | 5 | 9.65e-03 | 6.68e-01 | 5.04e-02 |
| Interleukin-21 signaling | 9 | 6.45e-04 | -6.57e-01 | 5.51e-03 |
| Response to metal ions | 6 | 5.35e-03 | -6.57e-01 | 3.20e-02 |
| Protein repair | 6 | 6.10e-03 | -6.46e-01 | 3.52e-02 |
| SMAC (DIABLO) binds to IAPs | 7 | 3.31e-03 | -6.41e-01 | 2.13e-02 |
| SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes | 7 | 3.31e-03 | -6.41e-01 | 2.13e-02 |
| SMAC, XIAP-regulated apoptotic response | 7 | 3.31e-03 | -6.41e-01 | 2.13e-02 |
| Butyrophilin (BTN) family interactions | 10 | 6.21e-04 | 6.25e-01 | 5.35e-03 |
| NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake | 5 | 1.57e-02 | 6.24e-01 | 7.26e-02 |
| Maturation of protein 3a 9683673 | 9 | 1.46e-03 | -6.12e-01 | 1.08e-02 |
| Maturation of protein 3a 9694719 | 9 | 1.46e-03 | -6.12e-01 | 1.08e-02 |
| Wax and plasmalogen biosynthesis | 5 | 1.79e-02 | -6.11e-01 | 8.05e-02 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | 6 | 9.64e-03 | -6.10e-01 | 5.04e-02 |
| ROBO receptors bind AKAP5 | 7 | 6.19e-03 | -5.97e-01 | 3.55e-02 |
| Interleukin-6 signaling | 10 | 1.08e-03 | -5.97e-01 | 8.45e-03 |
| Regulation of TP53 Activity through Association with Co-factors | 11 | 6.61e-04 | 5.93e-01 | 5.62e-03 |
| Type I hemidesmosome assembly | 8 | 4.92e-03 | -5.74e-01 | 2.96e-02 |
| RUNX3 regulates CDKN1A transcription | 7 | 9.30e-03 | 5.68e-01 | 4.91e-02 |
| Condensation of Prometaphase Chromosomes | 11 | 1.16e-03 | -5.66e-01 | 8.88e-03 |
| Mitotic Telophase/Cytokinesis | 13 | 4.21e-04 | -5.65e-01 | 3.78e-03 |
| Diseases of Mismatch Repair (MMR) | 5 | 3.19e-02 | -5.54e-01 | 1.23e-01 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | 9 | 4.03e-03 | -5.54e-01 | 2.52e-02 |
| Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus | 5 | 3.45e-02 | -5.46e-01 | 1.30e-01 |
| OAS antiviral response | 8 | 8.02e-03 | -5.41e-01 | 4.39e-02 |
| Metabolism of ingested SeMet, Sec, MeSec into H2Se | 7 | 1.33e-02 | 5.40e-01 | 6.39e-02 |
| Cohesin Loading onto Chromatin | 10 | 3.59e-03 | -5.32e-01 | 2.28e-02 |
| Negative regulation of TCF-dependent signaling by WNT ligand antagonists | 6 | 2.50e-02 | -5.28e-01 | 1.02e-01 |
| Platelet sensitization by LDL | 16 | 2.59e-04 | -5.27e-01 | 2.50e-03 |
| Ca2+ activated K+ channels | 6 | 2.67e-02 | 5.22e-01 | 1.08e-01 |
| Cytosolic iron-sulfur cluster assembly | 13 | 1.31e-03 | 5.15e-01 | 9.86e-03 |
| Cobalamin (Cbl) metabolism | 7 | 1.91e-02 | -5.11e-01 | 8.34e-02 |
| Regulation of NPAS4 gene expression | 11 | 4.31e-03 | -4.97e-01 | 2.65e-02 |
| Regulation of RUNX1 Expression and Activity | 18 | 2.79e-04 | -4.95e-01 | 2.68e-03 |
| Regulation of IFNG signaling | 14 | 1.41e-03 | -4.93e-01 | 1.05e-02 |
| Transcriptional regulation of testis differentiation | 5 | 5.65e-02 | 4.92e-01 | 1.88e-01 |
| NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose | 5 | 5.68e-02 | 4.92e-01 | 1.89e-01 |
| Interleukin-20 family signaling | 17 | 4.75e-04 | -4.89e-01 | 4.22e-03 |
| Signaling by PDGFRA extracellular domain mutants | 12 | 3.41e-03 | -4.88e-01 | 2.18e-02 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | 12 | 3.41e-03 | -4.88e-01 | 2.18e-02 |
| MASTL Facilitates Mitotic Progression | 10 | 7.86e-03 | -4.85e-01 | 4.35e-02 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | 10 | 7.98e-03 | -4.84e-01 | 4.38e-02 |
| RUNX1 regulates transcription of genes involved in differentiation of keratinocytes | 7 | 2.68e-02 | -4.83e-01 | 1.08e-01 |
| Golgi Cisternae Pericentriolar Stack Reorganization | 14 | 1.84e-03 | -4.81e-01 | 1.30e-02 |
| Formyl peptide receptors bind formyl peptides and many other ligands | 7 | 2.76e-02 | -4.81e-01 | 1.10e-01 |
| Interleukin-9 signaling | 8 | 2.17e-02 | -4.69e-01 | 9.16e-02 |
| Scavenging by Class F Receptors | 5 | 7.11e-02 | -4.66e-01 | 2.16e-01 |
| FCGR activation | 76 | 2.15e-12 | -4.66e-01 | 1.65e-10 |
| CREB phosphorylation | 7 | 3.31e-02 | -4.65e-01 | 1.26e-01 |
| Regulation of CDH19 Expression and Function | 5 | 7.41e-02 | 4.61e-01 | 2.20e-01 |
| Toxicity of botulinum toxin type D (botD) | 5 | 7.46e-02 | 4.60e-01 | 2.20e-01 |
| Toxicity of botulinum toxin type F (botF) | 5 | 7.46e-02 | 4.60e-01 | 2.20e-01 |
| N-Glycan antennae elongation | 12 | 5.84e-03 | -4.60e-01 | 3.41e-02 |
| Crosslinking of collagen fibrils | 12 | 5.86e-03 | 4.59e-01 | 3.41e-02 |
| CD22 mediated BCR regulation | 58 | 1.53e-09 | -4.58e-01 | 6.25e-08 |
| MET activates PI3K/AKT signaling | 5 | 7.61e-02 | -4.58e-01 | 2.24e-01 |
| Common Pathway of Fibrin Clot Formation | 13 | 4.45e-03 | -4.56e-01 | 2.70e-02 |
| Signaling by PDGFR in disease | 19 | 5.86e-04 | -4.56e-01 | 5.12e-03 |
| G0 and Early G1 | 27 | 4.39e-05 | -4.54e-01 | 6.07e-04 |
| RUNX3 regulates BCL2L11 (BIM) transcription | 5 | 7.88e-02 | 4.54e-01 | 2.29e-01 |
| Phosphorylation of Emi1 | 6 | 5.46e-02 | -4.53e-01 | 1.84e-01 |
| Removal of aminoterminal propeptides from gamma-carboxylated proteins | 6 | 5.47e-02 | -4.53e-01 | 1.84e-01 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | 16 | 1.73e-03 | -4.52e-01 | 1.23e-02 |
| SUMO is proteolytically processed | 6 | 5.56e-02 | -4.51e-01 | 1.86e-01 |
| GDP-fucose biosynthesis | 6 | 5.56e-02 | 4.51e-01 | 1.86e-01 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 13 | 5.01e-03 | -4.49e-01 | 3.01e-02 |
| Role of LAT2/NTAL/LAB on calcium mobilization | 77 | 1.22e-11 | -4.47e-01 | 7.31e-10 |
| Thyroxine biosynthesis | 5 | 8.51e-02 | 4.45e-01 | 2.40e-01 |
| AKT phosphorylates targets in the nucleus | 9 | 2.10e-02 | 4.44e-01 | 8.98e-02 |
| Reelin signalling pathway | 5 | 8.65e-02 | -4.43e-01 | 2.40e-01 |
| NADE modulates death signalling | 5 | 8.80e-02 | -4.41e-01 | 2.40e-01 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | 7 | 4.46e-02 | 4.38e-01 | 1.59e-01 |
| Formation of the active cofactor, UDP-glucuronate | 5 | 8.99e-02 | -4.38e-01 | 2.43e-01 |
| Interferon alpha/beta signaling | 63 | 1.87e-09 | -4.38e-01 | 7.19e-08 |
| G1/S-Specific Transcription | 29 | 4.54e-05 | -4.37e-01 | 6.23e-04 |
| ALK mutants bind TKIs | 11 | 1.25e-02 | -4.35e-01 | 6.11e-02 |
| Tandem pore domain potassium channels | 5 | 9.40e-02 | -4.33e-01 | 2.50e-01 |
| Scavenging of heme from plasma | 70 | 5.23e-10 | -4.29e-01 | 2.39e-08 |
| Transcription of E2F targets under negative control by DREAM complex | 19 | 1.24e-03 | -4.28e-01 | 9.44e-03 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | 83 | 2.26e-11 | -4.24e-01 | 1.24e-09 |
| FCGR3A-mediated phagocytosis | 121 | 7.66e-16 | -4.24e-01 | 1.34e-13 |
| Leishmania phagocytosis | 121 | 7.66e-16 | -4.24e-01 | 1.34e-13 |
| Parasite infection | 121 | 7.66e-16 | -4.24e-01 | 1.34e-13 |
| FCERI mediated Ca+2 mobilization | 92 | 2.58e-12 | -4.22e-01 | 1.90e-10 |
| Regulation of PTEN mRNA translation | 12 | 1.16e-02 | -4.21e-01 | 5.76e-02 |
| Post-transcriptional silencing by small RNAs | 7 | 5.44e-02 | -4.20e-01 | 1.84e-01 |
| RHO GTPases Activate NADPH Oxidases | 21 | 9.06e-04 | -4.18e-01 | 7.38e-03 |
| Polo-like kinase mediated events | 16 | 3.79e-03 | -4.18e-01 | 2.39e-02 |
| Signaling by MAPK mutants | 6 | 7.89e-02 | 4.14e-01 | 2.29e-01 |
| Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) | 9 | 3.18e-02 | -4.13e-01 | 1.23e-01 |
| E2F-enabled inhibition of pre-replication complex formation | 9 | 3.19e-02 | -4.13e-01 | 1.23e-01 |
| CS/DS degradation | 9 | 3.24e-02 | 4.12e-01 | 1.25e-01 |
| Maturation of hRSV A proteins | 13 | 1.02e-02 | -4.12e-01 | 5.23e-02 |
| SUMO is conjugated to E1 (UBA2:SAE1) | 5 | 1.13e-01 | -4.10e-01 | 2.83e-01 |
| Regulation of PTEN localization | 9 | 3.34e-02 | -4.09e-01 | 1.28e-01 |
| RHO GTPases Activate WASPs and WAVEs | 35 | 2.79e-05 | -4.09e-01 | 4.22e-04 |
| Acetylcholine binding and downstream events | 5 | 1.14e-01 | -4.09e-01 | 2.83e-01 |
| Postsynaptic nicotinic acetylcholine receptors | 5 | 1.14e-01 | -4.09e-01 | 2.83e-01 |
| ChREBP activates metabolic gene expression | 7 | 6.33e-02 | -4.05e-01 | 2.03e-01 |
| TP53 Regulates Transcription of Death Receptors and Ligands | 11 | 1.99e-02 | 4.05e-01 | 8.57e-02 |
| Phenylalanine metabolism | 5 | 1.17e-01 | 4.05e-01 | 2.87e-01 |
| Regulation of actin dynamics for phagocytic cup formation | 123 | 9.83e-15 | -4.04e-01 | 1.26e-12 |
| G2 Phase | 5 | 1.19e-01 | -4.03e-01 | 2.91e-01 |
| FCGR3A-mediated IL10 synthesis | 99 | 4.71e-12 | -4.02e-01 | 3.35e-10 |
| Regulation of CDH11 mRNA translation by microRNAs | 8 | 4.94e-02 | -4.01e-01 | 1.71e-01 |
| Regulation of NPAS4 mRNA translation | 8 | 4.94e-02 | -4.01e-01 | 1.71e-01 |
| Regulation of ornithine decarboxylase (ODC) | 38 | 2.10e-05 | -3.99e-01 | 3.38e-04 |
| Signaling by CSF1 (M-CSF) in myeloid cells | 30 | 1.60e-04 | -3.98e-01 | 1.69e-03 |
| Defective CFTR causes cystic fibrosis | 47 | 2.45e-06 | -3.97e-01 | 5.67e-05 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | 5 | 1.27e-01 | 3.94e-01 | 3.04e-01 |
| Caspase activation via Dependence Receptors in the absence of ligand | 9 | 4.10e-02 | -3.93e-01 | 1.48e-01 |
| Synthesis of diphthamide-EEF2 | 8 | 5.41e-02 | 3.93e-01 | 1.84e-01 |
| Hh mutants are degraded by ERAD | 42 | 1.10e-05 | -3.92e-01 | 2.09e-04 |
| Signaling by LTK in cancer | 7 | 7.30e-02 | -3.91e-01 | 2.18e-01 |
| Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | 39 | 2.49e-05 | -3.90e-01 | 3.85e-04 |
| p53-Independent DNA Damage Response | 39 | 2.49e-05 | -3.90e-01 | 3.85e-04 |
| p53-Independent G1/S DNA damage checkpoint | 39 | 2.49e-05 | -3.90e-01 | 3.85e-04 |
| EPHB-mediated forward signaling | 38 | 3.37e-05 | -3.89e-01 | 4.79e-04 |
| MAPK1 (ERK2) activation | 8 | 5.70e-02 | -3.89e-01 | 1.89e-01 |
| Class C/3 (Metabotropic glutamate/pheromone receptors) | 11 | 2.58e-02 | 3.88e-01 | 1.05e-01 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | 16 | 7.24e-03 | -3.88e-01 | 4.05e-02 |
| Formation of the nephric duct | 8 | 5.76e-02 | -3.88e-01 | 1.90e-01 |
| Triglyceride catabolism | 15 | 9.49e-03 | -3.87e-01 | 4.98e-02 |
| Classical antibody-mediated complement activation | 69 | 3.70e-08 | -3.83e-01 | 1.25e-06 |
| Cyclin A/B1/B2 associated events during G2/M transition | 25 | 9.42e-04 | -3.82e-01 | 7.57e-03 |
| Cytochrome c-mediated apoptotic response | 13 | 1.71e-02 | -3.82e-01 | 7.74e-02 |
| Cross-presentation of soluble exogenous antigens (endosomes) | 35 | 9.59e-05 | -3.81e-01 | 1.10e-03 |
| Interaction between L1 and Ankyrins | 26 | 7.84e-04 | -3.80e-01 | 6.55e-03 |
| Transcriptional regulation of granulopoiesis | 44 | 1.28e-05 | -3.80e-01 | 2.40e-04 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | 41 | 2.72e-05 | -3.79e-01 | 4.15e-04 |
| FCERI mediated NF-kB activation | 129 | 1.09e-13 | -3.79e-01 | 1.10e-11 |
| Fcgamma receptor (FCGR) dependent phagocytosis | 147 | 2.43e-15 | -3.78e-01 | 3.59e-13 |
| LTC4-CYSLTR mediated IL4 production | 5 | 1.44e-01 | -3.77e-01 | 3.29e-01 |
| MECP2 regulates neuronal receptors and channels | 13 | 1.89e-02 | -3.76e-01 | 8.33e-02 |
| FCERI mediated MAPK activation | 93 | 3.65e-10 | -3.76e-01 | 1.76e-08 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | 37 | 7.59e-05 | -3.76e-01 | 9.29e-04 |
| Vif-mediated degradation of APOBEC3G | 41 | 3.27e-05 | -3.75e-01 | 4.68e-04 |
| COPI-independent Golgi-to-ER retrograde traffic | 45 | 1.36e-05 | -3.75e-01 | 2.48e-04 |
| RUNX2 regulates genes involved in cell migration | 6 | 1.13e-01 | 3.74e-01 | 2.83e-01 |
| Role of phospholipids in phagocytosis | 88 | 1.32e-09 | -3.74e-01 | 5.63e-08 |
| Glucuronidation | 8 | 6.71e-02 | -3.74e-01 | 2.11e-01 |
| Anti-inflammatory response favouring Leishmania parasite infection | 131 | 1.91e-13 | -3.72e-01 | 1.74e-11 |
| Leishmania parasite growth and survival | 131 | 1.91e-13 | -3.72e-01 | 1.74e-11 |
| RUNX1 regulates estrogen receptor mediated transcription | 6 | 1.15e-01 | -3.71e-01 | 2.86e-01 |
| Gastrin-CREB signalling pathway via PKC and MAPK | 14 | 1.64e-02 | -3.70e-01 | 7.50e-02 |
| ADP signalling through P2Y purinoceptor 12 | 18 | 6.57e-03 | -3.70e-01 | 3.72e-02 |
| G beta:gamma signalling through BTK | 15 | 1.34e-02 | -3.69e-01 | 6.40e-02 |
| Initiation of Nuclear Envelope (NE) Reformation | 19 | 5.49e-03 | -3.68e-01 | 3.26e-02 |
| Degradation of GLI2 by the proteasome | 45 | 1.98e-05 | -3.68e-01 | 3.26e-04 |
| GLI3 is processed to GLI3R by the proteasome | 45 | 1.98e-05 | -3.68e-01 | 3.26e-04 |
| Regulation of Apoptosis | 40 | 5.86e-05 | -3.67e-01 | 7.55e-04 |
| Synthesis of 5-eicosatetraenoic acids | 7 | 9.28e-02 | 3.67e-01 | 2.48e-01 |
| Netrin mediated repulsion signals | 5 | 1.56e-01 | -3.66e-01 | 3.46e-01 |
| Prolonged ERK activation events | 13 | 2.27e-02 | -3.65e-01 | 9.59e-02 |
| Negative regulation of NOTCH4 signaling | 44 | 2.93e-05 | -3.64e-01 | 4.35e-04 |
| Hh mutants abrogate ligand secretion | 43 | 3.62e-05 | -3.64e-01 | 5.12e-04 |
| cGMP effects | 12 | 2.92e-02 | 3.64e-01 | 1.15e-01 |
| Hedgehog ligand biogenesis | 47 | 1.71e-05 | -3.62e-01 | 2.93e-04 |
| Maturation of spike protein 9683686 | 5 | 1.61e-01 | 3.62e-01 | 3.54e-01 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | 42 | 5.44e-05 | -3.60e-01 | 7.20e-04 |
| Phase 3 - rapid repolarisation | 7 | 9.99e-02 | -3.59e-01 | 2.60e-01 |
| Apoptotic cleavage of cellular proteins | 35 | 2.37e-04 | -3.59e-01 | 2.33e-03 |
| Signaling by the B Cell Receptor (BCR) | 150 | 3.18e-14 | -3.59e-01 | 3.40e-12 |
| Ethanol oxidation | 6 | 1.29e-01 | 3.58e-01 | 3.07e-01 |
| EGFR Transactivation by Gastrin | 7 | 1.01e-01 | -3.58e-01 | 2.62e-01 |
| Cargo concentration in the ER | 31 | 5.73e-04 | -3.57e-01 | 5.03e-03 |
| Somitogenesis | 41 | 7.98e-05 | -3.56e-01 | 9.46e-04 |
| Presynaptic depolarization and calcium channel opening | 8 | 8.14e-02 | 3.56e-01 | 2.32e-01 |
| DNA methylation | 18 | 8.97e-03 | -3.56e-01 | 4.79e-02 |
| Creation of C4 and C2 activators | 71 | 2.20e-07 | -3.56e-01 | 6.53e-06 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | 52 | 9.39e-06 | -3.55e-01 | 1.86e-04 |
| RHO GTPases activate IQGAPs | 25 | 2.36e-03 | -3.51e-01 | 1.60e-02 |
| Beta oxidation of butanoyl-CoA to acetyl-CoA | 5 | 1.74e-01 | 3.51e-01 | 3.71e-01 |
| tRNA modification in the mitochondrion | 9 | 6.82e-02 | 3.51e-01 | 2.12e-01 |
| Kidney development | 16 | 1.51e-02 | -3.51e-01 | 7.09e-02 |
| Signaling by CSF3 (G-CSF) | 29 | 1.08e-03 | -3.51e-01 | 8.45e-03 |
| DARPP-32 events | 22 | 4.45e-03 | -3.50e-01 | 2.70e-02 |
| Regulation of RAS by GAPs | 55 | 7.05e-06 | -3.50e-01 | 1.44e-04 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | 17 | 1.25e-02 | -3.50e-01 | 6.11e-02 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | 17 | 1.25e-02 | -3.50e-01 | 6.11e-02 |
| Ubiquitin-dependent degradation of Cyclin D | 39 | 1.56e-04 | -3.50e-01 | 1.66e-03 |
| Termination of O-glycan biosynthesis | 15 | 1.90e-02 | -3.50e-01 | 8.34e-02 |
| CDC6 association with the ORC:origin complex | 8 | 8.74e-02 | -3.49e-01 | 2.40e-01 |
| Gain-of-function MRAS complexes activate RAF signaling | 8 | 8.79e-02 | -3.48e-01 | 2.40e-01 |
| SHOC2 M1731 mutant abolishes MRAS complex function | 8 | 8.79e-02 | -3.48e-01 | 2.40e-01 |
| Signaling by MRAS-complex mutants | 8 | 8.79e-02 | -3.48e-01 | 2.40e-01 |
| N-glycan trimming and elongation in the cis-Golgi | 5 | 1.79e-01 | -3.47e-01 | 3.79e-01 |
| Activation of C3 and C5 | 7 | 1.13e-01 | 3.46e-01 | 2.83e-01 |
| p75NTR negatively regulates cell cycle via SC1 | 5 | 1.81e-01 | -3.46e-01 | 3.81e-01 |
| G beta:gamma signalling through CDC42 | 17 | 1.39e-02 | -3.45e-01 | 6.59e-02 |
| Autodegradation of the E3 ubiquitin ligase COP1 | 38 | 2.43e-04 | -3.44e-01 | 2.37e-03 |
| SCF-beta-TrCP mediated degradation of Emi1 | 42 | 1.18e-04 | -3.43e-01 | 1.31e-03 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | 64 | 2.04e-06 | -3.43e-01 | 4.79e-05 |
| N-glycan antennae elongation in the medial/trans-Golgi | 20 | 7.90e-03 | -3.43e-01 | 4.35e-02 |
| Degradation of GLI1 by the proteasome | 46 | 5.67e-05 | -3.43e-01 | 7.42e-04 |
| RUNX1 regulates transcription of genes involved in BCR signaling | 6 | 1.47e-01 | -3.42e-01 | 3.33e-01 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | 6 | 1.48e-01 | 3.41e-01 | 3.36e-01 |
| Nef and signal transduction | 8 | 9.63e-02 | -3.40e-01 | 2.54e-01 |
| Fc epsilon receptor (FCERI) signaling | 179 | 4.57e-15 | -3.39e-01 | 6.27e-13 |
| Orc1 removal from chromatin | 58 | 7.74e-06 | -3.39e-01 | 1.56e-04 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | 63 | 3.22e-06 | -3.39e-01 | 7.10e-05 |
| Negative regulation of MET activity | 18 | 1.28e-02 | -3.39e-01 | 6.18e-02 |
| MAPK6/MAPK4 signaling | 69 | 1.13e-06 | -3.39e-01 | 2.74e-05 |
| Frs2-mediated activation | 11 | 5.18e-02 | -3.39e-01 | 1.78e-01 |
| PDH complex synthesizes acetyl-CoA from PYR | 5 | 1.90e-01 | -3.38e-01 | 3.92e-01 |
| FBXW7 Mutants and NOTCH1 in Cancer | 5 | 1.93e-01 | -3.36e-01 | 3.95e-01 |
| Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling | 5 | 1.93e-01 | -3.36e-01 | 3.95e-01 |
| Vpu mediated degradation of CD4 | 39 | 2.82e-04 | -3.36e-01 | 2.68e-03 |
| Golgi-to-ER retrograde transport | 123 | 1.22e-10 | -3.36e-01 | 6.35e-09 |
| Uptake of dietary cobalamins into enterocytes | 5 | 1.94e-01 | -3.35e-01 | 3.97e-01 |
| Binding and Uptake of Ligands by Scavenger Receptors | 90 | 3.98e-08 | -3.35e-01 | 1.32e-06 |
| MAPK3 (ERK1) activation | 9 | 8.20e-02 | -3.35e-01 | 2.33e-01 |
| Apoptotic execution phase | 46 | 8.65e-05 | -3.34e-01 | 1.01e-03 |
| Nephrin family interactions | 19 | 1.17e-02 | -3.34e-01 | 5.78e-02 |
| Antimicrobial peptides | 33 | 8.99e-04 | -3.34e-01 | 7.35e-03 |
| RHOBTB2 GTPase cycle | 23 | 5.59e-03 | -3.34e-01 | 3.31e-02 |
| PP2A-mediated dephosphorylation of key metabolic factors | 7 | 1.27e-01 | -3.33e-01 | 3.04e-01 |
| RHO GTPases activate CIT | 18 | 1.45e-02 | -3.33e-01 | 6.84e-02 |
| ABC transporter disorders | 59 | 9.81e-06 | -3.33e-01 | 1.92e-04 |
| Killing mechanisms | 9 | 8.47e-02 | 3.32e-01 | 2.39e-01 |
| WNT5:FZD7-mediated leishmania damping | 9 | 8.47e-02 | 3.32e-01 | 2.39e-01 |
| Mucopolysaccharidoses | 11 | 5.74e-02 | 3.31e-01 | 1.90e-01 |
| Insulin processing | 19 | 1.25e-02 | -3.31e-01 | 6.12e-02 |
| Phase 4 - resting membrane potential | 9 | 8.63e-02 | -3.30e-01 | 2.40e-01 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | 48 | 7.78e-05 | -3.30e-01 | 9.34e-04 |
| Regulation of MITF-M-dependent genes involved in apoptosis | 16 | 2.28e-02 | -3.29e-01 | 9.61e-02 |
| Gamma-carboxylation of protein precursors | 6 | 1.64e-01 | -3.28e-01 | 3.57e-01 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | 59 | 1.35e-05 | -3.28e-01 | 2.48e-04 |
| Synthesis of bile acids and bile salts via 24-hydroxycholesterol | 9 | 8.90e-02 | -3.27e-01 | 2.41e-01 |
| Regulation of KIT signaling | 15 | 2.81e-02 | -3.27e-01 | 1.11e-01 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | 32 | 1.36e-03 | -3.27e-01 | 1.02e-02 |
| SCF(Skp2)-mediated degradation of p27/p21 | 50 | 6.38e-05 | -3.27e-01 | 8.12e-04 |
| APC truncation mutants have impaired AXIN binding | 14 | 3.44e-02 | -3.27e-01 | 1.30e-01 |
| AXIN missense mutants destabilize the destruction complex | 14 | 3.44e-02 | -3.27e-01 | 1.30e-01 |
| Signaling by AMER1 mutants | 14 | 3.44e-02 | -3.27e-01 | 1.30e-01 |
| Signaling by APC mutants | 14 | 3.44e-02 | -3.27e-01 | 1.30e-01 |
| Signaling by AXIN mutants | 14 | 3.44e-02 | -3.27e-01 | 1.30e-01 |
| Truncations of AMER1 destabilize the destruction complex | 14 | 3.44e-02 | -3.27e-01 | 1.30e-01 |
| Activated NTRK2 signals through FRS2 and FRS3 | 8 | 1.11e-01 | -3.26e-01 | 2.81e-01 |
| RUNX1 regulates transcription of genes involved in WNT signaling | 5 | 2.08e-01 | -3.25e-01 | 4.10e-01 |
| RHO GTPases activate PAKs | 20 | 1.18e-02 | -3.25e-01 | 5.85e-02 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | 44 | 1.96e-04 | -3.24e-01 | 1.98e-03 |
| RHO GTPases Activate ROCKs | 18 | 1.73e-02 | -3.24e-01 | 7.82e-02 |
| MET activates RAP1 and RAC1 | 10 | 7.61e-02 | -3.24e-01 | 2.24e-01 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | 42 | 2.81e-04 | -3.24e-01 | 2.68e-03 |
| Inactivation of CSF3 (G-CSF) signaling | 24 | 6.09e-03 | -3.23e-01 | 3.52e-02 |
| Mitochondrial unfolded protein response (UPRmt) | 17 | 2.11e-02 | 3.23e-01 | 9.00e-02 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | 69 | 3.51e-06 | -3.23e-01 | 7.57e-05 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | 29 | 2.73e-03 | -3.22e-01 | 1.83e-02 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | 61 | 1.51e-05 | -3.20e-01 | 2.71e-04 |
| Sodium/Proton exchangers | 7 | 1.43e-01 | -3.20e-01 | 3.27e-01 |
| Zygotic genome activation (ZGA) | 5 | 2.16e-01 | 3.19e-01 | 4.21e-01 |
| PECAM1 interactions | 12 | 5.56e-02 | -3.19e-01 | 1.86e-01 |
| Dectin-2 family | 18 | 1.92e-02 | -3.19e-01 | 8.35e-02 |
| Degradation of beta-catenin by the destruction complex | 72 | 2.94e-06 | -3.19e-01 | 6.65e-05 |
| Serine biosynthesis | 8 | 1.19e-01 | -3.18e-01 | 2.91e-01 |
| Signaling by FLT3 fusion proteins | 18 | 1.95e-02 | -3.18e-01 | 8.44e-02 |
| CD28 dependent Vav1 pathway | 12 | 5.69e-02 | -3.17e-01 | 1.89e-01 |
| Activation of RAC1 | 11 | 6.87e-02 | -3.17e-01 | 2.12e-01 |
| Assembly of the ORC complex at the origin of replication | 23 | 8.56e-03 | -3.17e-01 | 4.62e-02 |
| Synthesis of 15-eicosatetraenoic acid derivatives | 6 | 1.80e-01 | 3.16e-01 | 3.80e-01 |
| TICAM1, RIP1-mediated IKK complex recruitment | 19 | 1.70e-02 | -3.16e-01 | 7.73e-02 |
| RHOBTB1 GTPase cycle | 23 | 8.87e-03 | -3.15e-01 | 4.76e-02 |
| Degradation of DVL | 43 | 3.57e-04 | -3.15e-01 | 3.25e-03 |
| Interleukin receptor SHC signaling | 23 | 9.07e-03 | -3.14e-01 | 4.81e-02 |
| RAS signaling downstream of NF1 loss-of-function variants | 7 | 1.50e-01 | -3.14e-01 | 3.40e-01 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | 60 | 2.60e-05 | -3.14e-01 | 3.99e-04 |
| VxPx cargo-targeting to cilium | 19 | 1.80e-02 | -3.13e-01 | 8.08e-02 |
| Degradation of cysteine and homocysteine | 12 | 6.09e-02 | 3.12e-01 | 1.98e-01 |
| RHOBTB GTPase Cycle | 35 | 1.38e-03 | -3.12e-01 | 1.03e-02 |
| Proteasome assembly | 50 | 1.33e-04 | -3.12e-01 | 1.43e-03 |
| RNA Polymerase I Promoter Opening | 17 | 2.60e-02 | -3.12e-01 | 1.05e-01 |
| IRAK4 deficiency (TLR2/4) | 15 | 3.73e-02 | -3.11e-01 | 1.38e-01 |
| Tie2 Signaling | 16 | 3.15e-02 | -3.11e-01 | 1.23e-01 |
| Activated NTRK2 signals through RAS | 6 | 1.88e-01 | -3.11e-01 | 3.90e-01 |
| Activated NTRK3 signals through RAS | 6 | 1.88e-01 | -3.11e-01 | 3.90e-01 |
| Beta-catenin phosphorylation cascade | 17 | 2.72e-02 | -3.09e-01 | 1.09e-01 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | 18 | 2.31e-02 | 3.09e-01 | 9.70e-02 |
| Metabolism of polyamines | 46 | 2.85e-04 | -3.09e-01 | 2.69e-03 |
| P2Y receptors | 10 | 9.08e-02 | -3.09e-01 | 2.45e-01 |
| RHO GTPases activate KTN1 | 11 | 7.73e-02 | -3.08e-01 | 2.27e-01 |
| HS-GAG degradation | 18 | 2.39e-02 | 3.07e-01 | 9.93e-02 |
| Degradation of AXIN | 42 | 5.66e-04 | -3.07e-01 | 4.99e-03 |
| Formation of Fibrin Clot (Clotting Cascade) | 26 | 6.68e-03 | -3.07e-01 | 3.76e-02 |
| Tight junction interactions | 17 | 2.83e-02 | 3.07e-01 | 1.12e-01 |
| Regulation of signaling by CBL | 22 | 1.27e-02 | -3.07e-01 | 6.16e-02 |
| Signaling by cytosolic FGFR1 fusion mutants | 18 | 2.43e-02 | -3.07e-01 | 1.01e-01 |
| Keratan sulfate biosynthesis | 19 | 2.09e-02 | -3.06e-01 | 8.95e-02 |
| RUNX1 regulates expression of components of tight junctions | 5 | 2.37e-01 | -3.06e-01 | 4.45e-01 |
| Formation of apoptosome | 11 | 7.96e-02 | -3.05e-01 | 2.30e-01 |
| Regulation of the apoptosome activity | 11 | 7.96e-02 | -3.05e-01 | 2.30e-01 |
| ATF6 (ATF6-alpha) activates chaperones | 12 | 6.77e-02 | -3.05e-01 | 2.12e-01 |
| Maturation of spike protein 9694548 | 35 | 1.82e-03 | -3.05e-01 | 1.29e-02 |
| Activation of RAS in B cells | 5 | 2.39e-01 | -3.04e-01 | 4.46e-01 |
| E2F mediated regulation of DNA replication | 22 | 1.36e-02 | -3.04e-01 | 6.48e-02 |
| Uptake and function of anthrax toxins | 10 | 9.62e-02 | -3.04e-01 | 2.54e-01 |
| Glycogen synthesis | 11 | 8.20e-02 | -3.03e-01 | 2.33e-01 |
| RHOT1 GTPase cycle | 5 | 2.41e-01 | -3.03e-01 | 4.48e-01 |
| Translation of Replicase and Assembly of the Replication Transcription Complex 9679504 | 12 | 6.96e-02 | -3.02e-01 | 2.13e-01 |
| CHL1 interactions | 8 | 1.39e-01 | -3.02e-01 | 3.22e-01 |
| Reduction of cytosolic Ca++ levels | 9 | 1.17e-01 | -3.02e-01 | 2.87e-01 |
| IkBA variant leads to EDA-ID | 7 | 1.67e-01 | 3.02e-01 | 3.63e-01 |
| Nucleotide-like (purinergic) receptors | 14 | 5.06e-02 | -3.02e-01 | 1.75e-01 |
| Cell surface interactions at the vascular wall | 170 | 1.16e-11 | -3.02e-01 | 7.17e-10 |
| Stabilization of p53 | 43 | 6.27e-04 | -3.01e-01 | 5.38e-03 |
| Replacement of protamines by nucleosomes in the male pronucleus | 12 | 7.13e-02 | -3.01e-01 | 2.16e-01 |
| Pyrimidine catabolism | 9 | 1.19e-01 | -3.00e-01 | 2.91e-01 |
| Pentose phosphate pathway | 13 | 6.17e-02 | -2.99e-01 | 1.99e-01 |
| MyD88 deficiency (TLR2/4) | 14 | 5.30e-02 | -2.99e-01 | 1.81e-01 |
| Transport to the Golgi and subsequent modification | 170 | 1.84e-11 | -2.99e-01 | 1.04e-09 |
| Erythropoietin activates RAS | 13 | 6.28e-02 | -2.98e-01 | 2.01e-01 |
| Interleukin-15 signaling | 14 | 5.38e-02 | -2.98e-01 | 1.84e-01 |
| Cellular response to hypoxia | 59 | 7.85e-05 | -2.97e-01 | 9.36e-04 |
| Mitotic G1 phase and G1/S transition | 138 | 1.82e-09 | -2.96e-01 | 7.12e-08 |
| COPI-mediated anterograde transport | 92 | 9.25e-07 | -2.96e-01 | 2.34e-05 |
| COPI-dependent Golgi-to-ER retrograde traffic | 90 | 1.25e-06 | -2.96e-01 | 3.01e-05 |
| Initial triggering of complement | 79 | 6.00e-06 | -2.95e-01 | 1.25e-04 |
| NF-kB is activated and signals survival | 12 | 7.79e-02 | 2.94e-01 | 2.28e-01 |
| Caspase-mediated cleavage of cytoskeletal proteins | 12 | 7.81e-02 | -2.94e-01 | 2.29e-01 |
| Intrinsic Pathway of Fibrin Clot Formation | 15 | 4.92e-02 | -2.93e-01 | 1.71e-01 |
| Regulation of APC/C activators between G1/S and early anaphase | 68 | 2.93e-05 | -2.93e-01 | 4.35e-04 |
| Evasion by RSV of host interferon responses | 20 | 2.33e-02 | -2.93e-01 | 9.77e-02 |
| Glutathione synthesis and recycling | 10 | 1.09e-01 | -2.93e-01 | 2.78e-01 |
| Negative regulation of activity of TFAP2 (AP-2) family transcription factors | 6 | 2.14e-01 | 2.93e-01 | 4.19e-01 |
| Activation of G protein gated Potassium channels | 18 | 3.16e-02 | -2.93e-01 | 1.23e-01 |
| G protein gated Potassium channels | 18 | 3.16e-02 | -2.93e-01 | 1.23e-01 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | 18 | 3.16e-02 | -2.93e-01 | 1.23e-01 |
| Cellular response to mitochondrial stress | 9 | 1.29e-01 | -2.92e-01 | 3.07e-01 |
| Cyclin E associated events during G1/S transition | 73 | 1.61e-05 | -2.92e-01 | 2.86e-04 |
| Reversible hydration of carbon dioxide | 8 | 1.53e-01 | 2.92e-01 | 3.43e-01 |
| Resolution of Sister Chromatid Cohesion | 115 | 7.18e-08 | -2.91e-01 | 2.34e-06 |
| Anchoring fibril formation | 7 | 1.83e-01 | 2.90e-01 | 3.85e-01 |
| RUNX3 regulates WNT signaling | 8 | 1.55e-01 | -2.90e-01 | 3.45e-01 |
| ER to Golgi Anterograde Transport | 145 | 1.65e-09 | -2.90e-01 | 6.61e-08 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | 8 | 1.56e-01 | -2.90e-01 | 3.45e-01 |
| Formation of the beta-catenin:TCF transactivating complex | 44 | 8.90e-04 | -2.90e-01 | 7.31e-03 |
| Condensation of Prophase Chromosomes | 27 | 9.27e-03 | -2.89e-01 | 4.91e-02 |
| Unwinding of DNA | 12 | 8.27e-02 | -2.89e-01 | 2.35e-01 |
| Nuclear events stimulated by ALK signaling in cancer | 33 | 4.03e-03 | -2.89e-01 | 2.52e-02 |
| Platelet calcium homeostasis | 22 | 1.89e-02 | -2.89e-01 | 8.33e-02 |
| Glucagon signaling in metabolic regulation | 26 | 1.07e-02 | -2.89e-01 | 5.44e-02 |
| Signaling by KIT in disease | 20 | 2.56e-02 | -2.88e-01 | 1.04e-01 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | 20 | 2.56e-02 | -2.88e-01 | 1.04e-01 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | 12 | 8.41e-02 | -2.88e-01 | 2.38e-01 |
| Translation of Structural Proteins 9694635 | 55 | 2.21e-04 | -2.88e-01 | 2.21e-03 |
| CLEC7A (Dectin-1) induces NFAT activation | 11 | 9.84e-02 | -2.88e-01 | 2.58e-01 |
| APC/C-mediated degradation of cell cycle proteins | 75 | 1.65e-05 | -2.88e-01 | 2.89e-04 |
| Regulation of mitotic cell cycle | 75 | 1.65e-05 | -2.88e-01 | 2.89e-04 |
| Signal regulatory protein family interactions | 13 | 7.37e-02 | -2.86e-01 | 2.20e-01 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | 30 | 6.64e-03 | -2.86e-01 | 3.75e-02 |
| Downstream signaling events of B Cell Receptor (BCR) | 68 | 4.71e-05 | -2.85e-01 | 6.37e-04 |
| Calcineurin activates NFAT | 9 | 1.39e-01 | -2.85e-01 | 3.22e-01 |
| Late SARS-CoV-2 Infection Events | 63 | 9.30e-05 | -2.85e-01 | 1.08e-03 |
| Incretin synthesis, secretion, and inactivation | 14 | 6.53e-02 | -2.85e-01 | 2.07e-01 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | 14 | 6.53e-02 | -2.85e-01 | 2.07e-01 |
| NIK–>noncanonical NF-kB signaling | 46 | 8.45e-04 | -2.84e-01 | 6.99e-03 |
| Processing and activation of SUMO | 10 | 1.20e-01 | -2.84e-01 | 2.92e-01 |
| Activation of NF-kappaB in B cells | 54 | 3.16e-04 | -2.83e-01 | 2.95e-03 |
| Downstream signal transduction | 27 | 1.09e-02 | -2.83e-01 | 5.51e-02 |
| Drug-mediated inhibition of CDK4/CDK6 activity | 5 | 2.74e-01 | -2.83e-01 | 4.82e-01 |
| Signalling to ERKs | 32 | 5.64e-03 | -2.83e-01 | 3.32e-02 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | 23 | 1.91e-02 | -2.82e-01 | 8.34e-02 |
| Platelet Adhesion to exposed collagen | 14 | 6.75e-02 | -2.82e-01 | 2.12e-01 |
| G1/S Transition | 120 | 9.72e-08 | -2.82e-01 | 3.06e-06 |
| E3 ubiquitin ligases ubiquitinate target proteins | 51 | 5.00e-04 | -2.82e-01 | 4.43e-03 |
| Synthesis of PE | 12 | 9.13e-02 | 2.82e-01 | 2.45e-01 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | 7 | 1.98e-01 | 2.81e-01 | 3.99e-01 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | 11 | 1.06e-01 | -2.81e-01 | 2.74e-01 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | 62 | 1.30e-04 | -2.81e-01 | 1.41e-03 |
| Acyl chain remodeling of CL | 5 | 2.77e-01 | -2.81e-01 | 4.85e-01 |
| Elevation of cytosolic Ca2+ levels | 13 | 8.04e-02 | -2.80e-01 | 2.30e-01 |
| Gamma-carboxylation, transport, and amino-terminal cleavage of proteins | 7 | 2.00e-01 | -2.80e-01 | 4.01e-01 |
| COPII-mediated vesicle transport | 67 | 7.71e-05 | -2.79e-01 | 9.32e-04 |
| Packaging Of Telomere Ends | 18 | 4.04e-02 | -2.79e-01 | 1.47e-01 |
| Norepinephrine Neurotransmitter Release Cycle | 14 | 7.07e-02 | 2.79e-01 | 2.15e-01 |
| Regulation of HMOX1 expression and activity | 5 | 2.80e-01 | 2.79e-01 | 4.88e-01 |
| ADORA2B mediated anti-inflammatory cytokines production | 35 | 4.31e-03 | -2.79e-01 | 2.65e-02 |
| RHO GTPase Effectors | 257 | 1.42e-14 | -2.79e-01 | 1.71e-12 |
| Unblocking of NMDA receptors, glutamate binding and activation | 12 | 9.57e-02 | 2.78e-01 | 2.53e-01 |
| Regulation of MECP2 expression and activity | 28 | 1.10e-02 | -2.78e-01 | 5.51e-02 |
| Synthesis of PIPs at the early endosome membrane | 16 | 5.46e-02 | -2.78e-01 | 1.84e-01 |
| Apoptotic cleavage of cell adhesion proteins | 8 | 1.74e-01 | -2.77e-01 | 3.72e-01 |
| Constitutive Signaling by Overexpressed ERBB2 | 11 | 1.12e-01 | -2.77e-01 | 2.82e-01 |
| Apoptosis induced DNA fragmentation | 10 | 1.30e-01 | -2.77e-01 | 3.08e-01 |
| Regulation of PTEN stability and activity | 55 | 3.88e-04 | -2.77e-01 | 3.52e-03 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | 29 | 9.99e-03 | -2.76e-01 | 5.16e-02 |
| RAB geranylgeranylation | 62 | 1.72e-04 | -2.76e-01 | 1.78e-03 |
| ER-Phagosome pathway | 74 | 4.11e-05 | -2.76e-01 | 5.73e-04 |
| Interleukin-35 Signalling | 12 | 9.89e-02 | -2.75e-01 | 2.59e-01 |
| Protein ubiquitination | 71 | 6.47e-05 | -2.74e-01 | 8.13e-04 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | 11 | 1.16e-01 | -2.74e-01 | 2.87e-01 |
| SUMOylation of transcription factors | 16 | 5.80e-02 | 2.74e-01 | 1.91e-01 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | 20 | 3.43e-02 | -2.73e-01 | 1.30e-01 |
| Leishmania infection | 210 | 8.62e-12 | -2.73e-01 | 5.52e-10 |
| Parasitic Infection Pathways | 210 | 8.62e-12 | -2.73e-01 | 5.52e-10 |
| DAP12 signaling | 28 | 1.24e-02 | -2.73e-01 | 6.11e-02 |
| Detoxification of Reactive Oxygen Species | 30 | 9.75e-03 | -2.73e-01 | 5.06e-02 |
| Synthesis of glycosylphosphatidylinositol (GPI) | 18 | 4.55e-02 | 2.72e-01 | 1.61e-01 |
| Antigen processing-Cross presentation | 88 | 1.01e-05 | -2.72e-01 | 1.96e-04 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 183 | 2.19e-10 | -2.72e-01 | 1.08e-08 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | 25 | 1.86e-02 | -2.72e-01 | 8.23e-02 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | 25 | 1.86e-02 | -2.72e-01 | 8.23e-02 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | 25 | 1.86e-02 | -2.72e-01 | 8.23e-02 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | 25 | 1.86e-02 | -2.72e-01 | 8.23e-02 |
| Maturation of nucleoprotein 9694631 | 15 | 6.82e-02 | -2.72e-01 | 2.12e-01 |
| Prostacyclin signalling through prostacyclin receptor | 16 | 5.99e-02 | -2.72e-01 | 1.96e-01 |
| Signaling by FLT3 ITD and TKD mutants | 15 | 6.87e-02 | -2.71e-01 | 2.12e-01 |
| Specification of primordial germ cells | 6 | 2.50e-01 | 2.71e-01 | 4.59e-01 |
| CTNNB1 S33 mutants aren’t phosphorylated | 15 | 6.90e-02 | -2.71e-01 | 2.12e-01 |
| CTNNB1 S37 mutants aren’t phosphorylated | 15 | 6.90e-02 | -2.71e-01 | 2.12e-01 |
| CTNNB1 S45 mutants aren’t phosphorylated | 15 | 6.90e-02 | -2.71e-01 | 2.12e-01 |
| CTNNB1 T41 mutants aren’t phosphorylated | 15 | 6.90e-02 | -2.71e-01 | 2.12e-01 |
| Signaling by CTNNB1 phospho-site mutants | 15 | 6.90e-02 | -2.71e-01 | 2.12e-01 |
| Signaling by GSK3beta mutants | 15 | 6.90e-02 | -2.71e-01 | 2.12e-01 |
| Separation of Sister Chromatids | 167 | 1.50e-09 | -2.71e-01 | 6.25e-08 |
| Complex III assembly | 23 | 2.45e-02 | 2.71e-01 | 1.01e-01 |
| RHO GTPases activate PKNs | 46 | 1.51e-03 | -2.70e-01 | 1.11e-02 |
| Role of ABL in ROBO-SLIT signaling | 6 | 2.52e-01 | -2.70e-01 | 4.60e-01 |
| Potential therapeutics for SARS | 148 | 1.54e-08 | -2.69e-01 | 5.68e-07 |
| O-linked glycosylation of mucins | 46 | 1.63e-03 | -2.69e-01 | 1.18e-02 |
| Adenylate cyclase activating pathway | 8 | 1.90e-01 | 2.67e-01 | 3.92e-01 |
| EML4 and NUDC in mitotic spindle formation | 106 | 2.00e-06 | -2.67e-01 | 4.75e-05 |
| APC/C:Cdc20 mediated degradation of Securin | 55 | 6.14e-04 | -2.67e-01 | 5.31e-03 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | 191 | 2.02e-10 | -2.67e-01 | 1.02e-08 |
| SUMO is transferred from E1 to E2 (UBE2I, UBC9) | 7 | 2.22e-01 | -2.66e-01 | 4.29e-01 |
| Smooth Muscle Contraction | 34 | 7.17e-03 | -2.66e-01 | 4.03e-02 |
| G2/M Checkpoints | 126 | 2.42e-07 | -2.66e-01 | 7.03e-06 |
| Phase 2 - plateau phase | 12 | 1.10e-01 | -2.66e-01 | 2.81e-01 |
| SARS-CoV-1 modulates host translation machinery | 36 | 5.74e-03 | 2.66e-01 | 3.36e-02 |
| Dectin-1 mediated noncanonical NF-kB signaling | 47 | 1.65e-03 | -2.65e-01 | 1.19e-02 |
| Synthesis of Ketone Bodies | 6 | 2.61e-01 | -2.65e-01 | 4.69e-01 |
| Signaling by SCF-KIT | 40 | 3.76e-03 | -2.65e-01 | 2.37e-02 |
| NFE2L2 regulating ER-stress associated genes | 5 | 3.05e-01 | 2.65e-01 | 5.15e-01 |
| Regulation of MITF-M-dependent genes involved in lysosome biogenesis and autophagy | 16 | 6.69e-02 | -2.65e-01 | 2.11e-01 |
| p38MAPK events | 13 | 9.87e-02 | -2.65e-01 | 2.59e-01 |
| CLEC7A/inflammasome pathway | 6 | 2.62e-01 | 2.64e-01 | 4.70e-01 |
| Regulation of pyruvate dehydrogenase (PDH) complex | 14 | 8.68e-02 | -2.64e-01 | 2.40e-01 |
| Long-term potentiation | 14 | 8.82e-02 | 2.63e-01 | 2.40e-01 |
| Synthesis of PIPs at the late endosome membrane | 11 | 1.31e-01 | -2.63e-01 | 3.10e-01 |
| Peptide chain elongation | 88 | 2.05e-05 | 2.63e-01 | 3.33e-04 |
| SHC-related events triggered by IGF1R | 7 | 2.29e-01 | -2.63e-01 | 4.37e-01 |
| Acetylcholine Neurotransmitter Release Cycle | 11 | 1.32e-01 | 2.62e-01 | 3.12e-01 |
| ADP signalling through P2Y purinoceptor 1 | 21 | 3.77e-02 | -2.62e-01 | 1.38e-01 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | 6 | 2.67e-01 | -2.62e-01 | 4.76e-01 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | 90 | 1.80e-05 | -2.62e-01 | 3.03e-04 |
| Amplification of signal from the kinetochores | 90 | 1.80e-05 | -2.62e-01 | 3.03e-04 |
| Induction of Cell-Cell Fusion | 8 | 2.01e-01 | -2.61e-01 | 4.01e-01 |
| Sema3A PAK dependent Axon repulsion | 15 | 8.03e-02 | -2.61e-01 | 2.30e-01 |
| Impaired BRCA2 binding to PALB2 | 24 | 2.72e-02 | -2.60e-01 | 1.09e-01 |
| Cyclin A:Cdk2-associated events at S phase entry | 75 | 9.61e-05 | -2.60e-01 | 1.10e-03 |
| Regulation of RUNX2 expression and activity | 54 | 9.72e-04 | -2.59e-01 | 7.75e-03 |
| Sulfur amino acid metabolism | 22 | 3.53e-02 | 2.59e-01 | 1.32e-01 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | 17 | 6.44e-02 | -2.59e-01 | 2.05e-01 |
| FLT3 signaling in disease | 27 | 1.99e-02 | -2.59e-01 | 8.56e-02 |
| Assembly of the pre-replicative complex | 87 | 2.99e-05 | -2.59e-01 | 4.35e-04 |
| Cyclin D associated events in G1 | 47 | 2.13e-03 | -2.59e-01 | 1.46e-02 |
| G1 Phase | 47 | 2.13e-03 | -2.59e-01 | 1.46e-02 |
| eNOS activation | 10 | 1.57e-01 | -2.59e-01 | 3.47e-01 |
| Regulation of Complement cascade | 96 | 1.24e-05 | -2.58e-01 | 2.33e-04 |
| Formation of a pool of free 40S subunits | 100 | 8.40e-06 | 2.58e-01 | 1.68e-04 |
| Constitutive Signaling by EGFRvIII | 14 | 9.54e-02 | -2.57e-01 | 2.53e-01 |
| Signaling by EGFRvIII in Cancer | 14 | 9.54e-02 | -2.57e-01 | 2.53e-01 |
| Hedgehog ‘on’ state | 65 | 3.33e-04 | -2.57e-01 | 3.09e-03 |
| Prefoldin mediated transfer of substrate to CCT/TriC | 25 | 2.60e-02 | -2.57e-01 | 1.05e-01 |
| Kinesins | 51 | 1.49e-03 | -2.57e-01 | 1.09e-02 |
| Activation of the TFAP2 (AP-2) family of transcription factors | 7 | 2.40e-01 | 2.57e-01 | 4.46e-01 |
| G1/S DNA Damage Checkpoints | 54 | 1.10e-03 | -2.57e-01 | 8.59e-03 |
| Signaling by Erythropoietin | 24 | 2.98e-02 | -2.56e-01 | 1.17e-01 |
| Beta oxidation of hexanoyl-CoA to butanoyl-CoA | 5 | 3.21e-01 | 2.56e-01 | 5.32e-01 |
| EPHA-mediated growth cone collapse | 21 | 4.27e-02 | -2.55e-01 | 1.54e-01 |
| Sema4D mediated inhibition of cell attachment and migration | 7 | 2.42e-01 | 2.55e-01 | 4.49e-01 |
| p130Cas linkage to MAPK signaling for integrins | 11 | 1.43e-01 | -2.55e-01 | 3.27e-01 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | 14 | 9.85e-02 | 2.55e-01 | 2.58e-01 |
| ATF6 (ATF6-alpha) activates chaperone genes | 10 | 1.63e-01 | -2.55e-01 | 3.56e-01 |
| Nuclear events mediated by NFE2L2 | 81 | 7.36e-05 | -2.55e-01 | 9.12e-04 |
| FOXO-mediated transcription of cell death genes | 16 | 7.84e-02 | 2.54e-01 | 2.29e-01 |
| Eukaryotic Translation Elongation | 93 | 2.31e-05 | 2.54e-01 | 3.67e-04 |
| RHOV GTPase cycle | 36 | 8.52e-03 | -2.53e-01 | 4.61e-02 |
| Regulation of TLR by endogenous ligand | 15 | 9.01e-02 | -2.53e-01 | 2.44e-01 |
| Interleukin-2 family signaling | 38 | 7.19e-03 | -2.52e-01 | 4.03e-02 |
| Beta-oxidation of pristanoyl-CoA | 9 | 1.91e-01 | -2.52e-01 | 3.93e-01 |
| Response to elevated platelet cytosolic Ca2+ | 108 | 6.12e-06 | -2.52e-01 | 1.26e-04 |
| Vesicle-mediated transport | 663 | 2.36e-28 | -2.51e-01 | 2.27e-25 |
| Interleukin-1 processing | 8 | 2.19e-01 | 2.51e-01 | 4.26e-01 |
| Proton-coupled monocarboxylate transport | 6 | 2.88e-01 | -2.51e-01 | 4.98e-01 |
| Sulfide oxidation to sulfate | 5 | 3.32e-01 | 2.50e-01 | 5.45e-01 |
| 2-LTR circle formation | 7 | 2.51e-01 | -2.50e-01 | 4.59e-01 |
| Phospholipase C-mediated cascade: FGFR1 | 8 | 2.22e-01 | 2.50e-01 | 4.29e-01 |
| p75NTR signals via NF-kB | 15 | 9.45e-02 | 2.49e-01 | 2.51e-01 |
| ERBB2 Activates PTK6 Signaling | 8 | 2.22e-01 | 2.49e-01 | 4.29e-01 |
| Growth hormone receptor signaling | 20 | 5.40e-02 | -2.49e-01 | 1.84e-01 |
| Cell-extracellular matrix interactions | 15 | 9.56e-02 | -2.49e-01 | 2.53e-01 |
| RSK activation | 7 | 2.55e-01 | -2.48e-01 | 4.62e-01 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | 61 | 8.10e-04 | -2.48e-01 | 6.74e-03 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | 23 | 3.97e-02 | -2.48e-01 | 1.45e-01 |
| Glucagon-type ligand receptors | 19 | 6.15e-02 | -2.48e-01 | 1.99e-01 |
| Selenocysteine synthesis | 92 | 4.03e-05 | 2.48e-01 | 5.65e-04 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | 28 | 2.34e-02 | -2.48e-01 | 9.77e-02 |
| Abacavir ADME | 5 | 3.40e-01 | -2.46e-01 | 5.52e-01 |
| Mitotic Anaphase | 210 | 7.49e-10 | -2.46e-01 | 3.35e-08 |
| Neutrophil degranulation | 456 | 2.17e-19 | -2.46e-01 | 8.33e-17 |
| Mitotic Metaphase and Anaphase | 211 | 7.68e-10 | -2.46e-01 | 3.35e-08 |
| Interleukin-12 signaling | 44 | 4.90e-03 | -2.45e-01 | 2.96e-02 |
| TLR3-mediated TICAM1-dependent programmed cell death | 6 | 2.99e-01 | -2.45e-01 | 5.09e-01 |
| Interleukin-27 signaling | 11 | 1.60e-01 | -2.45e-01 | 3.53e-01 |
| Prolactin receptor signaling | 11 | 1.61e-01 | -2.44e-01 | 3.53e-01 |
| Platelet degranulation | 104 | 1.69e-05 | -2.44e-01 | 2.93e-04 |
| Switching of origins to a post-replicative state | 79 | 1.77e-04 | -2.44e-01 | 1.82e-03 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | 76 | 2.48e-04 | -2.43e-01 | 2.41e-03 |
| CDK-mediated phosphorylation and removal of Cdc6 | 60 | 1.13e-03 | -2.43e-01 | 8.75e-03 |
| Mitochondrial Uncoupling | 6 | 3.03e-01 | 2.43e-01 | 5.13e-01 |
| GPVI-mediated activation cascade | 31 | 1.94e-02 | -2.43e-01 | 8.39e-02 |
| Glycine degradation | 7 | 2.68e-01 | -2.42e-01 | 4.76e-01 |
| Interleukin-2 signaling | 11 | 1.66e-01 | -2.41e-01 | 3.62e-01 |
| HuR (ELAVL1) binds and stabilizes mRNA | 10 | 1.88e-01 | -2.40e-01 | 3.90e-01 |
| Synthesis of PI | 5 | 3.53e-01 | 2.40e-01 | 5.67e-01 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | 10 | 1.89e-01 | -2.40e-01 | 3.91e-01 |
| Regulation of RUNX3 expression and activity | 45 | 5.40e-03 | -2.40e-01 | 3.22e-02 |
| Mismatch Repair | 15 | 1.08e-01 | -2.39e-01 | 2.78e-01 |
| TCF dependent signaling in response to WNT | 151 | 4.04e-07 | -2.39e-01 | 1.10e-05 |
| p53-Dependent G1 DNA Damage Response | 52 | 2.89e-03 | -2.39e-01 | 1.92e-02 |
| p53-Dependent G1/S DNA damage checkpoint | 52 | 2.89e-03 | -2.39e-01 | 1.92e-02 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | 17 | 8.87e-02 | -2.38e-01 | 2.41e-01 |
| Early SARS-CoV-2 Infection Events | 30 | 2.39e-02 | -2.38e-01 | 9.93e-02 |
| RHO GTPases Activate Formins | 127 | 3.55e-06 | -2.38e-01 | 7.59e-05 |
| DNA replication initiation | 8 | 2.44e-01 | 2.38e-01 | 4.51e-01 |
| Formation of paraxial mesoderm | 52 | 3.01e-03 | -2.38e-01 | 1.99e-02 |
| Interleukin-37 signaling | 19 | 7.29e-02 | -2.38e-01 | 2.18e-01 |
| Estrogen-stimulated signaling through PRKCZ | 6 | 3.14e-01 | -2.37e-01 | 5.25e-01 |
| Fatty acyl-CoA biosynthesis | 35 | 1.51e-02 | -2.37e-01 | 7.09e-02 |
| Signalling to RAS | 19 | 7.43e-02 | -2.37e-01 | 2.20e-01 |
| Vitamin B1 (thiamin) metabolism | 5 | 3.60e-01 | 2.37e-01 | 5.75e-01 |
| Platelet homeostasis | 69 | 6.83e-04 | -2.36e-01 | 5.77e-03 |
| Signaling by ALK fusions and activated point mutants | 89 | 1.24e-04 | -2.35e-01 | 1.35e-03 |
| Signaling by ALK in cancer | 89 | 1.24e-04 | -2.35e-01 | 1.35e-03 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 94 | 8.33e-05 | 2.35e-01 | 9.82e-04 |
| Respiratory Syncytial Virus Infection Pathway | 97 | 6.48e-05 | -2.35e-01 | 8.13e-04 |
| Interleukin-12 family signaling | 53 | 3.15e-03 | -2.34e-01 | 2.06e-02 |
| MECP2 regulates transcription of neuronal ligands | 5 | 3.64e-01 | -2.34e-01 | 5.78e-01 |
| Folding of actin by CCT/TriC | 10 | 2.00e-01 | -2.34e-01 | 4.00e-01 |
| A tetrasaccharide linker sequence is required for GAG synthesis | 16 | 1.05e-01 | 2.34e-01 | 2.72e-01 |
| Constitutive Signaling by AKT1 E17K in Cancer | 25 | 4.31e-02 | 2.34e-01 | 1.55e-01 |
| Transport of nucleotide sugars | 9 | 2.26e-01 | 2.33e-01 | 4.34e-01 |
| Complement cascade | 100 | 5.68e-05 | -2.33e-01 | 7.42e-04 |
| Membrane Trafficking | 575 | 1.48e-21 | -2.33e-01 | 7.09e-19 |
| Viral mRNA Translation | 88 | 1.68e-04 | 2.32e-01 | 1.74e-03 |
| VEGFA-VEGFR2 Pathway | 93 | 1.10e-04 | -2.32e-01 | 1.25e-03 |
| Translation of Replicase and Assembly of the Replication Transcription Complex 9694676 | 13 | 1.48e-01 | -2.32e-01 | 3.35e-01 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | 55 | 2.93e-03 | -2.32e-01 | 1.94e-02 |
| Eukaryotic Translation Termination | 92 | 1.21e-04 | 2.32e-01 | 1.34e-03 |
| HS-GAG biosynthesis | 19 | 8.03e-02 | -2.32e-01 | 2.30e-01 |
| FGFR1 ligand binding and activation | 10 | 2.05e-01 | 2.32e-01 | 4.06e-01 |
| Displacement of DNA glycosylase by APEX1 | 9 | 2.29e-01 | 2.32e-01 | 4.37e-01 |
| Peptide hormone metabolism | 53 | 3.63e-03 | -2.31e-01 | 2.30e-02 |
| Gap junction assembly | 16 | 1.10e-01 | -2.31e-01 | 2.80e-01 |
| Small interfering RNA (siRNA) biogenesis | 9 | 2.31e-01 | -2.31e-01 | 4.38e-01 |
| Signaling by FGFR4 in disease | 11 | 1.86e-01 | -2.31e-01 | 3.88e-01 |
| Cell Cycle Checkpoints | 245 | 5.21e-10 | -2.30e-01 | 2.39e-08 |
| Transcriptional Regulation by MECP2 | 47 | 6.29e-03 | -2.30e-01 | 3.60e-02 |
| Signal amplification | 28 | 3.49e-02 | -2.30e-01 | 1.30e-01 |
| Interactions of Vpr with host cellular proteins | 37 | 1.56e-02 | 2.30e-01 | 7.24e-02 |
| Defective C1GALT1C1 causes TNPS | 9 | 2.33e-01 | -2.30e-01 | 4.41e-01 |
| FGFR1 mutant receptor activation | 25 | 4.68e-02 | -2.30e-01 | 1.64e-01 |
| Budding and maturation of HIV virion | 26 | 4.27e-02 | -2.30e-01 | 1.54e-01 |
| Defective LFNG causes SCDO3 | 5 | 3.76e-01 | -2.29e-01 | 5.91e-01 |
| Transcriptional regulation of pluripotent stem cells | 18 | 9.40e-02 | -2.28e-01 | 2.50e-01 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | 13 | 1.55e-01 | -2.28e-01 | 3.45e-01 |
| RAB GEFs exchange GTP for GDP on RABs | 89 | 2.01e-04 | -2.28e-01 | 2.02e-03 |
| Acyl chain remodelling of PG | 11 | 1.91e-01 | -2.28e-01 | 3.94e-01 |
| PKR-mediated signaling | 67 | 1.30e-03 | -2.27e-01 | 9.81e-03 |
| Purine salvage | 12 | 1.73e-01 | -2.27e-01 | 3.70e-01 |
| Downregulation of ERBB2:ERBB3 signaling | 12 | 1.73e-01 | 2.27e-01 | 3.70e-01 |
| Acetylcholine regulates insulin secretion | 9 | 2.38e-01 | 2.27e-01 | 4.46e-01 |
| Glycosphingolipid biosynthesis | 16 | 1.16e-01 | -2.27e-01 | 2.87e-01 |
| ABC-family proteins mediated transport | 81 | 4.31e-04 | -2.26e-01 | 3.85e-03 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | 12 | 1.75e-01 | -2.26e-01 | 3.72e-01 |
| alpha-linolenic acid (ALA) metabolism | 12 | 1.75e-01 | -2.26e-01 | 3.72e-01 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | 36 | 1.90e-02 | -2.26e-01 | 8.33e-02 |
| Interleukin-23 signaling | 7 | 3.02e-01 | -2.25e-01 | 5.13e-01 |
| Cholesterol biosynthesis | 26 | 4.70e-02 | -2.25e-01 | 1.65e-01 |
| Synthesis of UDP-N-acetyl-glucosamine | 8 | 2.70e-01 | 2.25e-01 | 4.78e-01 |
| ROS and RNS production in phagocytes | 30 | 3.30e-02 | -2.25e-01 | 1.26e-01 |
| Mitotic G2-G2/M phases | 179 | 2.21e-07 | -2.24e-01 | 6.53e-06 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | 85 | 3.51e-04 | -2.24e-01 | 3.21e-03 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | 85 | 3.51e-04 | -2.24e-01 | 3.21e-03 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | 85 | 3.51e-04 | -2.24e-01 | 3.21e-03 |
| EGFR interacts with phospholipase C-gamma | 6 | 3.42e-01 | 2.24e-01 | 5.54e-01 |
| Mitotic Prometaphase | 192 | 8.96e-08 | -2.24e-01 | 2.87e-06 |
| EPH-Ephrin signaling | 79 | 6.00e-04 | -2.23e-01 | 5.22e-03 |
| CD28 dependent PI3K/Akt signaling | 22 | 7.01e-02 | 2.23e-01 | 2.14e-01 |
| G2/M Transition | 177 | 3.24e-07 | -2.23e-01 | 9.29e-06 |
| Cap-dependent Translation Initiation | 118 | 2.99e-05 | 2.22e-01 | 4.35e-04 |
| Eukaryotic Translation Initiation | 118 | 2.99e-05 | 2.22e-01 | 4.35e-04 |
| Ketone body metabolism | 8 | 2.77e-01 | -2.22e-01 | 4.85e-01 |
| Signaling by activated point mutants of FGFR1 | 5 | 3.90e-01 | 2.22e-01 | 6.02e-01 |
| Defective HLCS causes multiple carboxylase deficiency | 7 | 3.10e-01 | 2.21e-01 | 5.20e-01 |
| Autodegradation of Cdh1 by Cdh1:APC/C | 54 | 4.90e-03 | -2.21e-01 | 2.96e-02 |
| Prostanoid ligand receptors | 8 | 2.79e-01 | -2.21e-01 | 4.87e-01 |
| Inwardly rectifying K+ channels | 22 | 7.31e-02 | -2.21e-01 | 2.18e-01 |
| Nitric oxide stimulates guanylate cyclase | 15 | 1.39e-01 | 2.21e-01 | 3.22e-01 |
| Major pathway of rRNA processing in the nucleolus and cytosol | 179 | 3.70e-07 | 2.20e-01 | 1.04e-05 |
| FGFR1c ligand binding and activation | 8 | 2.81e-01 | 2.20e-01 | 4.88e-01 |
| Defects in biotin (Btn) metabolism | 8 | 2.81e-01 | 2.20e-01 | 4.88e-01 |
| mRNA Editing | 8 | 2.82e-01 | -2.20e-01 | 4.88e-01 |
| Ca2+ pathway | 57 | 4.10e-03 | -2.20e-01 | 2.56e-02 |
| S Phase | 150 | 3.41e-06 | -2.20e-01 | 7.45e-05 |
| AMPK inhibits chREBP transcriptional activation activity | 6 | 3.52e-01 | 2.20e-01 | 5.65e-01 |
| p75NTR recruits signalling complexes | 12 | 1.88e-01 | 2.19e-01 | 3.90e-01 |
| rRNA processing in the nucleus and cytosol | 189 | 2.02e-07 | 2.19e-01 | 6.26e-06 |
| L13a-mediated translational silencing of Ceruloplasmin expression | 110 | 7.20e-05 | 2.19e-01 | 8.98e-04 |
| Vasopressin regulates renal water homeostasis via Aquaporins | 34 | 2.73e-02 | -2.19e-01 | 1.09e-01 |
| Deposition of new CENPA-containing nucleosomes at the centromere | 37 | 2.14e-02 | -2.19e-01 | 9.08e-02 |
| Nucleosome assembly | 37 | 2.14e-02 | -2.19e-01 | 9.08e-02 |
| NFE2L2 regulates pentose phosphate pathway genes | 8 | 2.85e-01 | -2.18e-01 | 4.93e-01 |
| RAF activation | 32 | 3.27e-02 | -2.18e-01 | 1.25e-01 |
| Signaling by NTRK2 (TRKB) | 20 | 9.14e-02 | -2.18e-01 | 2.45e-01 |
| Synthesis of PIPs at the Golgi membrane | 16 | 1.31e-01 | 2.18e-01 | 3.10e-01 |
| Regulation of CDH11 gene transcription | 5 | 3.99e-01 | 2.18e-01 | 6.11e-01 |
| mRNA decay by 5’ to 3’ exoribonuclease | 15 | 1.45e-01 | -2.17e-01 | 3.31e-01 |
| Selenoamino acid metabolism | 115 | 6.14e-05 | 2.16e-01 | 7.87e-04 |
| Mitotic Spindle Checkpoint | 107 | 1.13e-04 | -2.16e-01 | 1.27e-03 |
| Apoptosis | 157 | 3.08e-06 | -2.16e-01 | 6.87e-05 |
| Synthesis of very long-chain fatty acyl-CoAs | 22 | 7.99e-02 | -2.16e-01 | 2.30e-01 |
| Formation of the ternary complex, and subsequently, the 43S complex | 51 | 7.89e-03 | 2.15e-01 | 4.35e-02 |
| Ub-specific processing proteases | 153 | 4.44e-06 | -2.15e-01 | 9.36e-05 |
| Programmed Cell Death | 186 | 4.36e-07 | -2.15e-01 | 1.16e-05 |
| Disorders of Developmental Biology | 12 | 1.98e-01 | -2.15e-01 | 3.99e-01 |
| Disorders of Nervous System Development | 12 | 1.98e-01 | -2.15e-01 | 3.99e-01 |
| Loss of function of MECP2 in Rett syndrome | 12 | 1.98e-01 | -2.15e-01 | 3.99e-01 |
| Pervasive developmental disorders | 12 | 1.98e-01 | -2.15e-01 | 3.99e-01 |
| Metabolism of nitric oxide: NOS3 activation and regulation | 13 | 1.81e-01 | -2.14e-01 | 3.81e-01 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | 111 | 9.51e-05 | 2.14e-01 | 1.10e-03 |
| TCR signaling | 110 | 1.08e-04 | -2.14e-01 | 1.22e-03 |
| Synthesis of IP2, IP, and Ins in the cytosol | 13 | 1.82e-01 | -2.14e-01 | 3.84e-01 |
| Hemostasis | 553 | 8.54e-18 | -2.14e-01 | 2.73e-15 |
| RHOC GTPase cycle | 71 | 1.89e-03 | -2.13e-01 | 1.32e-02 |
| Estrogen-dependent gene expression | 96 | 3.05e-04 | -2.13e-01 | 2.87e-03 |
| DNA Replication Pre-Initiation | 103 | 1.88e-04 | -2.13e-01 | 1.92e-03 |
| Meiotic synapsis | 43 | 1.57e-02 | -2.13e-01 | 7.26e-02 |
| SARS-CoV-2 modulates host translation machinery | 49 | 9.98e-03 | 2.13e-01 | 5.16e-02 |
| Signaling by VEGF | 100 | 2.37e-04 | -2.13e-01 | 2.33e-03 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | 27 | 5.62e-02 | -2.12e-01 | 1.88e-01 |
| Telomere Extension By Telomerase | 23 | 7.83e-02 | -2.12e-01 | 2.29e-01 |
| MET activates RAS signaling | 10 | 2.46e-01 | -2.12e-01 | 4.53e-01 |
| Cell Cycle, Mitotic | 487 | 1.17e-15 | -2.12e-01 | 1.87e-13 |
| Pyroptosis | 24 | 7.26e-02 | -2.12e-01 | 2.18e-01 |
| M Phase | 345 | 1.45e-11 | -2.12e-01 | 8.44e-10 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | 14 | 1.72e-01 | -2.11e-01 | 3.70e-01 |
| G-protein activation | 19 | 1.12e-01 | -2.10e-01 | 2.83e-01 |
| Meiotic recombination | 36 | 2.92e-02 | -2.10e-01 | 1.15e-01 |
| Retrograde transport at the Trans-Golgi-Network | 49 | 1.10e-02 | -2.10e-01 | 5.51e-02 |
| Defective GALNT3 causes HFTC | 8 | 3.04e-01 | -2.10e-01 | 5.14e-01 |
| Regulation of pyruvate metabolism | 32 | 4.02e-02 | -2.10e-01 | 1.47e-01 |
| TGF-beta receptor signaling activates SMADs | 45 | 1.51e-02 | -2.09e-01 | 7.09e-02 |
| Formation of xylulose-5-phosphate | 5 | 4.18e-01 | 2.09e-01 | 6.30e-01 |
| Miscellaneous substrates | 7 | 3.38e-01 | 2.09e-01 | 5.51e-01 |
| SUMOylation of immune response proteins | 12 | 2.10e-01 | 2.09e-01 | 4.13e-01 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | 50 | 1.07e-02 | -2.09e-01 | 5.43e-02 |
| Arachidonate production from DAG | 5 | 4.19e-01 | 2.09e-01 | 6.30e-01 |
| Signaling by WNT | 237 | 3.21e-08 | -2.08e-01 | 1.10e-06 |
| Downregulation of ERBB4 signaling | 8 | 3.08e-01 | -2.08e-01 | 5.17e-01 |
| Translation of Structural Proteins 9683701 | 29 | 5.33e-02 | -2.07e-01 | 1.82e-01 |
| Signaling by TGF-beta Receptor Complex in Cancer | 8 | 3.10e-01 | -2.07e-01 | 5.20e-01 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | 32 | 4.25e-02 | -2.07e-01 | 1.54e-01 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | 18 | 1.29e-01 | -2.07e-01 | 3.07e-01 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | 18 | 1.29e-01 | -2.07e-01 | 3.07e-01 |
| Aquaporin-mediated transport | 38 | 2.76e-02 | -2.06e-01 | 1.10e-01 |
| rRNA processing | 213 | 2.06e-07 | 2.06e-01 | 6.29e-06 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 59 | 6.09e-03 | 2.06e-01 | 3.52e-02 |
| ABC transporters in lipid homeostasis | 14 | 1.81e-01 | 2.06e-01 | 3.82e-01 |
| Pyruvate metabolism | 44 | 1.79e-02 | -2.06e-01 | 8.05e-02 |
| rRNA modification in the nucleus and cytosol | 59 | 6.15e-03 | 2.06e-01 | 3.54e-02 |
| Pre-NOTCH Transcription and Translation | 47 | 1.45e-02 | -2.06e-01 | 6.85e-02 |
| Spry regulation of FGF signaling | 16 | 1.54e-01 | -2.06e-01 | 3.44e-01 |
| Signaling by FGFR1 in disease | 32 | 4.37e-02 | -2.06e-01 | 1.56e-01 |
| Signaling by ALK | 24 | 8.07e-02 | -2.06e-01 | 2.31e-01 |
| SUMOylation of ubiquitinylation proteins | 39 | 2.64e-02 | 2.05e-01 | 1.06e-01 |
| mitochondrial fatty acid beta-oxidation of unsaturated fatty acids | 6 | 3.84e-01 | -2.05e-01 | 5.97e-01 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | 14 | 1.84e-01 | -2.05e-01 | 3.85e-01 |
| Triglyceride metabolism | 24 | 8.20e-02 | -2.05e-01 | 2.33e-01 |
| Linoleic acid (LA) metabolism | 7 | 3.48e-01 | -2.05e-01 | 5.61e-01 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | 100 | 4.01e-04 | 2.05e-01 | 3.62e-03 |
| RSV-host interactions | 76 | 2.05e-03 | -2.04e-01 | 1.42e-02 |
| Metalloprotease DUBs | 20 | 1.14e-01 | -2.04e-01 | 2.83e-01 |
| Keratan sulfate degradation | 9 | 2.89e-01 | 2.04e-01 | 4.99e-01 |
| Germ layer formation at gastrulation | 9 | 2.89e-01 | -2.04e-01 | 4.99e-01 |
| Depolymerization of the Nuclear Lamina | 15 | 1.73e-01 | -2.03e-01 | 3.70e-01 |
| PI-3K cascade:FGFR2 | 13 | 2.06e-01 | -2.02e-01 | 4.08e-01 |
| Inhibition of Signaling by Overexpressed EGFR | 5 | 4.33e-01 | 2.02e-01 | 6.44e-01 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | 5 | 4.33e-01 | 2.02e-01 | 6.44e-01 |
| DNA Replication | 128 | 7.70e-05 | -2.02e-01 | 9.32e-04 |
| WNT mediated activation of DVL | 8 | 3.23e-01 | 2.02e-01 | 5.33e-01 |
| Apoptotic factor-mediated response | 19 | 1.28e-01 | -2.02e-01 | 3.06e-01 |
| Innate Immune System | 966 | 2.36e-26 | -2.02e-01 | 1.51e-23 |
| Signaling by NOTCH4 | 68 | 4.15e-03 | -2.01e-01 | 2.56e-02 |
| Defects in cobalamin (B12) metabolism | 13 | 2.10e-01 | -2.01e-01 | 4.12e-01 |
| Activation of AMPK downstream of NMDARs | 20 | 1.20e-01 | -2.01e-01 | 2.92e-01 |
| Signaling by ERBB2 ECD mutants | 15 | 1.79e-01 | -2.01e-01 | 3.79e-01 |
| FRS-mediated FGFR2 signaling | 15 | 1.79e-01 | -2.01e-01 | 3.79e-01 |
| Acyl chain remodelling of PI | 10 | 2.73e-01 | -2.00e-01 | 4.81e-01 |
| Activation of Ca-permeable Kainate Receptor | 8 | 3.27e-01 | -2.00e-01 | 5.38e-01 |
| Ionotropic activity of kainate receptors | 8 | 3.27e-01 | -2.00e-01 | 5.38e-01 |
| Gastrulation | 73 | 3.12e-03 | -2.00e-01 | 2.05e-02 |
| SARS-CoV-2 modulates autophagy | 11 | 2.51e-01 | 2.00e-01 | 4.59e-01 |
| Ribosomal scanning and start codon recognition | 58 | 8.43e-03 | 2.00e-01 | 4.59e-02 |
| UCH proteinases | 73 | 3.16e-03 | -2.00e-01 | 2.06e-02 |
| Advanced glycosylation endproduct receptor signaling | 12 | 2.31e-01 | -2.00e-01 | 4.38e-01 |
| PI-3K cascade:FGFR3 | 10 | 2.74e-01 | -2.00e-01 | 4.82e-01 |
| Cargo trafficking to the periciliary membrane | 48 | 1.68e-02 | -2.00e-01 | 7.63e-02 |
| Acyl chain remodelling of PC | 19 | 1.34e-01 | -1.99e-01 | 3.16e-01 |
| Maturation of nucleoprotein 9683610 | 11 | 2.54e-01 | -1.98e-01 | 4.62e-01 |
| Chondroitin sulfate/dermatan sulfate metabolism | 37 | 3.68e-02 | 1.98e-01 | 1.37e-01 |
| Gap junction trafficking and regulation | 29 | 6.50e-02 | -1.98e-01 | 2.07e-01 |
| FRS-mediated FGFR3 signaling | 12 | 2.36e-01 | -1.98e-01 | 4.43e-01 |
| Beta-catenin independent WNT signaling | 124 | 1.44e-04 | -1.98e-01 | 1.54e-03 |
| Meiosis | 66 | 5.49e-03 | -1.98e-01 | 3.26e-02 |
| Asymmetric localization of PCP proteins | 49 | 1.67e-02 | -1.98e-01 | 7.62e-02 |
| activated TAK1 mediates p38 MAPK activation | 23 | 1.01e-01 | -1.98e-01 | 2.62e-01 |
| Gap junction trafficking | 27 | 7.59e-02 | -1.97e-01 | 2.24e-01 |
| Vpr-mediated nuclear import of PICs | 34 | 4.65e-02 | 1.97e-01 | 1.63e-01 |
| Factors involved in megakaryocyte development and platelet production | 128 | 1.18e-04 | -1.97e-01 | 1.31e-03 |
| Removal of the Flap Intermediate from the C-strand | 17 | 1.60e-01 | -1.97e-01 | 3.53e-01 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | 16 | 1.73e-01 | -1.97e-01 | 3.70e-01 |
| Neurotoxicity of clostridium toxins | 9 | 3.07e-01 | 1.97e-01 | 5.17e-01 |
| STAT3 nuclear events downstream of ALK signaling | 11 | 2.61e-01 | -1.96e-01 | 4.70e-01 |
| Pre-NOTCH Processing in Golgi | 18 | 1.51e-01 | -1.95e-01 | 3.40e-01 |
| Cell Cycle | 609 | 1.93e-16 | -1.95e-01 | 4.64e-14 |
| Translation initiation complex formation | 58 | 1.06e-02 | 1.94e-01 | 5.43e-02 |
| Golgi Associated Vesicle Biogenesis | 55 | 1.29e-02 | -1.94e-01 | 6.22e-02 |
| Signaling by FGFR3 | 32 | 5.79e-02 | -1.94e-01 | 1.91e-01 |
| Platelet activation, signaling and aggregation | 219 | 7.87e-07 | -1.94e-01 | 2.02e-05 |
| Calnexin/calreticulin cycle | 26 | 8.76e-02 | -1.94e-01 | 2.40e-01 |
| Asparagine N-linked glycosylation | 284 | 2.00e-08 | -1.93e-01 | 7.26e-07 |
| Erythrocytes take up oxygen and release carbon dioxide | 7 | 3.75e-01 | -1.93e-01 | 5.91e-01 |
| Attachment and Entry 9694614 | 13 | 2.28e-01 | -1.93e-01 | 4.36e-01 |
| Noncanonical activation of NOTCH3 | 8 | 3.44e-01 | -1.93e-01 | 5.56e-01 |
| Downstream TCR signaling | 89 | 1.65e-03 | -1.93e-01 | 1.19e-02 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | 15 | 1.96e-01 | -1.93e-01 | 3.98e-01 |
| Signaling by WNT in cancer | 30 | 6.80e-02 | -1.93e-01 | 2.12e-01 |
| Regulated Necrosis | 55 | 1.36e-02 | -1.92e-01 | 6.48e-02 |
| Erythrocytes take up carbon dioxide and release oxygen | 11 | 2.70e-01 | -1.92e-01 | 4.78e-01 |
| O2/CO2 exchange in erythrocytes | 11 | 2.70e-01 | -1.92e-01 | 4.78e-01 |
| Transport of the SLBP independent Mature mRNA | 35 | 4.96e-02 | 1.92e-01 | 1.72e-01 |
| Influenza Viral RNA Transcription and Replication | 135 | 1.22e-04 | 1.91e-01 | 1.34e-03 |
| Transport of the SLBP Dependant Mature mRNA | 36 | 4.72e-02 | 1.91e-01 | 1.65e-01 |
| KEAP1-NFE2L2 pathway | 106 | 7.03e-04 | -1.90e-01 | 5.90e-03 |
| Axonal growth inhibition (RHOA activation) | 7 | 3.83e-01 | -1.90e-01 | 5.97e-01 |
| p75NTR regulates axonogenesis | 7 | 3.83e-01 | -1.90e-01 | 5.97e-01 |
| IKK complex recruitment mediated by RIP1 | 23 | 1.14e-01 | -1.90e-01 | 2.83e-01 |
| G2/M DNA damage checkpoint | 66 | 7.69e-03 | -1.90e-01 | 4.28e-02 |
| Hedgehog ‘off’ state | 91 | 1.77e-03 | -1.90e-01 | 1.26e-02 |
| Transcriptional regulation by RUNX1 | 170 | 2.16e-05 | -1.89e-01 | 3.46e-04 |
| Metabolism of Angiotensinogen to Angiotensins | 12 | 2.58e-01 | -1.89e-01 | 4.65e-01 |
| Synthesis, secretion, and deacylation of Ghrelin | 11 | 2.78e-01 | -1.89e-01 | 4.85e-01 |
| ERBB2 Regulates Cell Motility | 10 | 3.02e-01 | 1.89e-01 | 5.13e-01 |
| Cardiac conduction | 88 | 2.28e-03 | -1.88e-01 | 1.56e-02 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | 8 | 3.57e-01 | 1.88e-01 | 5.72e-01 |
| Sphingolipid de novo biosynthesis | 34 | 5.78e-02 | -1.88e-01 | 1.91e-01 |
| Synthesis of PIPs at the plasma membrane | 52 | 1.91e-02 | -1.88e-01 | 8.34e-02 |
| GPER1 signaling | 38 | 4.56e-02 | -1.87e-01 | 1.61e-01 |
| Repression of WNT target genes | 14 | 2.25e-01 | -1.87e-01 | 4.32e-01 |
| Alpha-protein kinase 1 signaling pathway | 11 | 2.82e-01 | -1.87e-01 | 4.89e-01 |
| Formation of tubulin folding intermediates by CCT/TriC | 21 | 1.38e-01 | -1.87e-01 | 3.22e-01 |
| The NLRP3 inflammasome | 16 | 1.95e-01 | 1.87e-01 | 3.98e-01 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | 12 | 2.62e-01 | -1.87e-01 | 4.70e-01 |
| Transport of connexons to the plasma membrane | 12 | 2.62e-01 | -1.87e-01 | 4.70e-01 |
| MAP2K and MAPK activation | 36 | 5.28e-02 | -1.86e-01 | 1.81e-01 |
| HDL remodeling | 6 | 4.29e-01 | 1.86e-01 | 6.40e-01 |
| InlB-mediated entry of Listeria monocytogenes into host cell | 12 | 2.64e-01 | -1.86e-01 | 4.72e-01 |
| Inhibition of DNA recombination at telomere | 33 | 6.48e-02 | -1.86e-01 | 2.06e-01 |
| Downstream signaling of activated FGFR2 | 20 | 1.51e-01 | -1.86e-01 | 3.40e-01 |
| Physiological factors | 9 | 3.39e-01 | -1.84e-01 | 5.52e-01 |
| FRS-mediated FGFR4 signaling | 13 | 2.52e-01 | -1.84e-01 | 4.59e-01 |
| Trafficking and processing of endosomal TLR | 13 | 2.52e-01 | -1.83e-01 | 4.60e-01 |
| Transcriptional Regulation by NPAS4 | 27 | 9.93e-02 | -1.83e-01 | 2.60e-01 |
| O-glycosylation of TSR domain-containing proteins | 25 | 1.13e-01 | 1.83e-01 | 2.83e-01 |
| PI-3K cascade:FGFR4 | 11 | 2.94e-01 | -1.83e-01 | 5.03e-01 |
| Synthesis of DNA | 108 | 1.04e-03 | -1.83e-01 | 8.19e-03 |
| Signaling by high-kinase activity BRAF mutants | 33 | 6.97e-02 | -1.82e-01 | 2.13e-01 |
| Nonhomologous End-Joining (NHEJ) | 40 | 4.60e-02 | -1.82e-01 | 1.62e-01 |
| PINK1-PRKN Mediated Mitophagy | 31 | 7.91e-02 | -1.82e-01 | 2.29e-01 |
| SLBP independent Processing of Histone Pre-mRNAs | 10 | 3.19e-01 | 1.82e-01 | 5.28e-01 |
| RHOG GTPase cycle | 70 | 8.53e-03 | -1.82e-01 | 4.61e-02 |
| Signaling by MET | 67 | 1.02e-02 | -1.81e-01 | 5.23e-02 |
| RHOU GTPase cycle | 40 | 4.71e-02 | -1.81e-01 | 1.65e-01 |
| Lipophagy | 7 | 4.06e-01 | -1.81e-01 | 6.19e-01 |
| Downstream signaling of activated FGFR3 | 17 | 1.97e-01 | -1.81e-01 | 3.98e-01 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | 11 | 2.99e-01 | 1.81e-01 | 5.09e-01 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | 6 | 4.43e-01 | -1.81e-01 | 6.54e-01 |
| MAPK family signaling cascades | 259 | 5.92e-07 | -1.80e-01 | 1.54e-05 |
| Late endosomal microautophagy | 30 | 8.76e-02 | -1.80e-01 | 2.40e-01 |
| RUNX3 regulates NOTCH signaling | 14 | 2.44e-01 | 1.80e-01 | 4.51e-01 |
| DNA Damage/Telomere Stress Induced Senescence | 42 | 4.45e-02 | -1.79e-01 | 1.58e-01 |
| CLEC7A (Dectin-1) signaling | 85 | 4.41e-03 | -1.79e-01 | 2.70e-02 |
| Membrane binding and targetting of GAG proteins | 13 | 2.66e-01 | -1.78e-01 | 4.73e-01 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | 13 | 2.66e-01 | -1.78e-01 | 4.73e-01 |
| Rap1 signalling | 14 | 2.48e-01 | -1.78e-01 | 4.57e-01 |
| Regulation of PLK1 Activity at G2/M Transition | 87 | 4.12e-03 | -1.78e-01 | 2.56e-02 |
| Adaptive Immune System | 765 | 6.80e-17 | -1.77e-01 | 1.87e-14 |
| RIPK1-mediated regulated necrosis | 31 | 8.84e-02 | -1.77e-01 | 2.40e-01 |
| Regulation of necroptotic cell death | 31 | 8.84e-02 | -1.77e-01 | 2.40e-01 |
| C-type lectin receptors (CLRs) | 116 | 1.00e-03 | -1.77e-01 | 7.95e-03 |
| Signaling by RNF43 mutants | 7 | 4.19e-01 | -1.77e-01 | 6.30e-01 |
| PCP/CE pathway | 74 | 8.65e-03 | -1.77e-01 | 4.65e-02 |
| Cleavage of the damaged pyrimidine | 26 | 1.20e-01 | -1.76e-01 | 2.91e-01 |
| Depyrimidination | 26 | 1.20e-01 | -1.76e-01 | 2.91e-01 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | 26 | 1.20e-01 | -1.76e-01 | 2.91e-01 |
| Impaired BRCA2 binding to RAD51 | 35 | 7.10e-02 | -1.76e-01 | 2.16e-01 |
| Pre-NOTCH Expression and Processing | 63 | 1.56e-02 | -1.76e-01 | 7.25e-02 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | 24 | 1.35e-01 | -1.76e-01 | 3.19e-01 |
| RHOF GTPase cycle | 38 | 6.12e-02 | -1.75e-01 | 1.98e-01 |
| PKA activation in glucagon signalling | 14 | 2.56e-01 | -1.75e-01 | 4.62e-01 |
| Muscle contraction | 142 | 3.11e-04 | -1.75e-01 | 2.91e-03 |
| Activation of the AP-1 family of transcription factors | 10 | 3.37e-01 | -1.75e-01 | 5.50e-01 |
| AURKA Activation by TPX2 | 72 | 1.02e-02 | -1.75e-01 | 5.23e-02 |
| PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases | 13 | 2.75e-01 | -1.75e-01 | 4.83e-01 |
| Metabolism of steroids | 120 | 9.35e-04 | -1.75e-01 | 7.55e-03 |
| Signaling by Hedgehog | 120 | 9.64e-04 | -1.74e-01 | 7.71e-03 |
| SHC-mediated cascade:FGFR2 | 13 | 2.77e-01 | -1.74e-01 | 4.85e-01 |
| RUNX3 Regulates Immune Response and Cell Migration | 5 | 5.00e-01 | -1.74e-01 | 7.09e-01 |
| Recycling of bile acids and salts | 8 | 3.94e-01 | -1.74e-01 | 6.05e-01 |
| Receptor Mediated Mitophagy | 11 | 3.18e-01 | -1.74e-01 | 5.28e-01 |
| Interleukin-7 signaling | 21 | 1.70e-01 | -1.73e-01 | 3.67e-01 |
| Export of Viral Ribonucleoproteins from Nucleus | 33 | 8.55e-02 | 1.73e-01 | 2.40e-01 |
| Receptor-type tyrosine-protein phosphatases | 11 | 3.21e-01 | 1.73e-01 | 5.31e-01 |
| AKT phosphorylates targets in the cytosol | 14 | 2.63e-01 | 1.73e-01 | 4.71e-01 |
| Sialic acid metabolism | 27 | 1.21e-01 | -1.72e-01 | 2.94e-01 |
| Miro GTPase Cycle | 8 | 4.00e-01 | -1.72e-01 | 6.12e-01 |
| Bile acid and bile salt metabolism | 28 | 1.16e-01 | -1.72e-01 | 2.86e-01 |
| Downstream signaling of activated FGFR4 | 18 | 2.07e-01 | -1.72e-01 | 4.09e-01 |
| Cell recruitment (pro-inflammatory response) | 25 | 1.39e-01 | 1.71e-01 | 3.22e-01 |
| Purinergic signaling in leishmaniasis infection | 25 | 1.39e-01 | 1.71e-01 | 3.22e-01 |
| TGFBR3 expression | 20 | 1.86e-01 | -1.71e-01 | 3.88e-01 |
| PKA activation | 15 | 2.53e-01 | -1.70e-01 | 4.61e-01 |
| L1CAM interactions | 100 | 3.28e-03 | -1.70e-01 | 2.13e-02 |
| Signaling by Rho GTPases | 603 | 9.67e-13 | -1.70e-01 | 8.08e-11 |
| RHOH GTPase cycle | 33 | 9.10e-02 | -1.70e-01 | 2.45e-01 |
| PKA-mediated phosphorylation of CREB | 17 | 2.25e-01 | -1.70e-01 | 4.32e-01 |
| ESR-mediated signaling | 157 | 2.40e-04 | -1.70e-01 | 2.35e-03 |
| Loss of Function of TGFBR1 in Cancer | 7 | 4.38e-01 | -1.69e-01 | 6.48e-01 |
| Negative regulation of FLT3 | 15 | 2.57e-01 | -1.69e-01 | 4.64e-01 |
| CDH11 homotypic and heterotypic interactions | 5 | 5.13e-01 | 1.69e-01 | 7.17e-01 |
| Post-chaperonin tubulin folding pathway | 18 | 2.14e-01 | -1.69e-01 | 4.19e-01 |
| Interleukin-10 signaling | 36 | 7.98e-02 | 1.69e-01 | 2.30e-01 |
| Insulin receptor recycling | 24 | 1.54e-01 | -1.68e-01 | 3.45e-01 |
| Signaling by Rho GTPases, Miro GTPases and RHOBTB3 | 619 | 1.08e-12 | -1.68e-01 | 8.61e-11 |
| Chaperonin-mediated protein folding | 77 | 1.11e-02 | -1.67e-01 | 5.53e-02 |
| Activation of gene expression by SREBF (SREBP) | 42 | 6.06e-02 | -1.67e-01 | 1.97e-01 |
| Interleukin-1 family signaling | 127 | 1.14e-03 | -1.67e-01 | 8.76e-03 |
| Glycogen metabolism | 21 | 1.85e-01 | -1.67e-01 | 3.88e-01 |
| Blood group systems biosynthesis | 16 | 2.47e-01 | 1.67e-01 | 4.55e-01 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | 35 | 8.72e-02 | -1.67e-01 | 2.40e-01 |
| Post-translational protein phosphorylation | 67 | 1.83e-02 | -1.67e-01 | 8.16e-02 |
| MET receptor recycling | 9 | 3.87e-01 | -1.67e-01 | 6.00e-01 |
| Antiviral mechanism by IFN-stimulated genes | 140 | 6.85e-04 | -1.66e-01 | 5.77e-03 |
| Rev-mediated nuclear export of HIV RNA | 35 | 8.94e-02 | 1.66e-01 | 2.42e-01 |
| Nicotinate metabolism | 26 | 1.43e-01 | -1.66e-01 | 3.28e-01 |
| Protein lipoylation | 10 | 3.65e-01 | -1.65e-01 | 5.78e-01 |
| Transport of Ribonucleoproteins into the Host Nucleus | 32 | 1.06e-01 | 1.65e-01 | 2.72e-01 |
| Signaling by NOTCH | 173 | 1.78e-04 | -1.65e-01 | 1.82e-03 |
| Immune System | 1828 | 1.22e-31 | -1.65e-01 | 2.34e-28 |
| Protein folding | 83 | 9.35e-03 | -1.65e-01 | 4.92e-02 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 114 | 2.37e-03 | 1.65e-01 | 1.60e-02 |
| Nonsense-Mediated Decay (NMD) | 114 | 2.37e-03 | 1.65e-01 | 1.60e-02 |
| MAPK1/MAPK3 signaling | 227 | 1.90e-05 | -1.65e-01 | 3.18e-04 |
| Signal transduction by L1 | 20 | 2.02e-01 | -1.65e-01 | 4.02e-01 |
| Ribavirin ADME | 11 | 3.45e-01 | -1.64e-01 | 5.57e-01 |
| Uptake and function of diphtheria toxin | 6 | 4.86e-01 | -1.64e-01 | 6.97e-01 |
| Presynaptic phase of homologous DNA pairing and strand exchange | 40 | 7.24e-02 | -1.64e-01 | 2.18e-01 |
| Activation of kainate receptors upon glutamate binding | 25 | 1.55e-01 | -1.64e-01 | 3.45e-01 |
| Cellular response to chemical stress | 178 | 1.61e-04 | -1.64e-01 | 1.69e-03 |
| Signaling by FGFR3 in disease | 14 | 2.90e-01 | -1.63e-01 | 4.99e-01 |
| Signaling by FGFR4 | 32 | 1.10e-01 | -1.63e-01 | 2.80e-01 |
| Ephrin signaling | 17 | 2.44e-01 | -1.63e-01 | 4.51e-01 |
| SHC-mediated cascade:FGFR3 | 10 | 3.72e-01 | -1.63e-01 | 5.88e-01 |
| Rab regulation of trafficking | 122 | 1.88e-03 | -1.63e-01 | 1.32e-02 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 74 | 1.55e-02 | -1.63e-01 | 7.23e-02 |
| Deactivation of the beta-catenin transactivating complex | 36 | 9.13e-02 | -1.63e-01 | 2.45e-01 |
| BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | 9 | 3.98e-01 | 1.63e-01 | 6.10e-01 |
| Signaling by RAF1 mutants | 36 | 9.14e-02 | -1.63e-01 | 2.45e-01 |
| Activation of GABAB receptors | 29 | 1.30e-01 | -1.62e-01 | 3.08e-01 |
| GABA B receptor activation | 29 | 1.30e-01 | -1.62e-01 | 3.08e-01 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | 41 | 7.20e-02 | -1.62e-01 | 2.18e-01 |
| Signaling by TGFB family members | 137 | 1.05e-03 | -1.62e-01 | 8.28e-03 |
| Signaling by TGF-beta Receptor Complex | 90 | 8.09e-03 | -1.62e-01 | 4.42e-02 |
| Deubiquitination | 225 | 3.02e-05 | -1.61e-01 | 4.36e-04 |
| Interleukin-6 family signaling | 18 | 2.37e-01 | -1.61e-01 | 4.45e-01 |
| Erythropoietin activates STAT5 | 6 | 4.95e-01 | -1.61e-01 | 7.05e-01 |
| VEGFR2 mediated cell proliferation | 18 | 2.38e-01 | -1.61e-01 | 4.45e-01 |
| POLB-Dependent Long Patch Base Excision Repair | 8 | 4.31e-01 | 1.61e-01 | 6.42e-01 |
| TNFR2 non-canonical NF-kB pathway | 84 | 1.10e-02 | -1.61e-01 | 5.51e-02 |
| PRC2 methylates histones and DNA | 27 | 1.50e-01 | -1.60e-01 | 3.40e-01 |
| The canonical retinoid cycle in rods (twilight vision) | 9 | 4.07e-01 | 1.60e-01 | 6.20e-01 |
| Class I MHC mediated antigen processing & presentation | 343 | 4.06e-07 | -1.59e-01 | 1.10e-05 |
| Suppression of phagosomal maturation | 12 | 3.40e-01 | -1.59e-01 | 5.52e-01 |
| Gluconeogenesis | 19 | 2.30e-01 | -1.59e-01 | 4.38e-01 |
| Oxidative Stress Induced Senescence | 77 | 1.58e-02 | -1.59e-01 | 7.28e-02 |
| RNA Polymerase I Transcription Initiation | 47 | 5.97e-02 | 1.59e-01 | 1.95e-01 |
| tRNA processing | 128 | 1.93e-03 | 1.59e-01 | 1.35e-02 |
| Negative regulation of FGFR2 signaling | 24 | 1.79e-01 | -1.59e-01 | 3.79e-01 |
| Deadenylation of mRNA | 22 | 1.98e-01 | -1.58e-01 | 3.99e-01 |
| Netrin-1 signaling | 34 | 1.10e-01 | -1.58e-01 | 2.80e-01 |
| Transcriptional regulation by RUNX2 | 87 | 1.10e-02 | -1.58e-01 | 5.51e-02 |
| RAF/MAP kinase cascade | 222 | 5.19e-05 | -1.58e-01 | 6.93e-04 |
| Processing of DNA double-strand break ends | 69 | 2.36e-02 | -1.58e-01 | 9.84e-02 |
| Defective pyroptosis | 27 | 1.57e-01 | -1.57e-01 | 3.47e-01 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | 43 | 7.45e-02 | 1.57e-01 | 2.20e-01 |
| Signaling by EGFR | 47 | 6.24e-02 | -1.57e-01 | 2.00e-01 |
| Transport of Mature mRNA Derived from an Intronless Transcript | 42 | 7.84e-02 | 1.57e-01 | 2.29e-01 |
| Sodium/Calcium exchangers | 9 | 4.15e-01 | -1.57e-01 | 6.29e-01 |
| Bicarbonate transporters | 9 | 4.16e-01 | -1.57e-01 | 6.29e-01 |
| LGI-ADAM interactions | 9 | 4.16e-01 | 1.57e-01 | 6.29e-01 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | 7 | 4.74e-01 | -1.56e-01 | 6.84e-01 |
| Downregulation of ERBB2 signaling | 24 | 1.86e-01 | 1.56e-01 | 3.88e-01 |
| NEP/NS2 Interacts with the Cellular Export Machinery | 32 | 1.27e-01 | 1.56e-01 | 3.04e-01 |
| Infection with Mycobacterium tuberculosis | 26 | 1.69e-01 | -1.56e-01 | 3.66e-01 |
| RAS processing | 23 | 1.96e-01 | -1.56e-01 | 3.98e-01 |
| Azathioprine ADME | 20 | 2.28e-01 | -1.56e-01 | 4.36e-01 |
| Regulation of TP53 Activity through Acetylation | 29 | 1.47e-01 | 1.56e-01 | 3.34e-01 |
| Hyaluronan metabolism | 15 | 2.97e-01 | 1.56e-01 | 5.07e-01 |
| GABA receptor activation | 35 | 1.12e-01 | -1.55e-01 | 2.82e-01 |
| Synthesis of PIPs at the ER membrane | 5 | 5.48e-01 | -1.55e-01 | 7.43e-01 |
| Response of Mtb to phagocytosis | 22 | 2.09e-01 | -1.55e-01 | 4.12e-01 |
| Metabolism of non-coding RNA | 53 | 5.15e-02 | 1.55e-01 | 1.77e-01 |
| snRNP Assembly | 53 | 5.15e-02 | 1.55e-01 | 1.77e-01 |
| Phase 0 - rapid depolarisation | 23 | 2.01e-01 | -1.54e-01 | 4.01e-01 |
| Mitochondrial protein import | 63 | 3.47e-02 | 1.54e-01 | 1.30e-01 |
| Defective B3GALTL causes PpS | 24 | 1.92e-01 | 1.54e-01 | 3.94e-01 |
| ER Quality Control Compartment (ERQC) | 21 | 2.24e-01 | -1.53e-01 | 4.31e-01 |
| Vitamin B5 (pantothenate) metabolism | 20 | 2.35e-01 | -1.53e-01 | 4.43e-01 |
| STAT5 activation downstream of FLT3 ITD mutants | 9 | 4.26e-01 | -1.53e-01 | 6.37e-01 |
| Glycogen breakdown (glycogenolysis) | 12 | 3.59e-01 | -1.53e-01 | 5.74e-01 |
| RND3 GTPase cycle | 35 | 1.18e-01 | -1.53e-01 | 2.89e-01 |
| Interleukin-1 signaling | 99 | 8.94e-03 | -1.52e-01 | 4.78e-02 |
| Dissolution of Fibrin Clot | 12 | 3.63e-01 | 1.52e-01 | 5.77e-01 |
| Influenza Infection | 154 | 1.16e-03 | 1.52e-01 | 8.88e-03 |
| Interferon Signaling | 237 | 5.82e-05 | -1.52e-01 | 7.55e-04 |
| Androgen biosynthesis | 5 | 5.57e-01 | -1.52e-01 | 7.49e-01 |
| IL-6-type cytokine receptor ligand interactions | 12 | 3.64e-01 | 1.51e-01 | 5.78e-01 |
| Regulation of insulin secretion | 62 | 3.94e-02 | -1.51e-01 | 1.44e-01 |
| Biosynthesis of maresins | 5 | 5.58e-01 | -1.51e-01 | 7.49e-01 |
| FGFR3 ligand binding and activation | 5 | 5.59e-01 | -1.51e-01 | 7.49e-01 |
| FGFR3c ligand binding and activation | 5 | 5.59e-01 | -1.51e-01 | 7.49e-01 |
| Negative regulation of FGFR3 signaling | 21 | 2.31e-01 | -1.51e-01 | 4.38e-01 |
| PI3K/AKT activation | 8 | 4.62e-01 | -1.50e-01 | 6.71e-01 |
| Activation of SMO | 14 | 3.31e-01 | -1.50e-01 | 5.43e-01 |
| Nephron development | 5 | 5.62e-01 | -1.50e-01 | 7.52e-01 |
| H139Hfs13* PPM1K causes a mild variant of MSUD | 5 | 5.62e-01 | -1.50e-01 | 7.52e-01 |
| Maple Syrup Urine Disease | 5 | 5.62e-01 | -1.50e-01 | 7.52e-01 |
| RUNX2 regulates bone development | 21 | 2.35e-01 | -1.50e-01 | 4.43e-01 |
| Caspase activation via extrinsic apoptotic signalling pathway | 25 | 1.96e-01 | -1.50e-01 | 3.98e-01 |
| Loss of Function of SMAD2/3 in Cancer | 7 | 4.93e-01 | -1.50e-01 | 7.03e-01 |
| SHC-mediated cascade:FGFR4 | 11 | 3.91e-01 | -1.50e-01 | 6.03e-01 |
| Biosynthesis of Lipoxins (LX) | 6 | 5.27e-01 | -1.49e-01 | 7.30e-01 |
| Nuclear Receptor transcription pathway | 38 | 1.12e-01 | 1.49e-01 | 2.82e-01 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | 10 | 4.15e-01 | 1.49e-01 | 6.29e-01 |
| Regulation of BACH1 activity | 11 | 3.93e-01 | -1.49e-01 | 6.05e-01 |
| Biotin transport and metabolism | 11 | 3.94e-01 | 1.49e-01 | 6.05e-01 |
| Gap junction degradation | 11 | 3.94e-01 | -1.48e-01 | 6.06e-01 |
| Regulation of localization of FOXO transcription factors | 11 | 3.95e-01 | 1.48e-01 | 6.06e-01 |
| Ion homeostasis | 40 | 1.05e-01 | -1.48e-01 | 2.72e-01 |
| HIV Transcription Initiation | 45 | 8.59e-02 | -1.48e-01 | 2.40e-01 |
| RNA Polymerase II HIV Promoter Escape | 45 | 8.59e-02 | -1.48e-01 | 2.40e-01 |
| RNA Polymerase II Promoter Escape | 45 | 8.59e-02 | -1.48e-01 | 2.40e-01 |
| RNA Polymerase II Transcription Initiation | 45 | 8.59e-02 | -1.48e-01 | 2.40e-01 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | 45 | 8.59e-02 | -1.48e-01 | 2.40e-01 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | 45 | 8.59e-02 | -1.48e-01 | 2.40e-01 |
| Signaling by BMP | 23 | 2.20e-01 | -1.48e-01 | 4.26e-01 |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | 9 | 4.44e-01 | -1.47e-01 | 6.54e-01 |
| Diseases of signal transduction by growth factor receptors and second messengers | 399 | 4.41e-07 | -1.47e-01 | 1.16e-05 |
| G beta:gamma signalling through PLC beta | 17 | 2.94e-01 | -1.47e-01 | 5.03e-01 |
| Presynaptic function of Kainate receptors | 17 | 2.94e-01 | -1.47e-01 | 5.03e-01 |
| Transcriptional Regulation by E2F6 | 34 | 1.38e-01 | -1.47e-01 | 3.22e-01 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | 8 | 4.72e-01 | -1.47e-01 | 6.82e-01 |
| Cellular response to starvation | 148 | 2.08e-03 | 1.47e-01 | 1.44e-02 |
| FASTK family proteins regulate processing and stability of mitochondrial RNAs | 19 | 2.69e-01 | 1.46e-01 | 4.78e-01 |
| HDR through MMEJ (alt-NHEJ) | 12 | 3.81e-01 | -1.46e-01 | 5.96e-01 |
| Synthesis of Dolichyl-phosphate | 6 | 5.36e-01 | -1.46e-01 | 7.34e-01 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | 12 | 3.82e-01 | -1.46e-01 | 5.97e-01 |
| Downregulation of TGF-beta receptor signaling | 26 | 1.99e-01 | -1.45e-01 | 4.00e-01 |
| Activation of ATR in response to replication stress | 37 | 1.27e-01 | -1.45e-01 | 3.04e-01 |
| Loss of Nlp from mitotic centrosomes | 69 | 3.73e-02 | -1.45e-01 | 1.38e-01 |
| Loss of proteins required for interphase microtubule organization from the centrosome | 69 | 3.73e-02 | -1.45e-01 | 1.38e-01 |
| MHC class II antigen presentation | 113 | 7.78e-03 | -1.45e-01 | 4.32e-02 |
| Negative regulation of FGFR4 signaling | 22 | 2.40e-01 | -1.45e-01 | 4.46e-01 |
| Signaling by Interleukins | 387 | 1.03e-06 | -1.45e-01 | 2.57e-05 |
| Defective Intrinsic Pathway for Apoptosis | 24 | 2.21e-01 | 1.44e-01 | 4.28e-01 |
| Thromboxane signalling through TP receptor | 20 | 2.64e-01 | -1.44e-01 | 4.72e-01 |
| NCAM1 interactions | 26 | 2.03e-01 | 1.44e-01 | 4.03e-01 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | 27 | 1.95e-01 | 1.44e-01 | 3.98e-01 |
| Recycling pathway of L1 | 40 | 1.15e-01 | -1.44e-01 | 2.86e-01 |
| Toll-like Receptor Cascades | 162 | 1.70e-03 | -1.43e-01 | 1.22e-02 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | 41 | 1.13e-01 | -1.43e-01 | 2.83e-01 |
| Diseases of DNA Double-Strand Break Repair | 41 | 1.13e-01 | -1.43e-01 | 2.83e-01 |
| trans-Golgi Network Vesicle Budding | 69 | 4.04e-02 | -1.43e-01 | 1.47e-01 |
| Formation of annular gap junctions | 10 | 4.35e-01 | -1.43e-01 | 6.45e-01 |
| The role of Nef in HIV-1 replication and disease pathogenesis | 28 | 1.92e-01 | -1.42e-01 | 3.94e-01 |
| Cell-Cell communication | 108 | 1.08e-02 | -1.42e-01 | 5.46e-02 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | 72 | 3.74e-02 | 1.42e-01 | 1.38e-01 |
| tRNA modification in the nucleus and cytosol | 43 | 1.09e-01 | 1.41e-01 | 2.78e-01 |
| FLT3 Signaling | 38 | 1.32e-01 | -1.41e-01 | 3.13e-01 |
| SUMOylation of SUMOylation proteins | 35 | 1.50e-01 | 1.41e-01 | 3.39e-01 |
| tRNA processing in the nucleus | 59 | 6.22e-02 | 1.40e-01 | 2.00e-01 |
| MITF-M-dependent gene expression | 81 | 2.91e-02 | -1.40e-01 | 1.14e-01 |
| DNA Damage Reversal | 8 | 4.93e-01 | 1.40e-01 | 7.03e-01 |
| PPARA activates gene expression | 105 | 1.32e-02 | -1.40e-01 | 6.36e-02 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | 60 | 6.11e-02 | -1.40e-01 | 1.98e-01 |
| IRF3-mediated induction of type I IFN | 12 | 4.03e-01 | 1.40e-01 | 6.15e-01 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | 7 | 5.23e-01 | 1.39e-01 | 7.27e-01 |
| Diseases of mitotic cell cycle | 38 | 1.37e-01 | -1.39e-01 | 3.21e-01 |
| Ion transport by P-type ATPases | 41 | 1.24e-01 | -1.39e-01 | 2.99e-01 |
| Interleukin-4 and Interleukin-13 signaling | 89 | 2.35e-02 | -1.39e-01 | 9.81e-02 |
| The activation of arylsulfatases | 10 | 4.48e-01 | 1.39e-01 | 6.57e-01 |
| Maternal to zygotic transition (MZT) | 71 | 4.38e-02 | -1.38e-01 | 1.56e-01 |
| RNA Polymerase I Transcription Termination | 30 | 1.90e-01 | 1.38e-01 | 3.92e-01 |
| Processive synthesis on the C-strand of the telomere | 19 | 2.97e-01 | -1.38e-01 | 5.07e-01 |
| Estrogen biosynthesis | 5 | 5.93e-01 | -1.38e-01 | 7.74e-01 |
| Mitophagy | 38 | 1.41e-01 | -1.38e-01 | 3.25e-01 |
| Eicosanoid ligand-binding receptors | 13 | 3.90e-01 | -1.38e-01 | 6.02e-01 |
| Ubiquinol biosynthesis | 13 | 3.90e-01 | 1.38e-01 | 6.02e-01 |
| PIWI-interacting RNA (piRNA) biogenesis | 23 | 2.53e-01 | -1.38e-01 | 4.61e-01 |
| Integration of energy metabolism | 87 | 2.68e-02 | -1.37e-01 | 1.08e-01 |
| Homologous DNA Pairing and Strand Exchange | 43 | 1.19e-01 | -1.37e-01 | 2.91e-01 |
| Oncogene Induced Senescence | 33 | 1.73e-01 | -1.37e-01 | 3.70e-01 |
| Synthesis of bile acids and bile salts | 25 | 2.35e-01 | -1.37e-01 | 4.43e-01 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | 28 | 2.10e-01 | 1.37e-01 | 4.12e-01 |
| Cleavage of the damaged purine | 21 | 2.78e-01 | -1.37e-01 | 4.85e-01 |
| Depurination | 21 | 2.78e-01 | -1.37e-01 | 4.85e-01 |
| Recognition and association of DNA glycosylase with site containing an affected purine | 21 | 2.78e-01 | -1.37e-01 | 4.85e-01 |
| SUMOylation of RNA binding proteins | 47 | 1.05e-01 | 1.37e-01 | 2.72e-01 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | 40 | 1.36e-01 | -1.36e-01 | 3.19e-01 |
| Signaling by RAS mutants | 40 | 1.36e-01 | -1.36e-01 | 3.19e-01 |
| Signaling by moderate kinase activity BRAF mutants | 40 | 1.36e-01 | -1.36e-01 | 3.19e-01 |
| Signaling downstream of RAS mutants | 40 | 1.36e-01 | -1.36e-01 | 3.19e-01 |
| Metabolism of amine-derived hormones | 10 | 4.56e-01 | 1.36e-01 | 6.65e-01 |
| APC-Cdc20 mediated degradation of Nek2A | 26 | 2.31e-01 | -1.36e-01 | 4.38e-01 |
| Cytokine Signaling in Immune system | 662 | 2.64e-09 | -1.36e-01 | 9.95e-08 |
| Lysine catabolism | 10 | 4.59e-01 | -1.35e-01 | 6.68e-01 |
| Creatine metabolism | 7 | 5.36e-01 | -1.35e-01 | 7.34e-01 |
| Tryptophan catabolism | 12 | 4.18e-01 | -1.35e-01 | 6.30e-01 |
| FGFR2c ligand binding and activation | 5 | 6.01e-01 | -1.35e-01 | 7.82e-01 |
| G alpha (z) signalling events | 36 | 1.61e-01 | -1.35e-01 | 3.54e-01 |
| TP53 Regulates Transcription of Cell Death Genes | 42 | 1.31e-01 | 1.35e-01 | 3.10e-01 |
| TP53 Regulates Metabolic Genes | 77 | 4.16e-02 | -1.34e-01 | 1.51e-01 |
| PI3K events in ERBB4 signaling | 6 | 5.69e-01 | 1.34e-01 | 7.56e-01 |
| Attenuation phase | 22 | 2.78e-01 | -1.34e-01 | 4.85e-01 |
| DCC mediated attractive signaling | 13 | 4.05e-01 | -1.34e-01 | 6.17e-01 |
| Opioid Signalling | 74 | 4.71e-02 | -1.33e-01 | 1.65e-01 |
| Resolution of Abasic Sites (AP sites) | 38 | 1.55e-01 | 1.33e-01 | 3.45e-01 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | 117 | 1.27e-02 | -1.33e-01 | 6.16e-02 |
| tRNA processing in the mitochondrion | 24 | 2.59e-01 | 1.33e-01 | 4.66e-01 |
| Activation of BH3-only proteins | 29 | 2.15e-01 | 1.33e-01 | 4.20e-01 |
| Eicosanoids | 6 | 5.73e-01 | -1.33e-01 | 7.58e-01 |
| NOTCH2 intracellular domain regulates transcription | 11 | 4.46e-01 | 1.33e-01 | 6.55e-01 |
| Synthesis of GDP-mannose | 6 | 5.73e-01 | 1.33e-01 | 7.58e-01 |
| DAP12 interactions | 39 | 1.53e-01 | -1.32e-01 | 3.43e-01 |
| RNA Polymerase II Pre-transcription Events | 77 | 4.50e-02 | -1.32e-01 | 1.60e-01 |
| Antigen processing: Ubiquitination & Proteasome degradation | 275 | 1.65e-04 | -1.32e-01 | 1.72e-03 |
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | 7 | 5.46e-01 | -1.32e-01 | 7.42e-01 |
| Infectious disease | 951 | 6.49e-12 | -1.32e-01 | 4.45e-10 |
| Other semaphorin interactions | 16 | 3.63e-01 | -1.31e-01 | 5.77e-01 |
| Assembly Of The HIV Virion | 15 | 3.79e-01 | -1.31e-01 | 5.94e-01 |
| Negative regulators of DDX58/IFIH1 signaling | 34 | 1.86e-01 | -1.31e-01 | 3.88e-01 |
| RAC2 GTPase cycle | 85 | 3.69e-02 | -1.31e-01 | 1.37e-01 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | 16 | 3.65e-01 | -1.31e-01 | 5.78e-01 |
| Activation of NOXA and translocation to mitochondria | 5 | 6.12e-01 | -1.31e-01 | 7.92e-01 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | 32 | 2.02e-01 | 1.30e-01 | 4.02e-01 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | 32 | 2.02e-01 | 1.30e-01 | 4.02e-01 |
| Mitotic Prophase | 96 | 2.81e-02 | -1.30e-01 | 1.11e-01 |
| Viral Messenger RNA Synthesis | 44 | 1.38e-01 | 1.29e-01 | 3.22e-01 |
| Signaling by Leptin | 10 | 4.79e-01 | -1.29e-01 | 6.90e-01 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | 21 | 3.06e-01 | -1.29e-01 | 5.15e-01 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | 21 | 3.06e-01 | -1.29e-01 | 5.15e-01 |
| Inactivation of CDC42 and RAC1 | 7 | 5.55e-01 | -1.29e-01 | 7.49e-01 |
| Pre-NOTCH Processing in the Endoplasmic Reticulum | 6 | 5.85e-01 | -1.29e-01 | 7.67e-01 |
| RNA Polymerase III Transcription Termination | 22 | 2.96e-01 | 1.29e-01 | 5.06e-01 |
| Activation of PUMA and translocation to mitochondria | 8 | 5.29e-01 | 1.28e-01 | 7.31e-01 |
| ISG15 antiviral mechanism | 72 | 5.97e-02 | -1.28e-01 | 1.95e-01 |
| Reproduction | 84 | 4.30e-02 | -1.28e-01 | 1.54e-01 |
| Toll Like Receptor 4 (TLR4) Cascade | 138 | 9.73e-03 | -1.27e-01 | 5.06e-02 |
| IFNG signaling activates MAPKs | 8 | 5.33e-01 | -1.27e-01 | 7.32e-01 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | 28 | 2.44e-01 | -1.27e-01 | 4.51e-01 |
| MET promotes cell motility | 32 | 2.13e-01 | -1.27e-01 | 4.18e-01 |
| Activation of the pre-replicative complex | 32 | 2.14e-01 | -1.27e-01 | 4.19e-01 |
| G alpha (s) signalling events | 93 | 3.49e-02 | -1.27e-01 | 1.30e-01 |
| Aggrephagy | 34 | 2.02e-01 | -1.27e-01 | 4.02e-01 |
| Synthesis of 12-eicosatetraenoic acid derivatives | 6 | 5.92e-01 | 1.26e-01 | 7.74e-01 |
| Neurexins and neuroligins | 35 | 1.97e-01 | 1.26e-01 | 3.98e-01 |
| Notch-HLH transcription pathway | 28 | 2.49e-01 | 1.26e-01 | 4.59e-01 |
| Postmitotic nuclear pore complex (NPC) reformation | 27 | 2.58e-01 | 1.26e-01 | 4.66e-01 |
| Regulation of lipid metabolism by PPARalpha | 107 | 2.49e-02 | -1.26e-01 | 1.02e-01 |
| RHO GTPase cycle | 408 | 1.50e-05 | -1.25e-01 | 2.71e-04 |
| GAB1 signalosome | 14 | 4.18e-01 | -1.25e-01 | 6.30e-01 |
| Defective B4GALT7 causes EDS, progeroid type | 10 | 4.94e-01 | 1.25e-01 | 7.04e-01 |
| CTLA4 inhibitory signaling | 21 | 3.22e-01 | -1.25e-01 | 5.33e-01 |
| Clathrin-mediated endocytosis | 127 | 1.54e-02 | -1.25e-01 | 7.19e-02 |
| TRAF6 mediated IRF7 activation | 15 | 4.04e-01 | -1.24e-01 | 6.16e-01 |
| Other interleukin signaling | 18 | 3.61e-01 | -1.24e-01 | 5.76e-01 |
| Neddylation | 215 | 1.69e-03 | -1.24e-01 | 1.22e-02 |
| SARS-CoV Infections | 428 | 1.06e-05 | -1.24e-01 | 2.03e-04 |
| Propionyl-CoA catabolism | 5 | 6.31e-01 | 1.24e-01 | 7.98e-01 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | 14 | 4.22e-01 | 1.24e-01 | 6.32e-01 |
| Interactions of Rev with host cellular proteins | 37 | 1.92e-01 | 1.24e-01 | 3.94e-01 |
| G beta:gamma signalling through PI3Kgamma | 22 | 3.16e-01 | -1.24e-01 | 5.27e-01 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | 34 | 2.13e-01 | -1.23e-01 | 4.18e-01 |
| Synaptic adhesion-like molecules | 14 | 4.27e-01 | 1.23e-01 | 6.37e-01 |
| Bacterial Infection Pathways | 65 | 8.79e-02 | -1.22e-01 | 2.40e-01 |
| PTEN Regulation | 126 | 1.77e-02 | -1.22e-01 | 7.98e-02 |
| Regulation of TP53 Activity through Methylation | 19 | 3.56e-01 | 1.22e-01 | 5.71e-01 |
| RHOD GTPase cycle | 49 | 1.39e-01 | -1.22e-01 | 3.22e-01 |
| Signaling by MST1 | 5 | 6.37e-01 | 1.22e-01 | 8.03e-01 |
| Signaling by PDGF | 48 | 1.44e-01 | -1.22e-01 | 3.29e-01 |
| Signaling by Activin | 13 | 4.47e-01 | -1.22e-01 | 6.57e-01 |
| Defective binding of VWF variant to GPIb:IX:V | 5 | 6.38e-01 | -1.21e-01 | 8.03e-01 |
| Enhanced binding of GP1BA variant to VWF multimer:collagen | 5 | 6.38e-01 | -1.21e-01 | 8.03e-01 |
| RNA Polymerase III Chain Elongation | 18 | 3.74e-01 | 1.21e-01 | 5.90e-01 |
| Signaling by EGFR in Cancer | 22 | 3.26e-01 | -1.21e-01 | 5.38e-01 |
| Translocation of ZAP-70 to Immunological synapse | 24 | 3.05e-01 | 1.21e-01 | 5.15e-01 |
| Surfactant metabolism | 20 | 3.50e-01 | -1.21e-01 | 5.64e-01 |
| Base-Excision Repair, AP Site Formation | 28 | 2.71e-01 | -1.20e-01 | 4.79e-01 |
| Selective autophagy | 77 | 6.84e-02 | -1.20e-01 | 2.12e-01 |
| Nucleotide salvage | 21 | 3.41e-01 | -1.20e-01 | 5.54e-01 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | 18 | 3.79e-01 | -1.20e-01 | 5.94e-01 |
| Signaling by Nuclear Receptors | 210 | 2.84e-03 | -1.20e-01 | 1.90e-02 |
| Heparan sulfate/heparin (HS-GAG) metabolism | 39 | 1.97e-01 | 1.20e-01 | 3.98e-01 |
| Signaling by FGFR in disease | 52 | 1.37e-01 | -1.19e-01 | 3.21e-01 |
| Glutathione conjugation | 26 | 2.93e-01 | -1.19e-01 | 5.03e-01 |
| Integrin cell surface interactions | 64 | 9.99e-02 | -1.19e-01 | 2.60e-01 |
| Transport and synthesis of PAPS | 6 | 6.14e-01 | -1.19e-01 | 7.92e-01 |
| Viral Infection Pathways | 770 | 2.09e-08 | -1.19e-01 | 7.45e-07 |
| Neurofascin interactions | 5 | 6.46e-01 | -1.19e-01 | 8.09e-01 |
| PI Metabolism | 79 | 6.88e-02 | -1.18e-01 | 2.12e-01 |
| Nuclear import of Rev protein | 34 | 2.33e-01 | 1.18e-01 | 4.41e-01 |
| EGFR downregulation | 26 | 2.98e-01 | -1.18e-01 | 5.08e-01 |
| CREB3 factors activate genes | 6 | 6.18e-01 | 1.18e-01 | 7.92e-01 |
| HIV Infection | 213 | 3.09e-03 | -1.18e-01 | 2.03e-02 |
| HDR through Single Strand Annealing (SSA) | 37 | 2.16e-01 | -1.17e-01 | 4.21e-01 |
| Diseases of carbohydrate metabolism | 29 | 2.74e-01 | 1.17e-01 | 4.82e-01 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | 10 | 5.20e-01 | -1.17e-01 | 7.26e-01 |
| Keratan sulfate/keratin metabolism | 27 | 2.91e-01 | -1.17e-01 | 5.01e-01 |
| Regulation of CDH11 Expression and Function | 22 | 3.43e-01 | -1.17e-01 | 5.54e-01 |
| Mitochondrial calcium ion transport | 22 | 3.43e-01 | 1.17e-01 | 5.54e-01 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | 46 | 1.70e-01 | -1.17e-01 | 3.67e-01 |
| PI5P Regulates TP53 Acetylation | 8 | 5.67e-01 | 1.17e-01 | 7.55e-01 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | 30 | 2.69e-01 | -1.17e-01 | 4.77e-01 |
| Collagen chain trimerization | 26 | 3.03e-01 | -1.17e-01 | 5.13e-01 |
| DNA Damage Bypass | 47 | 1.67e-01 | -1.16e-01 | 3.63e-01 |
| Diseases of DNA repair | 50 | 1.55e-01 | -1.16e-01 | 3.45e-01 |
| NrCAM interactions | 6 | 6.22e-01 | 1.16e-01 | 7.94e-01 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | 36 | 2.28e-01 | -1.16e-01 | 4.36e-01 |
| Transport of Mature Transcript to Cytoplasm | 81 | 7.11e-02 | 1.16e-01 | 2.16e-01 |
| PI3K events in ERBB2 signaling | 11 | 5.07e-01 | 1.16e-01 | 7.13e-01 |
| Cilium Assembly | 187 | 6.42e-03 | -1.16e-01 | 3.65e-02 |
| IRAK2 mediated activation of TAK1 complex | 10 | 5.27e-01 | -1.16e-01 | 7.30e-01 |
| RHOA GTPase cycle | 138 | 1.94e-02 | -1.15e-01 | 8.41e-02 |
| Leading Strand Synthesis | 14 | 4.57e-01 | 1.15e-01 | 6.65e-01 |
| Polymerase switching | 14 | 4.57e-01 | 1.15e-01 | 6.65e-01 |
| Cellular responses to mechanical stimuli | 83 | 7.28e-02 | -1.14e-01 | 2.18e-01 |
| Response of endothelial cells to shear stress | 83 | 7.28e-02 | -1.14e-01 | 2.18e-01 |
| RND1 GTPase cycle | 36 | 2.39e-01 | -1.13e-01 | 4.46e-01 |
| Attachment of GPI anchor to uPAR | 7 | 6.03e-01 | -1.13e-01 | 7.84e-01 |
| TRAIL signaling | 8 | 5.79e-01 | -1.13e-01 | 7.62e-01 |
| RUNX3 regulates p14-ARF | 10 | 5.35e-01 | -1.13e-01 | 7.34e-01 |
| Regulation of TP53 Activity through Phosphorylation | 88 | 6.63e-02 | -1.13e-01 | 2.09e-01 |
| mTORC1-mediated signalling | 24 | 3.37e-01 | -1.13e-01 | 5.50e-01 |
| Anchoring of the basal body to the plasma membrane | 97 | 5.41e-02 | -1.13e-01 | 1.84e-01 |
| Phospholipase C-mediated cascade; FGFR3 | 5 | 6.62e-01 | 1.13e-01 | 8.18e-01 |
| Chaperone Mediated Autophagy | 20 | 3.84e-01 | -1.12e-01 | 5.97e-01 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | 17 | 4.22e-01 | -1.12e-01 | 6.33e-01 |
| Cellular Senescence | 142 | 2.10e-02 | -1.12e-01 | 8.97e-02 |
| Deadenylation-dependent mRNA decay | 50 | 1.70e-01 | -1.12e-01 | 3.67e-01 |
| VLDLR internalisation and degradation | 16 | 4.38e-01 | 1.12e-01 | 6.48e-01 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | 52 | 1.62e-01 | 1.12e-01 | 3.55e-01 |
| Nucleotide biosynthesis | 12 | 5.02e-01 | 1.12e-01 | 7.11e-01 |
| Protein-protein interactions at synapses | 54 | 1.55e-01 | 1.12e-01 | 3.45e-01 |
| NOTCH3 Intracellular Domain Regulates Transcription | 20 | 3.86e-01 | -1.12e-01 | 5.99e-01 |
| Nef mediated downregulation of MHC class I complex cell surface expression | 10 | 5.41e-01 | -1.12e-01 | 7.38e-01 |
| Mitochondrial translation elongation | 90 | 6.94e-02 | 1.11e-01 | 2.13e-01 |
| Semaphorin interactions | 56 | 1.53e-01 | -1.10e-01 | 3.43e-01 |
| Resolution of D-Loop Structures | 35 | 2.59e-01 | -1.10e-01 | 4.66e-01 |
| NOTCH4 Intracellular Domain Regulates Transcription | 17 | 4.32e-01 | 1.10e-01 | 6.43e-01 |
| Post-translational protein modification | 1232 | 8.01e-11 | -1.10e-01 | 4.27e-09 |
| Purine ribonucleoside monophosphate biosynthesis | 9 | 5.69e-01 | 1.10e-01 | 7.56e-01 |
| NS1 Mediated Effects on Host Pathways | 40 | 2.33e-01 | 1.09e-01 | 4.41e-01 |
| Molecules associated with elastic fibres | 26 | 3.37e-01 | -1.09e-01 | 5.50e-01 |
| RHOJ GTPase cycle | 49 | 1.88e-01 | -1.09e-01 | 3.90e-01 |
| ATF4 activates genes in response to endoplasmic reticulum stress | 25 | 3.47e-01 | 1.09e-01 | 5.60e-01 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | 7 | 6.21e-01 | -1.08e-01 | 7.94e-01 |
| TP53 Regulates Transcription of Cell Cycle Genes | 47 | 2.01e-01 | -1.08e-01 | 4.01e-01 |
| Chromosome Maintenance | 102 | 6.00e-02 | -1.08e-01 | 1.96e-01 |
| Signaling by TGFBR3 | 39 | 2.46e-01 | -1.07e-01 | 4.53e-01 |
| Passive transport by Aquaporins | 6 | 6.49e-01 | 1.07e-01 | 8.11e-01 |
| Disease | 1606 | 9.07e-13 | -1.07e-01 | 7.92e-11 |
| APC/C:Cdc20 mediated degradation of Cyclin B | 24 | 3.65e-01 | -1.07e-01 | 5.78e-01 |
| BBSome-mediated cargo-targeting to cilium | 23 | 3.76e-01 | -1.07e-01 | 5.91e-01 |
| Integration of provirus | 9 | 5.81e-01 | -1.06e-01 | 7.65e-01 |
| ERKs are inactivated | 13 | 5.07e-01 | 1.06e-01 | 7.13e-01 |
| Recruitment of NuMA to mitotic centrosomes | 88 | 8.67e-02 | -1.06e-01 | 2.40e-01 |
| Pregnenolone biosynthesis | 10 | 5.65e-01 | 1.05e-01 | 7.54e-01 |
| Neurotransmitter receptors and postsynaptic signal transmission | 132 | 3.76e-02 | -1.05e-01 | 1.38e-01 |
| Response of EIF2AK1 (HRI) to heme deficiency | 14 | 4.98e-01 | -1.05e-01 | 7.07e-01 |
| Regulation of innate immune responses to cytosolic DNA | 14 | 4.98e-01 | 1.05e-01 | 7.07e-01 |
| RNA Polymerase III Abortive And Retractive Initiation | 40 | 2.55e-01 | 1.04e-01 | 4.62e-01 |
| RNA Polymerase III Transcription | 40 | 2.55e-01 | 1.04e-01 | 4.62e-01 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | 61 | 1.61e-01 | -1.04e-01 | 3.53e-01 |
| Zinc transporters | 12 | 5.33e-01 | -1.04e-01 | 7.33e-01 |
| Nuclear Envelope (NE) Reassembly | 68 | 1.39e-01 | -1.04e-01 | 3.22e-01 |
| Sensing of DNA Double Strand Breaks | 6 | 6.61e-01 | -1.03e-01 | 8.18e-01 |
| RAC3 GTPase cycle | 86 | 9.74e-02 | -1.03e-01 | 2.56e-01 |
| SIRT1 negatively regulates rRNA expression | 22 | 4.02e-01 | -1.03e-01 | 6.14e-01 |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol | 9 | 5.92e-01 | -1.03e-01 | 7.74e-01 |
| rRNA processing in the mitochondrion | 24 | 3.82e-01 | 1.03e-01 | 5.96e-01 |
| Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane | 11 | 5.54e-01 | 1.03e-01 | 7.47e-01 |
| Phosphorylation of the APC/C | 20 | 4.25e-01 | -1.03e-01 | 6.35e-01 |
| Cellular hexose transport | 14 | 5.06e-01 | 1.03e-01 | 7.13e-01 |
| Signal Transduction | 2034 | 2.49e-14 | -1.03e-01 | 2.81e-12 |
| Toll Like Receptor 2 (TLR2) Cascade | 109 | 6.56e-02 | -1.02e-01 | 2.07e-01 |
| Toll Like Receptor TLR1:TLR2 Cascade | 109 | 6.56e-02 | -1.02e-01 | 2.07e-01 |
| Fatty acids | 6 | 6.65e-01 | -1.02e-01 | 8.22e-01 |
| Defective B3GAT3 causes JDSSDHD | 10 | 5.79e-01 | 1.01e-01 | 7.62e-01 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 30 | 3.36e-01 | -1.01e-01 | 5.49e-01 |
| Transport of vitamins, nucleosides, and related molecules | 31 | 3.29e-01 | 1.01e-01 | 5.41e-01 |
| Interconversion of nucleotide di- and triphosphates | 27 | 3.62e-01 | -1.01e-01 | 5.77e-01 |
| Mitochondrial translation | 96 | 8.66e-02 | 1.01e-01 | 2.40e-01 |
| Autophagy | 142 | 3.78e-02 | -1.01e-01 | 1.39e-01 |
| Downstream signaling of activated FGFR1 | 22 | 4.12e-01 | -1.01e-01 | 6.26e-01 |
| Host Interactions of HIV factors | 118 | 5.83e-02 | -1.01e-01 | 1.91e-01 |
| Defective GALNT12 causes CRCS1 | 8 | 6.21e-01 | -1.01e-01 | 7.94e-01 |
| Diseases of hemostasis | 13 | 5.31e-01 | -1.00e-01 | 7.31e-01 |
| Ca-dependent events | 29 | 3.51e-01 | -1.00e-01 | 5.64e-01 |
| Mitochondrial translation termination | 90 | 1.01e-01 | 1.00e-01 | 2.62e-01 |
| BMAL1:CLOCK,NPAS2 activates circadian gene expression | 25 | 3.88e-01 | -9.97e-02 | 6.01e-01 |
| Disorders of transmembrane transporters | 134 | 4.63e-02 | -9.97e-02 | 1.63e-01 |
| G alpha (12/13) signalling events | 68 | 1.57e-01 | -9.92e-02 | 3.47e-01 |
| Amyloid fiber formation | 51 | 2.22e-01 | -9.89e-02 | 4.29e-01 |
| TBC/RABGAPs | 45 | 2.51e-01 | -9.88e-02 | 4.59e-01 |
| DNA Double Strand Break Response | 47 | 2.42e-01 | -9.87e-02 | 4.49e-01 |
| Extra-nuclear estrogen signaling | 65 | 1.69e-01 | -9.86e-02 | 3.66e-01 |
| RHOB GTPase cycle | 64 | 1.73e-01 | -9.86e-02 | 3.70e-01 |
| Glycerophospholipid catabolism | 6 | 6.76e-01 | 9.85e-02 | 8.25e-01 |
| Dermatan sulfate biosynthesis | 6 | 6.76e-01 | 9.85e-02 | 8.25e-01 |
| Class B/2 (Secretin family receptors) | 54 | 2.11e-01 | -9.84e-02 | 4.14e-01 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | 13 | 5.39e-01 | 9.84e-02 | 7.37e-01 |
| RHOT2 GTPase cycle | 7 | 6.53e-01 | -9.82e-02 | 8.13e-01 |
| Protein methylation | 15 | 5.10e-01 | 9.82e-02 | 7.16e-01 |
| Triglyceride biosynthesis | 9 | 6.11e-01 | 9.80e-02 | 7.91e-01 |
| Adherens junctions interactions | 37 | 3.02e-01 | -9.80e-02 | 5.13e-01 |
| Signaling by NTRK3 (TRKC) | 15 | 5.11e-01 | -9.79e-02 | 7.17e-01 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 49 | 2.38e-01 | -9.75e-02 | 4.45e-01 |
| Trafficking of GluR2-containing AMPA receptors | 11 | 5.76e-01 | -9.74e-02 | 7.60e-01 |
| RNA Polymerase III Transcription Initiation | 36 | 3.12e-01 | 9.74e-02 | 5.22e-01 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | 11 | 5.77e-01 | -9.71e-02 | 7.61e-01 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 104 | 8.70e-02 | -9.71e-02 | 2.40e-01 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | 36 | 3.15e-01 | -9.69e-02 | 5.25e-01 |
| MITF-M-regulated melanocyte development | 110 | 7.98e-02 | -9.67e-02 | 2.30e-01 |
| Organelle biogenesis and maintenance | 278 | 5.64e-03 | -9.65e-02 | 3.32e-02 |
| CRMPs in Sema3A signaling | 13 | 5.47e-01 | -9.64e-02 | 7.43e-01 |
| Intraflagellar transport | 47 | 2.54e-01 | -9.62e-02 | 4.62e-01 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | 6 | 6.85e-01 | -9.56e-02 | 8.34e-01 |
| TGFBR1 KD Mutants in Cancer | 6 | 6.85e-01 | -9.56e-02 | 8.34e-01 |
| Josephin domain DUBs | 10 | 6.01e-01 | -9.54e-02 | 7.82e-01 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | 15 | 5.25e-01 | -9.49e-02 | 7.29e-01 |
| Mitochondrial RNA degradation | 25 | 4.12e-01 | 9.48e-02 | 6.26e-01 |
| Metabolism of lipids | 632 | 4.88e-05 | -9.47e-02 | 6.55e-04 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | 23 | 4.32e-01 | 9.46e-02 | 6.43e-01 |
| Cardiogenesis | 13 | 5.56e-01 | 9.44e-02 | 7.49e-01 |
| RORA activates gene expression | 18 | 4.89e-01 | -9.43e-02 | 6.99e-01 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | 7 | 6.67e-01 | -9.40e-02 | 8.22e-01 |
| Regulation of gene expression by Hypoxia-inducible Factor | 8 | 6.45e-01 | -9.40e-02 | 8.09e-01 |
| G-protein beta:gamma signalling | 29 | 3.82e-01 | -9.38e-02 | 5.96e-01 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | 108 | 9.22e-02 | -9.38e-02 | 2.46e-01 |
| Toll Like Receptor TLR6:TLR2 Cascade | 108 | 9.22e-02 | -9.38e-02 | 2.46e-01 |
| Centrosome maturation | 81 | 1.45e-01 | -9.38e-02 | 3.29e-01 |
| Recruitment of mitotic centrosome proteins and complexes | 81 | 1.45e-01 | -9.38e-02 | 3.29e-01 |
| Glycosphingolipid catabolism | 31 | 3.68e-01 | 9.35e-02 | 5.82e-01 |
| Intra-Golgi traffic | 43 | 2.89e-01 | -9.34e-02 | 4.99e-01 |
| HSF1 activation | 25 | 4.19e-01 | -9.33e-02 | 6.30e-01 |
| SUMOylation of chromatin organization proteins | 57 | 2.25e-01 | 9.30e-02 | 4.32e-01 |
| Defective EXT1 causes exostoses 1, TRPS2 and CHDS | 9 | 6.31e-01 | -9.24e-02 | 7.98e-01 |
| Defective EXT2 causes exostoses 2 | 9 | 6.31e-01 | -9.24e-02 | 7.98e-01 |
| DNA Double-Strand Break Repair | 137 | 6.21e-02 | -9.23e-02 | 2.00e-01 |
| Regulation of endogenous retroelements | 92 | 1.26e-01 | -9.23e-02 | 3.04e-01 |
| Collagen degradation | 41 | 3.07e-01 | -9.21e-02 | 5.17e-01 |
| GRB2 events in ERBB2 signaling | 11 | 5.97e-01 | 9.20e-02 | 7.78e-01 |
| Phospholipase C-mediated cascade; FGFR4 | 6 | 6.97e-01 | 9.17e-02 | 8.37e-01 |
| InlA-mediated entry of Listeria monocytogenes into host cells | 9 | 6.34e-01 | 9.17e-02 | 8.00e-01 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | 23 | 4.49e-01 | -9.12e-02 | 6.58e-01 |
| Transcriptional regulation of white adipocyte differentiation | 77 | 1.67e-01 | -9.11e-02 | 3.63e-01 |
| Toll Like Receptor 3 (TLR3) Cascade | 104 | 1.09e-01 | -9.11e-02 | 2.78e-01 |
| Integrin signaling | 22 | 4.60e-01 | -9.10e-02 | 6.69e-01 |
| Expression and translocation of olfactory receptors | 49 | 2.75e-01 | -9.02e-02 | 4.83e-01 |
| SRP-dependent cotranslational protein targeting to membrane | 111 | 1.01e-01 | 9.01e-02 | 2.62e-01 |
| Interleukin-18 signaling | 6 | 7.02e-01 | -9.01e-02 | 8.40e-01 |
| Macroautophagy | 128 | 7.85e-02 | -9.01e-02 | 2.29e-01 |
| RAF-independent MAPK1/3 activation | 21 | 4.78e-01 | 8.95e-02 | 6.88e-01 |
| Signaling by BRAF and RAF1 fusions | 59 | 2.36e-01 | -8.92e-02 | 4.44e-01 |
| EPH-ephrin mediated repulsion of cells | 42 | 3.19e-01 | -8.90e-02 | 5.28e-01 |
| Formation of RNA Pol II elongation complex | 56 | 2.50e-01 | -8.88e-02 | 4.59e-01 |
| RNA Polymerase II Transcription Elongation | 56 | 2.50e-01 | -8.88e-02 | 4.59e-01 |
| Cytosolic sulfonation of small molecules | 18 | 5.16e-01 | 8.85e-02 | 7.20e-01 |
| Zinc influx into cells by the SLC39 gene family | 9 | 6.47e-01 | -8.82e-02 | 8.10e-01 |
| Striated Muscle Contraction | 25 | 4.46e-01 | -8.81e-02 | 6.55e-01 |
| mitochondrial fatty acid beta-oxidation of saturated fatty acids | 11 | 6.13e-01 | 8.81e-02 | 7.92e-01 |
| Myoclonic epilepsy of Lafora | 8 | 6.67e-01 | -8.79e-02 | 8.22e-01 |
| TGFBR3 PTM regulation | 10 | 6.30e-01 | -8.79e-02 | 7.98e-01 |
| mRNA decay by 3’ to 5’ exoribonuclease | 13 | 5.83e-01 | 8.78e-02 | 7.66e-01 |
| Post NMDA receptor activation events | 60 | 2.40e-01 | -8.77e-02 | 4.46e-01 |
| Signaling by Insulin receptor | 63 | 2.29e-01 | -8.77e-02 | 4.37e-01 |
| RNA Polymerase II Transcription | 1185 | 3.84e-07 | -8.76e-02 | 1.07e-05 |
| Mitochondrial translation initiation | 90 | 1.51e-01 | 8.76e-02 | 3.40e-01 |
| GP1b-IX-V activation signalling | 10 | 6.33e-01 | -8.73e-02 | 8.00e-01 |
| Synthesis of PG | 8 | 6.70e-01 | 8.71e-02 | 8.22e-01 |
| Laminin interactions | 25 | 4.51e-01 | -8.70e-02 | 6.60e-01 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | 22 | 4.80e-01 | 8.70e-02 | 6.90e-01 |
| Synthesis of IP3 and IP4 in the cytosol | 22 | 4.81e-01 | 8.69e-02 | 6.90e-01 |
| Olfactory Signaling Pathway | 54 | 2.70e-01 | -8.69e-02 | 4.78e-01 |
| TRAF6 mediated NF-kB activation | 23 | 4.71e-01 | 8.68e-02 | 6.81e-01 |
| Plasma lipoprotein clearance | 33 | 3.89e-01 | 8.67e-02 | 6.02e-01 |
| Phosphate bond hydrolysis by NTPDase proteins | 6 | 7.13e-01 | 8.67e-02 | 8.48e-01 |
| Signaling by ERBB2 in Cancer | 21 | 4.92e-01 | -8.65e-02 | 7.03e-01 |
| Protein hydroxylation | 17 | 5.37e-01 | 8.65e-02 | 7.35e-01 |
| Digestion | 5 | 7.38e-01 | -8.63e-02 | 8.63e-01 |
| Transcriptional regulation by RUNX3 | 80 | 1.83e-01 | -8.61e-02 | 3.84e-01 |
| Nef Mediated CD8 Down-regulation | 7 | 6.93e-01 | -8.61e-02 | 8.35e-01 |
| Non-integrin membrane-ECM interactions | 46 | 3.12e-01 | 8.61e-02 | 5.22e-01 |
| Nucleotide catabolism | 29 | 4.23e-01 | -8.59e-02 | 6.33e-01 |
| Nectin/Necl trans heterodimerization | 5 | 7.40e-01 | -8.58e-02 | 8.64e-01 |
| Cytosolic tRNA aminoacylation | 24 | 4.67e-01 | -8.57e-02 | 6.76e-01 |
| Translation | 293 | 1.16e-02 | 8.57e-02 | 5.77e-02 |
| FGFR2 alternative splicing | 25 | 4.58e-01 | 8.57e-02 | 6.68e-01 |
| PIP3 activates AKT signaling | 232 | 2.48e-02 | -8.55e-02 | 1.02e-01 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | 50 | 2.96e-01 | -8.54e-02 | 5.06e-01 |
| MyD88-independent TLR4 cascade | 108 | 1.26e-01 | -8.51e-02 | 3.04e-01 |
| TRIF (TICAM1)-mediated TLR4 signaling | 108 | 1.26e-01 | -8.51e-02 | 3.04e-01 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | 10 | 6.42e-01 | 8.49e-02 | 8.06e-01 |
| Generic Transcription Pathway | 1067 | 2.89e-06 | -8.48e-02 | 6.62e-05 |
| STAT5 Activation | 7 | 6.98e-01 | -8.46e-02 | 8.37e-01 |
| Dopamine Neurotransmitter Release Cycle | 20 | 5.13e-01 | 8.44e-02 | 7.18e-01 |
| SLC transporter disorders | 75 | 2.07e-01 | 8.43e-02 | 4.08e-01 |
| Signaling by ERBB4 | 45 | 3.29e-01 | -8.41e-02 | 5.41e-01 |
| Thrombin signalling through proteinase activated receptors (PARs) | 27 | 4.50e-01 | -8.41e-02 | 6.58e-01 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | 19 | 5.27e-01 | -8.39e-02 | 7.30e-01 |
| Trafficking of AMPA receptors | 19 | 5.27e-01 | -8.39e-02 | 7.30e-01 |
| Signaling by Receptor Tyrosine Kinases | 443 | 2.54e-03 | -8.37e-02 | 1.71e-02 |
| Telomere Maintenance | 78 | 2.02e-01 | -8.35e-02 | 4.02e-01 |
| TRAF3-dependent IRF activation pathway | 13 | 6.02e-01 | -8.35e-02 | 7.83e-01 |
| RET signaling | 32 | 4.19e-01 | -8.25e-02 | 6.30e-01 |
| Digestion and absorption | 7 | 7.06e-01 | -8.24e-02 | 8.42e-01 |
| Peroxisomal protein import | 58 | 2.81e-01 | -8.19e-02 | 4.88e-01 |
| Phase I - Functionalization of compounds | 62 | 2.65e-01 | 8.18e-02 | 4.73e-01 |
| SUMOylation of DNA methylation proteins | 16 | 5.72e-01 | 8.16e-02 | 7.58e-01 |
| Vitamin C (ascorbate) metabolism | 8 | 6.90e-01 | -8.16e-02 | 8.34e-01 |
| Miscellaneous transport and binding events | 20 | 5.28e-01 | -8.15e-02 | 7.30e-01 |
| Homology Directed Repair | 110 | 1.42e-01 | -8.10e-02 | 3.27e-01 |
| Defective factor IX causes hemophilia B | 6 | 7.32e-01 | -8.07e-02 | 8.59e-01 |
| Interferon gamma signaling | 87 | 1.93e-01 | -8.07e-02 | 3.95e-01 |
| Aspirin ADME | 13 | 6.15e-01 | -8.06e-02 | 7.92e-01 |
| Intracellular signaling by second messengers | 264 | 2.48e-02 | -8.03e-02 | 1.02e-01 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | 38 | 3.93e-01 | -8.02e-02 | 6.05e-01 |
| Respiratory syncytial virus (RSV) attachment and entry | 17 | 5.67e-01 | -8.01e-02 | 7.55e-01 |
| Oncogenic MAPK signaling | 75 | 2.31e-01 | -8.00e-02 | 4.38e-01 |
| Metabolism of proteins | 1761 | 2.79e-08 | -7.98e-02 | 9.73e-07 |
| Signaling by NTRKs | 116 | 1.39e-01 | -7.96e-02 | 3.22e-01 |
| RAC1 GTPase cycle | 170 | 7.36e-02 | -7.95e-02 | 2.20e-01 |
| Sphingolipid metabolism | 92 | 1.89e-01 | -7.93e-02 | 3.91e-01 |
| G alpha (q) signalling events | 139 | 1.07e-01 | -7.92e-02 | 2.75e-01 |
| Activation of the phototransduction cascade | 8 | 6.98e-01 | -7.91e-02 | 8.37e-01 |
| Reversal of alkylation damage by DNA dioxygenases | 7 | 7.19e-01 | 7.85e-02 | 8.51e-01 |
| Fibronectin matrix formation | 6 | 7.39e-01 | -7.85e-02 | 8.64e-01 |
| MET activates PTK2 signaling | 21 | 5.35e-01 | -7.83e-02 | 7.34e-01 |
| Signaling by Hippo | 18 | 5.66e-01 | -7.82e-02 | 7.54e-01 |
| Gene expression (Transcription) | 1391 | 1.05e-06 | -7.82e-02 | 2.58e-05 |
| Signaling by FGFR1 | 42 | 3.81e-01 | -7.81e-02 | 5.96e-01 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | 8 | 7.03e-01 | -7.79e-02 | 8.40e-01 |
| Heme degradation | 10 | 6.70e-01 | 7.79e-02 | 8.22e-01 |
| Transport of inorganic cations/anions and amino acids/oligopeptides | 78 | 2.35e-01 | -7.78e-02 | 4.43e-01 |
| GRB2 events in EGFR signaling | 10 | 6.71e-01 | -7.76e-02 | 8.22e-01 |
| SHC1 events in EGFR signaling | 11 | 6.57e-01 | -7.74e-02 | 8.15e-01 |
| Inactivation, recovery and regulation of the phototransduction cascade | 25 | 5.04e-01 | -7.73e-02 | 7.12e-01 |
| TNF signaling | 56 | 3.17e-01 | -7.73e-02 | 5.28e-01 |
| Uptake and actions of bacterial toxins | 27 | 4.87e-01 | -7.72e-02 | 6.97e-01 |
| PCNA-Dependent Long Patch Base Excision Repair | 21 | 5.41e-01 | 7.70e-02 | 7.38e-01 |
| Association of TriC/CCT with target proteins during biosynthesis | 35 | 4.34e-01 | -7.64e-02 | 6.45e-01 |
| Signaling by NTRK1 (TRKA) | 102 | 1.83e-01 | -7.64e-02 | 3.84e-01 |
| Class I peroxisomal membrane protein import | 20 | 5.55e-01 | -7.62e-02 | 7.49e-01 |
| Adrenaline,noradrenaline inhibits insulin secretion | 24 | 5.19e-01 | -7.60e-02 | 7.25e-01 |
| Listeria monocytogenes entry into host cells | 17 | 5.88e-01 | -7.58e-02 | 7.71e-01 |
| Release of apoptotic factors from the mitochondria | 6 | 7.48e-01 | -7.58e-02 | 8.67e-01 |
| Diseases of branched-chain amino acid catabolism | 13 | 6.37e-01 | -7.56e-02 | 8.03e-01 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | 66 | 2.89e-01 | -7.55e-02 | 4.99e-01 |
| Inositol phosphate metabolism | 42 | 3.97e-01 | -7.55e-02 | 6.09e-01 |
| SARS-CoV-1 Infection | 137 | 1.28e-01 | -7.53e-02 | 3.07e-01 |
| Post-translational modification: synthesis of GPI-anchored proteins | 57 | 3.27e-01 | 7.51e-02 | 5.38e-01 |
| MAP kinase activation | 63 | 3.03e-01 | -7.50e-02 | 5.13e-01 |
| Alpha-oxidation of phytanate | 6 | 7.53e-01 | 7.41e-02 | 8.70e-01 |
| Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA | 6 | 7.54e-01 | 7.40e-02 | 8.70e-01 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | 25 | 5.23e-01 | 7.39e-02 | 7.27e-01 |
| Formation of the cornified envelope | 33 | 4.63e-01 | -7.38e-02 | 6.72e-01 |
| CaM pathway | 27 | 5.07e-01 | -7.37e-02 | 7.13e-01 |
| Calmodulin induced events | 27 | 5.07e-01 | -7.37e-02 | 7.13e-01 |
| Vitamin B2 (riboflavin) metabolism | 6 | 7.55e-01 | 7.37e-02 | 8.71e-01 |
| Role of second messengers in netrin-1 signaling | 6 | 7.55e-01 | -7.34e-02 | 8.71e-01 |
| Regulation of Expression and Function of Type II Classical Cadherins | 23 | 5.42e-01 | -7.34e-02 | 7.38e-01 |
| Regulation of Homotypic Cell-Cell Adhesion | 23 | 5.42e-01 | -7.34e-02 | 7.38e-01 |
| Degradation of the extracellular matrix | 92 | 2.24e-01 | -7.33e-02 | 4.32e-01 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | 28 | 5.02e-01 | 7.33e-02 | 7.11e-01 |
| Regulation of FZD by ubiquitination | 15 | 6.25e-01 | -7.28e-02 | 7.95e-01 |
| Diseases associated with N-glycosylation of proteins | 20 | 5.73e-01 | 7.28e-02 | 7.58e-01 |
| Platelet Aggregation (Plug Formation) | 28 | 5.08e-01 | -7.23e-02 | 7.14e-01 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | 13 | 6.52e-01 | 7.23e-02 | 8.12e-01 |
| Developmental Biology | 906 | 2.30e-04 | -7.22e-02 | 2.29e-03 |
| Biosynthesis of specialized proresolving mediators (SPMs) | 15 | 6.29e-01 | -7.21e-02 | 7.98e-01 |
| HDMs demethylate histones | 22 | 5.58e-01 | -7.21e-02 | 7.49e-01 |
| Coenzyme A biosynthesis | 7 | 7.42e-01 | -7.19e-02 | 8.64e-01 |
| Regulation of gene expression in beta cells | 7 | 7.43e-01 | -7.17e-02 | 8.64e-01 |
| Regulation of TP53 Degradation | 35 | 4.63e-01 | -7.17e-02 | 6.72e-01 |
| Diseases associated with the TLR signaling cascade | 29 | 5.05e-01 | -7.15e-02 | 7.13e-01 |
| Diseases of Immune System | 29 | 5.05e-01 | -7.15e-02 | 7.13e-01 |
| Defensins | 8 | 7.26e-01 | 7.15e-02 | 8.56e-01 |
| Transcription of the HIV genome | 67 | 3.12e-01 | -7.14e-02 | 5.22e-01 |
| Transferrin endocytosis and recycling | 26 | 5.28e-01 | -7.14e-02 | 7.30e-01 |
| Drug ADME | 55 | 3.61e-01 | -7.12e-02 | 5.76e-01 |
| SUMOylation of intracellular receptors | 26 | 5.32e-01 | 7.08e-02 | 7.32e-01 |
| MECP2 regulates transcription factors | 5 | 7.84e-01 | -7.07e-02 | 8.88e-01 |
| Amino acid transport across the plasma membrane | 24 | 5.50e-01 | -7.05e-02 | 7.44e-01 |
| SARS-CoV-1 activates/modulates innate immune responses | 40 | 4.42e-01 | -7.03e-02 | 6.52e-01 |
| Cellular responses to stimuli | 776 | 8.79e-04 | -7.02e-02 | 7.25e-03 |
| TGFBR3 regulates TGF-beta signaling | 8 | 7.31e-01 | -7.01e-02 | 8.58e-01 |
| LDL clearance | 18 | 6.13e-01 | 6.89e-02 | 7.92e-01 |
| Early Phase of HIV Life Cycle | 14 | 6.55e-01 | 6.89e-02 | 8.15e-01 |
| Signaling by LTK | 10 | 7.06e-01 | -6.88e-02 | 8.42e-01 |
| DNA strand elongation | 32 | 5.01e-01 | -6.88e-02 | 7.10e-01 |
| Glycosphingolipid transport | 7 | 7.54e-01 | 6.84e-02 | 8.70e-01 |
| CASP8 activity is inhibited | 11 | 6.95e-01 | -6.83e-02 | 8.35e-01 |
| Dimerization of procaspase-8 | 11 | 6.95e-01 | -6.83e-02 | 8.35e-01 |
| Regulation by c-FLIP | 11 | 6.95e-01 | -6.83e-02 | 8.35e-01 |
| Sensory perception of taste | 23 | 5.71e-01 | 6.82e-02 | 7.58e-01 |
| Transport of small molecules | 548 | 6.35e-03 | -6.82e-02 | 3.62e-02 |
| HDR through Homologous Recombination (HRR) | 68 | 3.31e-01 | -6.81e-02 | 5.44e-01 |
| Voltage gated Potassium channels | 26 | 5.50e-01 | 6.77e-02 | 7.44e-01 |
| Cell junction organization | 77 | 3.04e-01 | -6.77e-02 | 5.14e-01 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | 25 | 5.58e-01 | 6.76e-02 | 7.49e-01 |
| Defective RIPK1-mediated regulated necrosis | 7 | 7.57e-01 | -6.75e-02 | 8.71e-01 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | 12 | 6.86e-01 | -6.75e-02 | 8.34e-01 |
| Citric acid cycle (TCA cycle) | 34 | 4.97e-01 | -6.73e-02 | 7.07e-01 |
| FGFRL1 modulation of FGFR1 signaling | 7 | 7.58e-01 | -6.72e-02 | 8.71e-01 |
| HDACs deacetylate histones | 45 | 4.38e-01 | -6.69e-02 | 6.48e-01 |
| DNA Damage Recognition in GG-NER | 38 | 4.76e-01 | 6.68e-02 | 6.86e-01 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 84 | 2.90e-01 | -6.68e-02 | 4.99e-01 |
| FGFR2 ligand binding and activation | 9 | 7.30e-01 | 6.65e-02 | 8.57e-01 |
| Nervous system development | 473 | 1.33e-02 | -6.64e-02 | 6.39e-02 |
| Interleukin-17 signaling | 68 | 3.45e-01 | -6.62e-02 | 5.57e-01 |
| Recognition of DNA damage by PCNA-containing replication complex | 30 | 5.30e-01 | -6.62e-02 | 7.31e-01 |
| Assembly and cell surface presentation of NMDA receptors | 30 | 5.31e-01 | 6.62e-02 | 7.31e-01 |
| Regulation of PTEN gene transcription | 59 | 3.80e-01 | 6.61e-02 | 5.95e-01 |
| Ovarian tumor domain proteases | 37 | 4.87e-01 | -6.61e-02 | 6.97e-01 |
| mRNA Splicing - Minor Pathway | 50 | 4.19e-01 | 6.61e-02 | 6.30e-01 |
| G alpha (i) signalling events | 196 | 1.12e-01 | -6.58e-02 | 2.83e-01 |
| Axon guidance | 455 | 1.62e-02 | -6.58e-02 | 7.41e-02 |
| Hyaluronan uptake and degradation | 12 | 6.93e-01 | 6.58e-02 | 8.35e-01 |
| Adipogenesis | 95 | 2.71e-01 | -6.53e-02 | 4.79e-01 |
| Metabolism of porphyrins | 22 | 5.96e-01 | 6.52e-02 | 7.78e-01 |
| Senescence-Associated Secretory Phenotype (SASP) | 64 | 3.67e-01 | -6.52e-02 | 5.81e-01 |
| Sema4D induced cell migration and growth-cone collapse | 19 | 6.23e-01 | -6.51e-02 | 7.94e-01 |
| Peroxisomal lipid metabolism | 27 | 5.63e-01 | -6.44e-02 | 7.52e-01 |
| Diseases associated with O-glycosylation of proteins | 46 | 4.51e-01 | 6.42e-02 | 6.60e-01 |
| Fatty acid metabolism | 152 | 1.73e-01 | -6.40e-02 | 3.70e-01 |
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | 16 | 6.58e-01 | 6.38e-02 | 8.17e-01 |
| Ion channel transport | 136 | 2.00e-01 | -6.37e-02 | 4.00e-01 |
| Metabolism of water-soluble vitamins and cofactors | 114 | 2.40e-01 | -6.37e-02 | 4.47e-01 |
| Lagging Strand Synthesis | 20 | 6.22e-01 | 6.36e-02 | 7.94e-01 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | 20 | 6.24e-01 | 6.33e-02 | 7.94e-01 |
| Phospholipid metabolism | 182 | 1.42e-01 | -6.32e-02 | 3.26e-01 |
| Prevention of phagosomal-lysosomal fusion | 9 | 7.43e-01 | -6.31e-02 | 8.65e-01 |
| Pausing and recovery of Tat-mediated HIV elongation | 30 | 5.51e-01 | 6.29e-02 | 7.44e-01 |
| Tat-mediated HIV elongation arrest and recovery | 30 | 5.51e-01 | 6.29e-02 | 7.44e-01 |
| FRS-mediated FGFR1 signaling | 15 | 6.74e-01 | -6.28e-02 | 8.25e-01 |
| Processing of SMDT1 | 15 | 6.74e-01 | 6.27e-02 | 8.25e-01 |
| Signaling by NOTCH3 | 42 | 4.82e-01 | -6.27e-02 | 6.92e-01 |
| Organic anion transporters | 7 | 7.74e-01 | 6.26e-02 | 8.82e-01 |
| Signaling by NOTCH2 | 33 | 5.37e-01 | 6.21e-02 | 7.35e-01 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | 10 | 7.34e-01 | 6.20e-02 | 8.60e-01 |
| Transcriptional activation of mitochondrial biogenesis | 52 | 4.40e-01 | -6.19e-02 | 6.51e-01 |
| Cytoprotection by HMOX1 | 53 | 4.37e-01 | -6.18e-02 | 6.47e-01 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models | 21 | 6.24e-01 | 6.17e-02 | 7.94e-01 |
| Neurodegenerative Diseases | 21 | 6.24e-01 | 6.17e-02 | 7.94e-01 |
| Death Receptor Signaling | 145 | 2.00e-01 | -6.17e-02 | 4.00e-01 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | 5 | 8.12e-01 | 6.16e-02 | 9.00e-01 |
| Energy dependent regulation of mTOR by LKB1-AMPK | 27 | 5.81e-01 | -6.14e-02 | 7.65e-01 |
| RHO GTPases Activate Rhotekin and Rhophilins | 8 | 7.64e-01 | 6.14e-02 | 8.75e-01 |
| Sperm Motility And Taxes | 6 | 7.95e-01 | 6.13e-02 | 8.91e-01 |
| Transport of bile salts and organic acids, metal ions and amine compounds | 51 | 4.52e-01 | -6.09e-02 | 6.60e-01 |
| Activation of HOX genes during differentiation | 68 | 3.86e-01 | -6.08e-02 | 5.99e-01 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | 68 | 3.86e-01 | -6.08e-02 | 5.99e-01 |
| Lewis blood group biosynthesis | 13 | 7.05e-01 | 6.07e-02 | 8.41e-01 |
| Syndecan interactions | 23 | 6.15e-01 | 6.05e-02 | 7.92e-01 |
| Mitochondrial tRNA aminoacylation | 21 | 6.31e-01 | 6.05e-02 | 7.98e-01 |
| Transmission across Chemical Synapses | 179 | 1.63e-01 | -6.05e-02 | 3.56e-01 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | 23 | 6.17e-01 | -6.02e-02 | 7.92e-01 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | 8 | 7.69e-01 | -5.99e-02 | 8.79e-01 |
| SARS-CoV-2-host interactions | 181 | 1.67e-01 | 5.95e-02 | 3.63e-01 |
| Carnitine shuttle | 12 | 7.21e-01 | 5.95e-02 | 8.52e-01 |
| STING mediated induction of host immune responses | 15 | 6.91e-01 | 5.94e-02 | 8.34e-01 |
| MyD88 cascade initiated on plasma membrane | 95 | 3.18e-01 | -5.93e-02 | 5.28e-01 |
| Toll Like Receptor 10 (TLR10) Cascade | 95 | 3.18e-01 | -5.93e-02 | 5.28e-01 |
| Toll Like Receptor 5 (TLR5) Cascade | 95 | 3.18e-01 | -5.93e-02 | 5.28e-01 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | 21 | 6.39e-01 | -5.91e-02 | 8.04e-01 |
| Lysosome Vesicle Biogenesis | 32 | 5.64e-01 | -5.90e-02 | 7.53e-01 |
| Regulation of beta-cell development | 21 | 6.41e-01 | 5.88e-02 | 8.06e-01 |
| RND2 GTPase cycle | 36 | 5.42e-01 | -5.88e-02 | 7.38e-01 |
| Molybdenum cofactor biosynthesis | 6 | 8.04e-01 | -5.85e-02 | 8.97e-01 |
| Nef Mediated CD4 Down-regulation | 9 | 7.62e-01 | 5.83e-02 | 8.74e-01 |
| Metabolism of nucleotides | 86 | 3.50e-01 | -5.83e-02 | 5.64e-01 |
| Transcriptional Regulation by TP53 | 343 | 6.41e-02 | -5.82e-02 | 2.05e-01 |
| Nicotinamide salvaging | 15 | 6.97e-01 | -5.81e-02 | 8.37e-01 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | 24 | 6.23e-01 | -5.80e-02 | 7.94e-01 |
| Biosynthesis of DHA-derived SPMs | 13 | 7.18e-01 | 5.79e-02 | 8.51e-01 |
| CD163 mediating an anti-inflammatory response | 8 | 7.77e-01 | 5.79e-02 | 8.83e-01 |
| Epigenetic regulation of gene expression | 263 | 1.09e-01 | -5.75e-02 | 2.78e-01 |
| Activated point mutants of FGFR2 | 7 | 7.93e-01 | -5.73e-02 | 8.91e-01 |
| Fertilization | 12 | 7.31e-01 | 5.73e-02 | 8.58e-01 |
| Signaling by FGFR2 in disease | 33 | 5.73e-01 | -5.67e-02 | 7.58e-01 |
| Negative regulation of MAPK pathway | 42 | 5.26e-01 | -5.66e-02 | 7.30e-01 |
| CaMK IV-mediated phosphorylation of CREB | 8 | 7.82e-01 | -5.66e-02 | 8.87e-01 |
| Phase II - Conjugation of compounds | 68 | 4.20e-01 | -5.66e-02 | 6.30e-01 |
| PTK6 Regulates Cell Cycle | 6 | 8.11e-01 | -5.65e-02 | 8.99e-01 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | 13 | 7.24e-01 | -5.65e-02 | 8.54e-01 |
| GPCR downstream signalling | 396 | 5.43e-02 | -5.64e-02 | 1.84e-01 |
| RNA Pol II CTD phosphorylation and interaction with CE | 27 | 6.14e-01 | -5.61e-02 | 7.92e-01 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | 27 | 6.14e-01 | -5.61e-02 | 7.92e-01 |
| Translesion synthesis by POLK | 17 | 6.89e-01 | -5.61e-02 | 8.34e-01 |
| Alternative complement activation | 5 | 8.28e-01 | 5.60e-02 | 9.09e-01 |
| SUMOylation of DNA replication proteins | 46 | 5.12e-01 | 5.58e-02 | 7.17e-01 |
| Mitochondrial biogenesis | 91 | 3.58e-01 | -5.57e-02 | 5.73e-01 |
| Extracellular matrix organization | 213 | 1.63e-01 | -5.54e-02 | 3.56e-01 |
| Cargo recognition for clathrin-mediated endocytosis | 88 | 3.71e-01 | -5.52e-02 | 5.86e-01 |
| Signaling by ERBB2 KD Mutants | 20 | 6.70e-01 | -5.51e-02 | 8.22e-01 |
| Synthesis of pyrophosphates in the cytosol | 8 | 7.87e-01 | -5.51e-02 | 8.88e-01 |
| FGFR1b ligand binding and activation | 5 | 8.32e-01 | 5.49e-02 | 9.10e-01 |
| DNA Repair | 288 | 1.12e-01 | -5.45e-02 | 2.82e-01 |
| RNA Polymerase II Transcription Termination | 66 | 4.46e-01 | 5.43e-02 | 6.55e-01 |
| Beta-oxidation of very long chain fatty acids | 11 | 7.57e-01 | -5.39e-02 | 8.71e-01 |
| Cellular responses to stress | 694 | 1.60e-02 | -5.37e-02 | 7.36e-02 |
| TICAM1-dependent activation of IRF3/IRF7 | 13 | 7.38e-01 | -5.36e-02 | 8.63e-01 |
| Negative regulation of the PI3K/AKT network | 91 | 3.77e-01 | -5.36e-02 | 5.92e-01 |
| Toll Like Receptor 9 (TLR9) Cascade | 108 | 3.36e-01 | -5.36e-02 | 5.49e-01 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | 7 | 8.08e-01 | 5.31e-02 | 8.98e-01 |
| RNA polymerase II transcribes snRNA genes | 71 | 4.42e-01 | -5.28e-02 | 6.52e-01 |
| Reactions specific to the complex N-glycan synthesis pathway | 7 | 8.09e-01 | -5.27e-02 | 8.98e-01 |
| NFE2L2 regulating tumorigenic genes | 11 | 7.62e-01 | -5.27e-02 | 8.74e-01 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | 20 | 6.83e-01 | 5.27e-02 | 8.32e-01 |
| RHOQ GTPase cycle | 54 | 5.03e-01 | -5.27e-02 | 7.12e-01 |
| Aspartate and asparagine metabolism | 8 | 7.97e-01 | 5.24e-02 | 8.92e-01 |
| Polymerase switching on the C-strand of the telomere | 26 | 6.46e-01 | 5.21e-02 | 8.09e-01 |
| Synthesis of PA | 31 | 6.17e-01 | -5.19e-02 | 7.92e-01 |
| TNFs bind their physiological receptors | 25 | 6.54e-01 | -5.17e-02 | 8.14e-01 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | 23 | 6.71e-01 | 5.12e-02 | 8.22e-01 |
| PTK6 promotes HIF1A stabilization | 6 | 8.29e-01 | -5.11e-02 | 9.09e-01 |
| Glutamate Neurotransmitter Release Cycle | 20 | 6.93e-01 | -5.10e-02 | 8.35e-01 |
| NoRC negatively regulates rRNA expression | 60 | 4.94e-01 | -5.10e-02 | 7.04e-01 |
| Diseases associated with surfactant metabolism | 5 | 8.44e-01 | -5.10e-02 | 9.17e-01 |
| Intrinsic Pathway for Apoptosis | 53 | 5.21e-01 | -5.09e-02 | 7.26e-01 |
| Regulation of TP53 Expression and Degradation | 36 | 5.97e-01 | -5.09e-02 | 7.78e-01 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | 14 | 7.42e-01 | 5.08e-02 | 8.64e-01 |
| Paracetamol ADME | 19 | 7.02e-01 | 5.07e-02 | 8.40e-01 |
| Activation of NMDA receptors and postsynaptic events | 70 | 4.64e-01 | -5.07e-02 | 6.72e-01 |
| Signaling by Non-Receptor Tyrosine Kinases | 47 | 5.48e-01 | -5.06e-02 | 7.43e-01 |
| Signaling by PTK6 | 47 | 5.48e-01 | -5.06e-02 | 7.43e-01 |
| Adenylate cyclase inhibitory pathway | 11 | 7.72e-01 | 5.05e-02 | 8.79e-01 |
| Diseases of glycosylation | 104 | 3.74e-01 | 5.04e-02 | 5.90e-01 |
| Negative regulation of FGFR1 signaling | 25 | 6.63e-01 | -5.04e-02 | 8.19e-01 |
| DAG and IP3 signaling | 33 | 6.18e-01 | -5.02e-02 | 7.92e-01 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | 105 | 3.76e-01 | -5.00e-02 | 5.91e-01 |
| Assembly of active LPL and LIPC lipase complexes | 10 | 7.85e-01 | -4.99e-02 | 8.88e-01 |
| G-protein mediated events | 43 | 5.71e-01 | -4.99e-02 | 7.58e-01 |
| Regulation of CDH11 function | 9 | 7.96e-01 | -4.99e-02 | 8.91e-01 |
| Gene Silencing by RNA | 87 | 4.23e-01 | -4.97e-02 | 6.33e-01 |
| PD-1 signaling | 28 | 6.50e-01 | 4.96e-02 | 8.12e-01 |
| Plasma lipoprotein assembly, remodeling, and clearance | 56 | 5.21e-01 | 4.96e-02 | 7.26e-01 |
| MicroRNA (miRNA) biogenesis | 24 | 6.75e-01 | 4.94e-02 | 8.25e-01 |
| Endogenous sterols | 17 | 7.25e-01 | 4.94e-02 | 8.54e-01 |
| IRE1alpha activates chaperones | 46 | 5.64e-01 | -4.92e-02 | 7.53e-01 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | 13 | 7.60e-01 | 4.89e-02 | 8.72e-01 |
| Inflammasomes | 21 | 6.99e-01 | 4.87e-02 | 8.37e-01 |
| Keratinization | 34 | 6.23e-01 | -4.87e-02 | 7.94e-01 |
| mRNA 3’-end processing | 57 | 5.28e-01 | 4.83e-02 | 7.30e-01 |
| MAPK targets/ Nuclear events mediated by MAP kinases | 31 | 6.42e-01 | -4.82e-02 | 8.06e-01 |
| FasL/ CD95L signaling | 5 | 8.53e-01 | -4.80e-02 | 9.23e-01 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | 20 | 7.11e-01 | 4.79e-02 | 8.46e-01 |
| Metabolism of folate and pterines | 16 | 7.41e-01 | 4.78e-02 | 8.64e-01 |
| Vitamin D (calciferol) metabolism | 10 | 7.94e-01 | -4.77e-02 | 8.91e-01 |
| SARS-CoV-2 Infection | 263 | 1.89e-01 | -4.71e-02 | 3.91e-01 |
| Cation-coupled Chloride cotransporters | 6 | 8.42e-01 | 4.71e-02 | 9.16e-01 |
| Regulation of FOXO transcriptional activity by acetylation | 10 | 7.97e-01 | 4.71e-02 | 8.92e-01 |
| Nuclear signaling by ERBB4 | 24 | 6.91e-01 | 4.68e-02 | 8.34e-01 |
| SUMOylation of transcription cofactors | 44 | 5.92e-01 | 4.67e-02 | 7.74e-01 |
| Collagen biosynthesis and modifying enzymes | 45 | 5.93e-01 | -4.61e-02 | 7.74e-01 |
| Regulation of TNFR1 signaling | 47 | 5.85e-01 | -4.61e-02 | 7.67e-01 |
| Respiratory electron transport | 149 | 3.33e-01 | 4.60e-02 | 5.45e-01 |
| WNT ligand biogenesis and trafficking | 20 | 7.22e-01 | -4.60e-02 | 8.52e-01 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | 38 | 6.24e-01 | -4.60e-02 | 7.94e-01 |
| Regulation of expression of SLITs and ROBOs | 149 | 3.33e-01 | 4.60e-02 | 5.45e-01 |
| TRIF-mediated programmed cell death | 9 | 8.12e-01 | -4.58e-02 | 9.00e-01 |
| Pyrimidine salvage | 10 | 8.02e-01 | -4.57e-02 | 8.96e-01 |
| Transport of RCbl within the body | 8 | 8.24e-01 | -4.55e-02 | 9.08e-01 |
| Aflatoxin activation and detoxification | 14 | 7.69e-01 | -4.54e-02 | 8.79e-01 |
| Regulated proteolysis of p75NTR | 11 | 7.95e-01 | -4.52e-02 | 8.91e-01 |
| Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA | 5 | 8.62e-01 | 4.50e-02 | 9.28e-01 |
| Suppression of apoptosis | 7 | 8.37e-01 | -4.50e-02 | 9.13e-01 |
| HIV elongation arrest and recovery | 32 | 6.61e-01 | 4.48e-02 | 8.18e-01 |
| Pausing and recovery of HIV elongation | 32 | 6.61e-01 | 4.48e-02 | 8.18e-01 |
| Signaling by FGFR2 | 61 | 5.49e-01 | -4.43e-02 | 7.44e-01 |
| Removal of the Flap Intermediate | 14 | 7.76e-01 | -4.40e-02 | 8.82e-01 |
| FGFR4 ligand binding and activation | 5 | 8.65e-01 | 4.38e-02 | 9.30e-01 |
| Global Genome Nucleotide Excision Repair (GG-NER) | 84 | 4.88e-01 | 4.38e-02 | 6.98e-01 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | 9 | 8.20e-01 | -4.38e-02 | 9.07e-01 |
| PI-3K cascade:FGFR1 | 13 | 7.86e-01 | -4.35e-02 | 8.88e-01 |
| Formation of WDR5-containing histone-modifying complexes | 42 | 6.26e-01 | 4.35e-02 | 7.95e-01 |
| Late Phase of HIV Life Cycle | 131 | 3.91e-01 | -4.34e-02 | 6.03e-01 |
| Signaling by GPCR | 441 | 1.20e-01 | -4.33e-02 | 2.91e-01 |
| NGF-stimulated transcription | 32 | 6.75e-01 | 4.28e-02 | 8.25e-01 |
| Nucleotide Excision Repair | 108 | 4.45e-01 | 4.26e-02 | 6.55e-01 |
| NFE2L2 regulating MDR associated enzymes | 8 | 8.36e-01 | -4.24e-02 | 9.13e-01 |
| MyD88 dependent cascade initiated on endosome | 101 | 4.62e-01 | -4.24e-02 | 6.71e-01 |
| Regulation of NFE2L2 gene expression | 8 | 8.36e-01 | 4.23e-02 | 9.13e-01 |
| Signaling by ERBB2 | 44 | 6.28e-01 | -4.23e-02 | 7.97e-01 |
| Extension of Telomeres | 51 | 6.04e-01 | -4.19e-02 | 7.85e-01 |
| Methionine salvage pathway | 6 | 8.60e-01 | 4.16e-02 | 9.26e-01 |
| NOD1/2 Signaling Pathway | 36 | 6.71e-01 | -4.09e-02 | 8.22e-01 |
| Termination of translesion DNA synthesis | 32 | 6.89e-01 | -4.08e-02 | 8.34e-01 |
| Signaling by NODAL | 15 | 7.84e-01 | 4.08e-02 | 8.88e-01 |
| Pexophagy | 10 | 8.23e-01 | 4.08e-02 | 9.08e-01 |
| Defects in vitamin and cofactor metabolism | 21 | 7.48e-01 | -4.06e-02 | 8.67e-01 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | 42 | 6.51e-01 | 4.03e-02 | 8.12e-01 |
| HIV Transcription Elongation | 42 | 6.51e-01 | 4.03e-02 | 8.12e-01 |
| Tat-mediated elongation of the HIV-1 transcript | 42 | 6.51e-01 | 4.03e-02 | 8.12e-01 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | 15 | 7.89e-01 | -4.00e-02 | 8.89e-01 |
| Basigin interactions | 21 | 7.52e-01 | -3.99e-02 | 8.70e-01 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | 27 | 7.20e-01 | 3.99e-02 | 8.51e-01 |
| Branched-chain ketoacid dehydrogenase kinase deficiency | 5 | 8.77e-01 | 3.98e-02 | 9.36e-01 |
| Nuclear Pore Complex (NPC) Disassembly | 36 | 6.81e-01 | 3.96e-02 | 8.30e-01 |
| The phototransduction cascade | 26 | 7.28e-01 | -3.94e-02 | 8.57e-01 |
| FGFR2b ligand binding and activation | 6 | 8.67e-01 | -3.94e-02 | 9.31e-01 |
| Negative feedback regulation of MAPK pathway | 6 | 8.68e-01 | 3.92e-02 | 9.31e-01 |
| FLT3 signaling through SRC family kinases | 6 | 8.68e-01 | -3.92e-02 | 9.31e-01 |
| SARS-CoV-1-host interactions | 94 | 5.12e-01 | 3.91e-02 | 7.17e-01 |
| Serotonin Neurotransmitter Release Cycle | 15 | 7.94e-01 | 3.90e-02 | 8.91e-01 |
| Dual Incision in GG-NER | 41 | 6.67e-01 | 3.89e-02 | 8.22e-01 |
| Glycolysis | 68 | 5.82e-01 | -3.86e-02 | 7.65e-01 |
| Formation of TC-NER Pre-Incision Complex | 51 | 6.34e-01 | -3.85e-02 | 8.00e-01 |
| Sema4D in semaphorin signaling | 22 | 7.58e-01 | -3.80e-02 | 8.71e-01 |
| Biosynthesis of E-series 18(S)-resolvins | 5 | 8.84e-01 | -3.78e-02 | 9.38e-01 |
| p75 NTR receptor-mediated signalling | 89 | 5.41e-01 | -3.75e-02 | 7.38e-01 |
| Positive epigenetic regulation of rRNA expression | 60 | 6.16e-01 | 3.74e-02 | 7.92e-01 |
| Heme signaling | 45 | 6.66e-01 | -3.72e-02 | 8.22e-01 |
| Metabolism of vitamins and cofactors | 163 | 4.13e-01 | -3.71e-02 | 6.27e-01 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | 13 | 8.17e-01 | -3.71e-02 | 9.05e-01 |
| RMTs methylate histone arginines | 35 | 7.05e-01 | 3.70e-02 | 8.41e-01 |
| Metal ion SLC transporters | 19 | 7.80e-01 | -3.70e-02 | 8.86e-01 |
| Complex IV assembly | 45 | 6.70e-01 | 3.68e-02 | 8.22e-01 |
| Negative epigenetic regulation of rRNA expression | 63 | 6.16e-01 | -3.66e-02 | 7.92e-01 |
| Cell death signalling via NRAGE, NRIF and NADE | 69 | 6.02e-01 | -3.64e-02 | 7.82e-01 |
| Recycling of eIF2:GDP | 8 | 8.59e-01 | -3.63e-02 | 9.26e-01 |
| GABA synthesis, release, reuptake and degradation | 12 | 8.29e-01 | -3.60e-02 | 9.09e-01 |
| Class A/1 (Rhodopsin-like receptors) | 176 | 4.10e-01 | -3.60e-02 | 6.24e-01 |
| PI3K/AKT Signaling in Cancer | 83 | 5.74e-01 | 3.57e-02 | 7.58e-01 |
| RIP-mediated NFkB activation via ZBP1 | 17 | 7.99e-01 | 3.56e-02 | 8.93e-01 |
| Biological oxidations | 135 | 4.80e-01 | 3.52e-02 | 6.90e-01 |
| Formation of ATP by chemiosmotic coupling | 20 | 7.85e-01 | -3.52e-02 | 8.88e-01 |
| HIV Life Cycle | 144 | 4.67e-01 | -3.51e-02 | 6.76e-01 |
| Constitutive Signaling by Aberrant PI3K in Cancer | 57 | 6.49e-01 | -3.49e-02 | 8.11e-01 |
| Myogenesis | 20 | 7.87e-01 | -3.49e-02 | 8.88e-01 |
| Carboxyterminal post-translational modifications of tubulin | 33 | 7.29e-01 | 3.48e-02 | 8.57e-01 |
| Insulin receptor signalling cascade | 40 | 7.05e-01 | -3.46e-02 | 8.41e-01 |
| Plasma lipoprotein remodeling | 18 | 8.00e-01 | 3.44e-02 | 8.94e-01 |
| Iron uptake and transport | 52 | 6.70e-01 | -3.42e-02 | 8.22e-01 |
| HCMV Infection | 106 | 5.45e-01 | -3.41e-02 | 7.41e-01 |
| Collagen formation | 63 | 6.45e-01 | -3.35e-02 | 8.09e-01 |
| Xenobiotics | 9 | 8.62e-01 | 3.34e-02 | 9.28e-01 |
| Protein localization | 157 | 4.74e-01 | 3.31e-02 | 6.84e-01 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 100 | 5.69e-01 | -3.30e-02 | 7.56e-01 |
| Modulation by Mtb of host immune system | 7 | 8.80e-01 | -3.29e-02 | 9.37e-01 |
| Sensory processing of sound by outer hair cells of the cochlea | 40 | 7.19e-01 | 3.29e-02 | 8.51e-01 |
| Methylation | 13 | 8.38e-01 | 3.28e-02 | 9.14e-01 |
| Acyl chain remodelling of PE | 19 | 8.05e-01 | 3.28e-02 | 8.97e-01 |
| NPAS4 regulates expression of target genes | 16 | 8.21e-01 | 3.27e-02 | 9.07e-01 |
| Glucose metabolism | 76 | 6.23e-01 | -3.26e-02 | 7.94e-01 |
| TYSND1 cleaves peroxisomal proteins | 7 | 8.82e-01 | -3.24e-02 | 9.38e-01 |
| Mitochondrial iron-sulfur cluster biogenesis | 13 | 8.40e-01 | 3.23e-02 | 9.16e-01 |
| O-linked glycosylation | 81 | 6.16e-01 | -3.23e-02 | 7.92e-01 |
| Organic cation transport | 8 | 8.75e-01 | 3.20e-02 | 9.35e-01 |
| Organic cation/anion/zwitterion transport | 8 | 8.75e-01 | 3.20e-02 | 9.35e-01 |
| ZBP1(DAI) mediated induction of type I IFNs | 20 | 8.05e-01 | 3.19e-02 | 8.97e-01 |
| Processing of Capped Intronless Pre-mRNA | 29 | 7.66e-01 | 3.19e-02 | 8.77e-01 |
| Metabolism | 1808 | 2.52e-02 | -3.18e-02 | 1.03e-01 |
| Complex I biogenesis | 66 | 6.56e-01 | 3.18e-02 | 8.15e-01 |
| Cytochrome P450 - arranged by substrate type | 33 | 7.53e-01 | -3.17e-02 | 8.70e-01 |
| TNFR1-induced NF-kappa-B signaling pathway | 32 | 7.57e-01 | -3.16e-02 | 8.71e-01 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | 53 | 6.91e-01 | 3.16e-02 | 8.34e-01 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | 53 | 6.91e-01 | 3.16e-02 | 8.34e-01 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | 53 | 6.91e-01 | 3.16e-02 | 8.34e-01 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | 53 | 6.91e-01 | 3.16e-02 | 8.34e-01 |
| Signaling by NOTCH1 in Cancer | 53 | 6.91e-01 | 3.16e-02 | 8.34e-01 |
| Chemokine receptors bind chemokines | 39 | 7.33e-01 | 3.15e-02 | 8.60e-01 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | 11 | 8.56e-01 | -3.15e-02 | 9.25e-01 |
| Hydrolysis of LPC | 8 | 8.78e-01 | 3.14e-02 | 9.36e-01 |
| Phenylalanine and tyrosine metabolism | 9 | 8.71e-01 | 3.13e-02 | 9.32e-01 |
| PKMTs methylate histone lysines | 42 | 7.27e-01 | -3.12e-02 | 8.56e-01 |
| Na+/Cl- dependent neurotransmitter transporters | 7 | 8.87e-01 | -3.11e-02 | 9.39e-01 |
| Diseases associated with glycosylation precursor biosynthesis | 15 | 8.35e-01 | 3.10e-02 | 9.13e-01 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | 12 | 8.53e-01 | -3.09e-02 | 9.23e-01 |
| Purine catabolism | 16 | 8.31e-01 | 3.08e-02 | 9.10e-01 |
| Formation of definitive endoderm | 8 | 8.80e-01 | -3.07e-02 | 9.37e-01 |
| GPCR ligand binding | 241 | 4.12e-01 | -3.07e-02 | 6.26e-01 |
| Effects of PIP2 hydrolysis | 24 | 7.95e-01 | 3.06e-02 | 8.91e-01 |
| Generation of second messenger molecules | 38 | 7.51e-01 | 2.98e-02 | 8.70e-01 |
| SUMOylation | 167 | 5.10e-01 | -2.95e-02 | 7.16e-01 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | 15 | 8.46e-01 | -2.90e-02 | 9.19e-01 |
| Glyoxylate metabolism and glycine degradation | 13 | 8.57e-01 | -2.89e-02 | 9.25e-01 |
| Telomere C-strand (Lagging Strand) Synthesis | 34 | 7.71e-01 | 2.88e-02 | 8.79e-01 |
| XBP1(S) activates chaperone genes | 44 | 7.41e-01 | -2.88e-02 | 8.64e-01 |
| Cell-cell junction organization | 56 | 7.12e-01 | 2.86e-02 | 8.46e-01 |
| Regulation of MITF-M-dependent genes involved in pigmentation | 35 | 7.70e-01 | 2.85e-02 | 8.79e-01 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | 35 | 7.71e-01 | 2.85e-02 | 8.79e-01 |
| FGFR2 mutant receptor activation | 23 | 8.14e-01 | 2.84e-02 | 9.02e-01 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | 32 | 7.82e-01 | -2.83e-02 | 8.87e-01 |
| Formation of HIV elongation complex in the absence of HIV Tat | 44 | 7.46e-01 | 2.82e-02 | 8.67e-01 |
| Metabolism of steroid hormones | 21 | 8.23e-01 | 2.81e-02 | 9.08e-01 |
| SLC-mediated transmembrane transport | 171 | 5.28e-01 | -2.80e-02 | 7.30e-01 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | 21 | 8.26e-01 | -2.77e-02 | 9.08e-01 |
| CD28 co-stimulation | 33 | 7.85e-01 | -2.74e-02 | 8.88e-01 |
| Defects of platelet adhesion to exposed collagen | 6 | 9.08e-01 | -2.73e-02 | 9.52e-01 |
| FLT3 signaling by CBL mutants | 7 | 9.00e-01 | 2.73e-02 | 9.47e-01 |
| TP53 Regulates Transcription of DNA Repair Genes | 61 | 7.14e-01 | -2.71e-02 | 8.49e-01 |
| Metabolism of RNA | 717 | 2.17e-01 | 2.71e-02 | 4.21e-01 |
| Biosynthesis of EPA-derived SPMs | 6 | 9.09e-01 | 2.70e-02 | 9.53e-01 |
| Metabolic disorders of biological oxidation enzymes | 23 | 8.25e-01 | 2.66e-02 | 9.08e-01 |
| Dual incision in TC-NER | 63 | 7.16e-01 | -2.65e-02 | 8.51e-01 |
| RNA Polymerase I Promoter Clearance | 64 | 7.18e-01 | 2.61e-02 | 8.51e-01 |
| RNA Polymerase I Transcription | 64 | 7.18e-01 | 2.61e-02 | 8.51e-01 |
| Unfolded Protein Response (UPR) | 84 | 6.83e-01 | -2.58e-02 | 8.32e-01 |
| Stimuli-sensing channels | 78 | 6.97e-01 | -2.55e-02 | 8.37e-01 |
| Activation of Matrix Metalloproteinases | 20 | 8.44e-01 | 2.55e-02 | 9.17e-01 |
| PLC beta mediated events | 39 | 7.83e-01 | -2.54e-02 | 8.88e-01 |
| Signaling by FGFR2 IIIa TM | 18 | 8.52e-01 | -2.54e-02 | 9.23e-01 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | 14 | 8.70e-01 | 2.53e-02 | 9.31e-01 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | 14 | 8.70e-01 | 2.53e-02 | 9.31e-01 |
| Neurotransmitter release cycle | 38 | 7.88e-01 | -2.52e-02 | 8.89e-01 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | 11 | 8.86e-01 | -2.50e-02 | 9.39e-01 |
| IGF1R signaling cascade | 37 | 7.94e-01 | -2.48e-02 | 8.91e-01 |
| IRS-mediated signalling | 35 | 7.99e-01 | -2.48e-02 | 8.93e-01 |
| Formation of the Early Elongation Complex | 33 | 8.06e-01 | 2.47e-02 | 8.97e-01 |
| Formation of the HIV-1 Early Elongation Complex | 33 | 8.06e-01 | 2.47e-02 | 8.97e-01 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | 20 | 8.49e-01 | 2.46e-02 | 9.22e-01 |
| Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580 K2555) Translocation Mutant | 6 | 9.17e-01 | 2.45e-02 | 9.57e-01 |
| Signaling by NOTCH1 t(7;9)(NOTCH1:M1580 K2555) Translocation Mutant | 6 | 9.17e-01 | 2.45e-02 | 9.57e-01 |
| Metabolism of cofactors | 25 | 8.32e-01 | 2.45e-02 | 9.10e-01 |
| Retrograde neurotrophin signalling | 12 | 8.83e-01 | -2.45e-02 | 9.38e-01 |
| Glutamate and glutamine metabolism | 12 | 8.84e-01 | -2.43e-02 | 9.38e-01 |
| Amino acids regulate mTORC1 | 48 | 7.71e-01 | 2.43e-02 | 8.79e-01 |
| Glycerophospholipid biosynthesis | 104 | 6.69e-01 | -2.42e-02 | 8.22e-01 |
| Telomere C-strand synthesis initiation | 13 | 8.80e-01 | 2.41e-02 | 9.37e-01 |
| TNFR1-mediated ceramide production | 6 | 9.20e-01 | 2.38e-02 | 9.57e-01 |
| HSF1-dependent transactivation | 28 | 8.28e-01 | 2.37e-02 | 9.09e-01 |
| Sensory processing of sound | 57 | 7.57e-01 | -2.37e-02 | 8.71e-01 |
| Formation of axial mesoderm | 6 | 9.20e-01 | 2.36e-02 | 9.57e-01 |
| Synthesis of wybutosine at G37 of tRNA(Phe) | 6 | 9.21e-01 | 2.35e-02 | 9.57e-01 |
| IRS-related events triggered by IGF1R | 36 | 8.08e-01 | -2.34e-02 | 8.98e-01 |
| mRNA Splicing | 211 | 5.62e-01 | -2.31e-02 | 7.52e-01 |
| APOBEC3G mediated resistance to HIV-1 infection | 5 | 9.29e-01 | -2.31e-02 | 9.62e-01 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | 22 | 8.51e-01 | 2.31e-02 | 9.23e-01 |
| SHC1 events in ERBB4 signaling | 10 | 9.00e-01 | 2.30e-02 | 9.47e-01 |
| Cytosolic sensors of pathogen-associated DNA | 63 | 7.53e-01 | 2.30e-02 | 8.70e-01 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | 73 | 7.36e-01 | 2.28e-02 | 8.62e-01 |
| SHC1 events in ERBB2 signaling | 17 | 8.72e-01 | -2.26e-02 | 9.32e-01 |
| ECM proteoglycans | 45 | 7.94e-01 | 2.25e-02 | 8.91e-01 |
| Branched-chain amino acid catabolism | 21 | 8.60e-01 | -2.22e-02 | 9.26e-01 |
| Signaling by FGFR | 73 | 7.45e-01 | -2.20e-02 | 8.66e-01 |
| Cristae formation | 33 | 8.27e-01 | -2.19e-02 | 9.09e-01 |
| Diseases of programmed cell death | 58 | 7.75e-01 | -2.17e-02 | 8.82e-01 |
| Costimulation by the CD28 family | 74 | 7.47e-01 | -2.17e-02 | 8.67e-01 |
| Lysosphingolipid and LPA receptors | 11 | 9.01e-01 | -2.16e-02 | 9.48e-01 |
| Urea cycle | 6 | 9.28e-01 | 2.14e-02 | 9.62e-01 |
| VEGF binds to VEGFR leading to receptor dimerization | 5 | 9.34e-01 | 2.13e-02 | 9.64e-01 |
| VEGF ligand-receptor interactions | 5 | 9.34e-01 | 2.13e-02 | 9.64e-01 |
| Sensory Perception | 188 | 6.16e-01 | -2.12e-02 | 7.92e-01 |
| Diseases of metabolism | 198 | 6.09e-01 | 2.11e-02 | 7.90e-01 |
| B-WICH complex positively regulates rRNA expression | 45 | 8.07e-01 | 2.10e-02 | 8.98e-01 |
| Signal attenuation | 9 | 9.13e-01 | 2.10e-02 | 9.54e-01 |
| Cellular response to heat stress | 92 | 7.28e-01 | 2.10e-02 | 8.57e-01 |
| Regulation of TP53 Activity | 151 | 6.60e-01 | -2.08e-02 | 8.18e-01 |
| Activated NOTCH1 Transmits Signal to the Nucleus | 27 | 8.53e-01 | -2.05e-02 | 9.23e-01 |
| Translesion synthesis by REV1 | 16 | 8.90e-01 | -1.99e-02 | 9.42e-01 |
| Processive synthesis on the lagging strand | 15 | 8.94e-01 | 1.98e-02 | 9.43e-01 |
| Neuronal System | 262 | 5.83e-01 | -1.97e-02 | 7.66e-01 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | 16 | 8.92e-01 | 1.97e-02 | 9.43e-01 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | 17 | 8.88e-01 | 1.97e-02 | 9.41e-01 |
| Regulation of HSF1-mediated heat shock response | 78 | 7.68e-01 | -1.93e-02 | 8.79e-01 |
| RA biosynthesis pathway | 13 | 9.05e-01 | 1.91e-02 | 9.50e-01 |
| tRNA Aminoacylation | 42 | 8.31e-01 | -1.91e-02 | 9.10e-01 |
| Glycosaminoglycan metabolism | 95 | 7.50e-01 | -1.89e-02 | 8.70e-01 |
| RHOBTB3 ATPase cycle | 10 | 9.18e-01 | 1.88e-02 | 9.57e-01 |
| Circadian Clock | 67 | 7.91e-01 | -1.87e-02 | 8.91e-01 |
| MTOR signalling | 39 | 8.41e-01 | -1.85e-02 | 9.16e-01 |
| NRAGE signals death through JNK | 52 | 8.18e-01 | -1.85e-02 | 9.05e-01 |
| Mitochondrial protein degradation | 96 | 7.58e-01 | 1.82e-02 | 8.71e-01 |
| SUMO E3 ligases SUMOylate target proteins | 161 | 6.92e-01 | -1.81e-02 | 8.34e-01 |
| TNFR1-induced proapoptotic signaling | 24 | 8.80e-01 | -1.79e-02 | 9.37e-01 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | 29 | 8.69e-01 | 1.77e-02 | 9.31e-01 |
| Nuclear Envelope Breakdown | 53 | 8.25e-01 | -1.76e-02 | 9.08e-01 |
| FOXO-mediated transcription of cell cycle genes | 14 | 9.10e-01 | -1.75e-02 | 9.53e-01 |
| Translesion Synthesis by POLH | 18 | 8.98e-01 | -1.75e-02 | 9.46e-01 |
| PI3K Cascade | 31 | 8.68e-01 | 1.73e-02 | 9.31e-01 |
| Relaxin receptors | 5 | 9.48e-01 | -1.69e-02 | 9.70e-01 |
| NCAM signaling for neurite out-growth | 47 | 8.42e-01 | -1.69e-02 | 9.16e-01 |
| HATs acetylate histones | 92 | 7.87e-01 | 1.63e-02 | 8.88e-01 |
| Endosomal/Vacuolar pathway | 11 | 9.25e-01 | 1.63e-02 | 9.61e-01 |
| KSRP (KHSRP) binds and destabilizes mRNA | 17 | 9.09e-01 | -1.60e-02 | 9.53e-01 |
| RNA Polymerase I Promoter Escape | 45 | 8.55e-01 | -1.58e-02 | 9.24e-01 |
| Glycosphingolipid metabolism | 47 | 8.54e-01 | -1.56e-02 | 9.23e-01 |
| SHC-mediated cascade:FGFR1 | 13 | 9.24e-01 | -1.53e-02 | 9.61e-01 |
| Phosphate bond hydrolysis by NUDT proteins | 7 | 9.44e-01 | 1.52e-02 | 9.68e-01 |
| Elastic fibre formation | 33 | 8.81e-01 | 1.51e-02 | 9.37e-01 |
| Free fatty acids regulate insulin secretion | 10 | 9.35e-01 | 1.49e-02 | 9.64e-01 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | 76 | 8.25e-01 | 1.47e-02 | 9.08e-01 |
| Retinoid metabolism and transport | 23 | 9.03e-01 | -1.46e-02 | 9.49e-01 |
| mRNA Splicing - Major Pathway | 203 | 7.20e-01 | -1.46e-02 | 8.51e-01 |
| Plasma lipoprotein assembly | 10 | 9.37e-01 | -1.45e-02 | 9.64e-01 |
| Translesion synthesis by POLI | 17 | 9.20e-01 | 1.41e-02 | 9.57e-01 |
| Aerobic respiration and respiratory electron transport | 245 | 7.07e-01 | -1.40e-02 | 8.42e-01 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | 21 | 9.13e-01 | 1.38e-02 | 9.54e-01 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | 11 | 9.38e-01 | 1.36e-02 | 9.64e-01 |
| Sphingolipid catabolism | 11 | 9.38e-01 | -1.35e-02 | 9.64e-01 |
| Metabolism of amino acids and derivatives | 304 | 6.87e-01 | 1.34e-02 | 8.34e-01 |
| Activation of RAC1 downstream of NMDARs | 7 | 9.52e-01 | -1.32e-02 | 9.72e-01 |
| Transcriptional regulation by small RNAs | 61 | 8.60e-01 | 1.31e-02 | 9.26e-01 |
| Histidine catabolism | 7 | 9.55e-01 | -1.24e-02 | 9.73e-01 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | 107 | 8.26e-01 | -1.23e-02 | 9.08e-01 |
| Caspase activation via Death Receptors in the presence of ligand | 16 | 9.33e-01 | -1.22e-02 | 9.64e-01 |
| WNT5A-dependent internalization of FZD4 | 13 | 9.40e-01 | -1.21e-02 | 9.65e-01 |
| mRNA Capping | 29 | 9.10e-01 | -1.21e-02 | 9.53e-01 |
| Formation of Incision Complex in GG-NER | 43 | 8.94e-01 | -1.18e-02 | 9.43e-01 |
| SOS-mediated signalling | 7 | 9.57e-01 | -1.18e-02 | 9.74e-01 |
| HCMV Early Events | 84 | 8.53e-01 | 1.17e-02 | 9.23e-01 |
| Regulation of NF-kappa B signaling | 18 | 9.33e-01 | -1.14e-02 | 9.64e-01 |
| TRP channels | 21 | 9.31e-01 | -1.09e-02 | 9.64e-01 |
| Potassium Channels | 62 | 8.82e-01 | -1.09e-02 | 9.38e-01 |
| RUNX2 regulates osteoblast differentiation | 16 | 9.41e-01 | -1.07e-02 | 9.66e-01 |
| SUMOylation of DNA damage response and repair proteins | 77 | 8.75e-01 | 1.04e-02 | 9.35e-01 |
| FOXO-mediated transcription | 57 | 8.95e-01 | -1.01e-02 | 9.44e-01 |
| Beta oxidation of octanoyl-CoA to hexanoyl-CoA | 5 | 9.69e-01 | -1.00e-02 | 9.82e-01 |
| Peptide ligand-binding receptors | 100 | 8.65e-01 | 9.85e-03 | 9.30e-01 |
| Chondroitin sulfate biosynthesis | 12 | 9.53e-01 | 9.76e-03 | 9.72e-01 |
| ERK/MAPK targets | 22 | 9.37e-01 | -9.73e-03 | 9.64e-01 |
| Arachidonate metabolism | 42 | 9.13e-01 | -9.70e-03 | 9.54e-01 |
| Transcriptional regulation of brown and beige adipocyte differentiation | 23 | 9.36e-01 | 9.61e-03 | 9.64e-01 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | 23 | 9.36e-01 | 9.61e-03 | 9.64e-01 |
| Synthesis of substrates in N-glycan biosythesis | 58 | 9.02e-01 | 9.35e-03 | 9.48e-01 |
| IRAK1 recruits IKK complex | 14 | 9.53e-01 | -9.15e-03 | 9.72e-01 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | 14 | 9.53e-01 | -9.15e-03 | 9.72e-01 |
| Acyl chain remodelling of PS | 14 | 9.54e-01 | -8.82e-03 | 9.73e-01 |
| Phospholipase C-mediated cascade; FGFR2 | 8 | 9.66e-01 | -8.72e-03 | 9.80e-01 |
| Signaling by ERBB2 TMD/JMD mutants | 17 | 9.51e-01 | -8.57e-03 | 9.72e-01 |
| Diseases associated with glycosaminoglycan metabolism | 24 | 9.42e-01 | 8.53e-03 | 9.67e-01 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | 18 | 9.51e-01 | 8.36e-03 | 9.72e-01 |
| Heme biosynthesis | 13 | 9.59e-01 | 8.23e-03 | 9.75e-01 |
| Synthesis of PC | 23 | 9.46e-01 | -8.17e-03 | 9.69e-01 |
| Phosphorylation of CD3 and TCR zeta chains | 27 | 9.43e-01 | -7.98e-03 | 9.67e-01 |
| HCMV Late Events | 67 | 9.11e-01 | -7.88e-03 | 9.53e-01 |
| Visual phototransduction | 58 | 9.18e-01 | 7.86e-03 | 9.57e-01 |
| NOTCH1 Intracellular Domain Regulates Transcription | 44 | 9.29e-01 | 7.78e-03 | 9.62e-01 |
| Processing of Capped Intron-Containing Pre-mRNA | 279 | 8.26e-01 | -7.65e-03 | 9.08e-01 |
| Assembly of collagen fibrils and other multimeric structures | 41 | 9.33e-01 | 7.61e-03 | 9.64e-01 |
| Aryl hydrocarbon receptor signalling | 6 | 9.76e-01 | 7.20e-03 | 9.86e-01 |
| Sensory processing of sound by inner hair cells of the cochlea | 54 | 9.29e-01 | -7.04e-03 | 9.62e-01 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | 62 | 9.25e-01 | -6.91e-03 | 9.61e-01 |
| CDC42 GTPase cycle | 139 | 8.91e-01 | -6.75e-03 | 9.42e-01 |
| VEGFR2 mediated vascular permeability | 26 | 9.53e-01 | 6.63e-03 | 9.72e-01 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | 56 | 9.33e-01 | -6.50e-03 | 9.64e-01 |
| Nuclear Events (kinase and transcription factor activation) | 54 | 9.35e-01 | -6.46e-03 | 9.64e-01 |
| NR1H2 and NR1H3-mediated signaling | 38 | 9.47e-01 | -6.20e-03 | 9.70e-01 |
| CD209 (DC-SIGN) signaling | 20 | 9.63e-01 | -6.01e-03 | 9.78e-01 |
| Scavenging by Class A Receptors | 10 | 9.74e-01 | -5.86e-03 | 9.85e-01 |
| Malate-aspartate shuttle | 8 | 9.79e-01 | 5.35e-03 | 9.88e-01 |
| Signaling by Retinoic Acid | 29 | 9.60e-01 | -5.35e-03 | 9.76e-01 |
| Chromatin modifying enzymes | 213 | 8.94e-01 | -5.32e-03 | 9.43e-01 |
| Chromatin organization | 213 | 8.94e-01 | -5.32e-03 | 9.43e-01 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | 7 | 9.81e-01 | 5.30e-03 | 9.89e-01 |
| Mitochondrial Fatty Acid Beta-Oxidation | 36 | 9.58e-01 | 5.07e-03 | 9.75e-01 |
| Activation of BAD and translocation to mitochondria | 15 | 9.73e-01 | 5.05e-03 | 9.85e-01 |
| Processing of Intronless Pre-mRNAs | 20 | 9.69e-01 | 5.04e-03 | 9.82e-01 |
| Metabolism of carbohydrates | 236 | 8.99e-01 | -4.82e-03 | 9.46e-01 |
| Fanconi Anemia Pathway | 36 | 9.60e-01 | -4.77e-03 | 9.76e-01 |
| Metabolism of fat-soluble vitamins | 26 | 9.70e-01 | 4.20e-03 | 9.83e-01 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | 36 | 9.65e-01 | -4.20e-03 | 9.80e-01 |
| NRIF signals cell death from the nucleus | 15 | 9.79e-01 | 3.92e-03 | 9.88e-01 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | 7 | 9.87e-01 | -3.44e-03 | 9.95e-01 |
| PERK regulates gene expression | 30 | 9.74e-01 | -3.41e-03 | 9.85e-01 |
| Regulation of signaling by NODAL | 6 | 9.92e-01 | 2.48e-03 | 9.96e-01 |
| rRNA modification in the mitochondrion | 8 | 9.91e-01 | -2.26e-03 | 9.96e-01 |
| Maturation of TCA enzymes and regulation of TCA cycle | 20 | 9.87e-01 | -2.11e-03 | 9.95e-01 |
| TAK1-dependent IKK and NF-kappa-B activation | 43 | 9.84e-01 | 1.72e-03 | 9.93e-01 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | 16 | 9.91e-01 | -1.71e-03 | 9.96e-01 |
| HDL assembly | 6 | 9.95e-01 | 1.40e-03 | 9.99e-01 |
| Base Excision Repair | 56 | 9.92e-01 | 7.92e-04 | 9.96e-01 |
| Glycogen storage diseases | 13 | 9.96e-01 | 7.24e-04 | 9.99e-01 |
| Amine ligand-binding receptors | 10 | 9.97e-01 | 6.87e-04 | 9.99e-01 |
| Ras activation upon Ca2+ influx through NMDA receptor | 15 | 9.97e-01 | -5.96e-04 | 9.99e-01 |
| Signaling by ROBO receptors | 189 | 9.89e-01 | -5.86e-04 | 9.96e-01 |
| Signaling by NOTCH1 | 66 | 9.94e-01 | -5.13e-04 | 9.98e-01 |
| SLC15A4:TASL-dependent IRF5 activation | 6 | 9.99e-01 | -4.24e-04 | 9.99e-01 |
| Formation of the Editosome | 6 | 9.99e-01 | 3.45e-04 | 9.99e-01 |
| mRNA Editing: C to U Conversion | 6 | 9.99e-01 | 3.45e-04 | 9.99e-01 |
| Transcriptional Regulation by VENTX | 38 | 9.99e-01 | -7.19e-05 | 9.99e-01 |
Detailed Gene set reports
Activation of caspases through apoptosome-mediated cleavage
| set | Activation of caspases through apoptosome-mediated cleavage |
| setSize | 6 |
| pANOVA | 0.000926 |
| s.dist | -0.781 |
| p.adjustANOVA | 0.0075 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CASP3 | -10564 |
| XIAP | -10076 |
| CASP9 | -9502 |
| APAF1 | -8943 |
| CASP7 | -7309 |
| CYCS | -5790 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CASP3 | -10564 |
| XIAP | -10076 |
| CASP9 | -9502 |
| APAF1 | -8943 |
| CASP7 | -7309 |
| CYCS | -5790 |
Neurotransmitter clearance
| set | Neurotransmitter clearance |
| setSize | 6 |
| pANOVA | 0.00196 |
| s.dist | 0.73 |
| p.adjustANOVA | 0.0136 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MAOA | 10060 |
| ALDH2 | 10010 |
| SLC22A1 | 9883 |
| LRTOMT | 7629 |
| COMT | 6626 |
| SLC6A4 | -95 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MAOA | 10060 |
| ALDH2 | 10010 |
| SLC22A1 | 9883 |
| LRTOMT | 7629 |
| COMT | 6626 |
| SLC6A4 | -95 |
Activation of NIMA Kinases NEK9, NEK6, NEK7
| set | Activation of NIMA Kinases NEK9, NEK6, NEK7 |
| setSize | 7 |
| pANOVA | 0.00117 |
| s.dist | -0.708 |
| p.adjustANOVA | 0.00891 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CDK1 | -10879 |
| CCNB1 | -10137 |
| NEK9 | -9603 |
| CCNB2 | -9036 |
| NEK7 | -8805 |
| PLK1 | -6724 |
| NEK6 | -320 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CDK1 | -10879 |
| CCNB1 | -10137 |
| NEK9 | -9603 |
| CCNB2 | -9036 |
| NEK7 | -8805 |
| PLK1 | -6724 |
| NEK6 | -320 |
Fructose metabolism
| set | Fructose metabolism |
| setSize | 7 |
| pANOVA | 0.00127 |
| s.dist | 0.703 |
| p.adjustANOVA | 0.00962 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ALDH1A1 | 10191 |
| TKFC | 10041 |
| AKR1B1 | 9594 |
| KHK | 9275 |
| SORD | 6388 |
| GLYCTK | 4047 |
| ALDOB | -66 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| ALDH1A1 | 10191 |
| TKFC | 10041 |
| AKR1B1 | 9594 |
| KHK | 9275 |
| SORD | 6388 |
| GLYCTK | 4047 |
| ALDOB | -66 |
Establishment of Sister Chromatid Cohesion
| set | Establishment of Sister Chromatid Cohesion |
| setSize | 11 |
| pANOVA | 7.48e-05 |
| s.dist | -0.69 |
| p.adjustANOVA | 0.000921 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ESCO2 | -10349 |
| CDCA5 | -9972 |
| ESCO1 | -9325 |
| PDS5A | -9186 |
| STAG2 | -8933 |
| SMC3 | -8596 |
| STAG1 | -7923 |
| WAPL | -7805 |
| RAD21 | -6485 |
| SMC1A | -4346 |
| PDS5B | -2072 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| ESCO2 | -10349 |
| CDCA5 | -9972 |
| ESCO1 | -9325 |
| PDS5A | -9186 |
| STAG2 | -8933 |
| SMC3 | -8596 |
| STAG1 | -7923 |
| WAPL | -7805 |
| RAD21 | -6485 |
| SMC1A | -4346 |
| PDS5B | -2072 |
Regulation of IFNA/IFNB signaling
| set | Regulation of IFNA/IFNB signaling |
| setSize | 12 |
| pANOVA | 4.63e-05 |
| s.dist | -0.679 |
| p.adjustANOVA | 0.00063 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| STAT1 | -10928 |
| SOCS3 | -10421 |
| IFNAR2 | -10357 |
| IFNAR1 | -10332 |
| PTPN1 | -10313 |
| JAK1 | -9176 |
| SOCS1 | -9115 |
| USP18 | -8824 |
| PTPN11 | -8706 |
| STAT2 | -7381 |
| PTPN6 | -4480 |
| TYK2 | 8655 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| STAT1 | -10928 |
| SOCS3 | -10421 |
| IFNAR2 | -10357 |
| IFNAR1 | -10332 |
| PTPN1 | -10313 |
| JAK1 | -9176 |
| SOCS1 | -9115 |
| USP18 | -8824 |
| PTPN11 | -8706 |
| STAT2 | -7381 |
| PTPN6 | -4480 |
| TYK2 | 8655 |
ARMS-mediated activation
| set | ARMS-mediated activation |
| setSize | 6 |
| pANOVA | 0.00415 |
| s.dist | -0.676 |
| p.adjustANOVA | 0.0256 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| NTRK1 | -10996 |
| YWHAB | -9769 |
| KIDINS220 | -7453 |
| RAP1A | -7134 |
| BRAF | -5960 |
| CRK | -4174 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| NTRK1 | -10996 |
| YWHAB | -9769 |
| KIDINS220 | -7453 |
| RAP1A | -7134 |
| BRAF | -5960 |
| CRK | -4174 |
G2/M DNA replication checkpoint
| set | G2/M DNA replication checkpoint |
| setSize | 5 |
| pANOVA | 0.00899 |
| s.dist | -0.675 |
| p.adjustANOVA | 0.0479 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CDK1 | -10879 |
| CCNB1 | -10137 |
| CCNB2 | -9036 |
| PKMYT1 | -4319 |
| WEE1 | -3477 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CDK1 | -10879 |
| CCNB1 | -10137 |
| CCNB2 | -9036 |
| PKMYT1 | -4319 |
| WEE1 | -3477 |
Fructose catabolism
| set | Fructose catabolism |
| setSize | 5 |
| pANOVA | 0.00965 |
| s.dist | 0.668 |
| p.adjustANOVA | 0.0504 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ALDH1A1 | 10191 |
| TKFC | 10041 |
| KHK | 9275 |
| GLYCTK | 4047 |
| ALDOB | -66 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| ALDH1A1 | 10191 |
| TKFC | 10041 |
| KHK | 9275 |
| GLYCTK | 4047 |
| ALDOB | -66 |
Interleukin-21 signaling
| set | Interleukin-21 signaling |
| setSize | 9 |
| pANOVA | 0.000645 |
| s.dist | -0.657 |
| p.adjustANOVA | 0.00551 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| STAT1 | -10928 |
| JAK3 | -10659 |
| IL21R | -10243 |
| STAT3 | -9901 |
| JAK1 | -9176 |
| IL2RG | -8059 |
| STAT4 | -6553 |
| STAT5B | -3345 |
| STAT5A | 2457 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| STAT1 | -10928 |
| JAK3 | -10659 |
| IL21R | -10243 |
| STAT3 | -9901 |
| JAK1 | -9176 |
| IL2RG | -8059 |
| STAT4 | -6553 |
| STAT5B | -3345 |
| STAT5A | 2457 |
Response to metal ions
| set | Response to metal ions |
| setSize | 6 |
| pANOVA | 0.00535 |
| s.dist | -0.657 |
| p.adjustANOVA | 0.032 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MT1X | -9543 |
| MTF1 | -8963 |
| CSRP1 | -8366 |
| MT1F | -7121 |
| MT2A | -5340 |
| MT1E | -4932 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MT1X | -9543 |
| MTF1 | -8963 |
| CSRP1 | -8366 |
| MT1F | -7121 |
| MT2A | -5340 |
| MT1E | -4932 |
Protein repair
| set | Protein repair |
| setSize | 6 |
| pANOVA | 0.0061 |
| s.dist | -0.646 |
| p.adjustANOVA | 0.0352 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PCMT1 | -9732 |
| MSRA | -9728 |
| TXN | -9485 |
| MSRB3 | -8247 |
| MSRB1 | -7661 |
| MSRB2 | 1227 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PCMT1 | -9732 |
| MSRA | -9728 |
| TXN | -9485 |
| MSRB3 | -8247 |
| MSRB1 | -7661 |
| MSRB2 | 1227 |
SMAC (DIABLO) binds to IAPs
| set | SMAC (DIABLO) binds to IAPs |
| setSize | 7 |
| pANOVA | 0.00331 |
| s.dist | -0.641 |
| p.adjustANOVA | 0.0213 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CASP3 | -10564 |
| XIAP | -10076 |
| CASP9 | -9502 |
| APAF1 | -8943 |
| CASP7 | -7309 |
| CYCS | -5790 |
| DIABLO | 1695 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CASP3 | -10564 |
| XIAP | -10076 |
| CASP9 | -9502 |
| APAF1 | -8943 |
| CASP7 | -7309 |
| CYCS | -5790 |
| DIABLO | 1695 |
SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes
| set | SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes |
| setSize | 7 |
| pANOVA | 0.00331 |
| s.dist | -0.641 |
| p.adjustANOVA | 0.0213 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CASP3 | -10564 |
| XIAP | -10076 |
| CASP9 | -9502 |
| APAF1 | -8943 |
| CASP7 | -7309 |
| CYCS | -5790 |
| DIABLO | 1695 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CASP3 | -10564 |
| XIAP | -10076 |
| CASP9 | -9502 |
| APAF1 | -8943 |
| CASP7 | -7309 |
| CYCS | -5790 |
| DIABLO | 1695 |
SMAC, XIAP-regulated apoptotic response
| set | SMAC, XIAP-regulated apoptotic response |
| setSize | 7 |
| pANOVA | 0.00331 |
| s.dist | -0.641 |
| p.adjustANOVA | 0.0213 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CASP3 | -10564 |
| XIAP | -10076 |
| CASP9 | -9502 |
| APAF1 | -8943 |
| CASP7 | -7309 |
| CYCS | -5790 |
| DIABLO | 1695 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CASP3 | -10564 |
| XIAP | -10076 |
| CASP9 | -9502 |
| APAF1 | -8943 |
| CASP7 | -7309 |
| CYCS | -5790 |
| DIABLO | 1695 |
Butyrophilin (BTN) family interactions
| set | Butyrophilin (BTN) family interactions |
| setSize | 10 |
| pANOVA | 0.000621 |
| s.dist | 0.625 |
| p.adjustANOVA | 0.00535 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| BTN2A2 | 10074 |
| BTN3A1 | 9859 |
| BTN2A1 | 9340 |
| BTNL8 | 9199 |
| CD209 | 7737 |
| PPL | 6597 |
| BTN3A3 | 5904 |
| BTN3A2 | 2904 |
| BTN1A1 | 1752 |
| BTNL9 | -1019 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| BTN2A2 | 10074 |
| BTN3A1 | 9859 |
| BTN2A1 | 9340 |
| BTNL8 | 9199 |
| CD209 | 7737 |
| PPL | 6597 |
| BTN3A3 | 5904 |
| BTN3A2 | 2904 |
| BTN1A1 | 1752 |
| BTNL9 | -1019 |
NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake
| set | NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake |
| setSize | 5 |
| pANOVA | 0.0157 |
| s.dist | 0.624 |
| p.adjustANOVA | 0.0726 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MYLIP | 10014 |
| NR1H3 | 9468 |
| RXRA | 4552 |
| RXRB | 4529 |
| NR1H2 | 2553 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MYLIP | 10014 |
| NR1H3 | 9468 |
| RXRA | 4552 |
| RXRB | 4529 |
| NR1H2 | 2553 |
Maturation of protein 3a_9683673
| set | Maturation of protein 3a_9683673 |
| setSize | 9 |
| pANOVA | 0.00146 |
| s.dist | -0.612 |
| p.adjustANOVA | 0.0108 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GALNT1 | -10568 |
| ST3GAL4 | -9937 |
| ST6GALNAC3 | -9647 |
| ST3GAL2 | -9254 |
| ST6GALNAC2 | -6953 |
| ST3GAL1 | -5684 |
| ST6GAL1 | -5289 |
| ST3GAL3 | -2695 |
| ST6GALNAC4 | -2150 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| GALNT1 | -10568 |
| ST3GAL4 | -9937 |
| ST6GALNAC3 | -9647 |
| ST3GAL2 | -9254 |
| ST6GALNAC2 | -6953 |
| ST3GAL1 | -5684 |
| ST6GAL1 | -5289 |
| ST3GAL3 | -2695 |
| ST6GALNAC4 | -2150 |
Maturation of protein 3a_9694719
| set | Maturation of protein 3a_9694719 |
| setSize | 9 |
| pANOVA | 0.00146 |
| s.dist | -0.612 |
| p.adjustANOVA | 0.0108 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GALNT1 | -10568 |
| ST3GAL4 | -9937 |
| ST6GALNAC3 | -9647 |
| ST3GAL2 | -9254 |
| ST6GALNAC2 | -6953 |
| ST3GAL1 | -5684 |
| ST6GAL1 | -5289 |
| ST3GAL3 | -2695 |
| ST6GALNAC4 | -2150 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| GALNT1 | -10568 |
| ST3GAL4 | -9937 |
| ST6GALNAC3 | -9647 |
| ST3GAL2 | -9254 |
| ST6GALNAC2 | -6953 |
| ST3GAL1 | -5684 |
| ST6GAL1 | -5289 |
| ST3GAL3 | -2695 |
| ST6GALNAC4 | -2150 |
Wax and plasmalogen biosynthesis
| set | Wax and plasmalogen biosynthesis |
| setSize | 5 |
| pANOVA | 0.0179 |
| s.dist | -0.611 |
| p.adjustANOVA | 0.0805 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| FAR1 | -9703 |
| GNPAT | -8955 |
| DHRS7B | -5671 |
| AGPS | -5644 |
| FAR2 | -4511 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| FAR1 | -9703 |
| GNPAT | -8955 |
| DHRS7B | -5671 |
| AGPS | -5644 |
| FAR2 | -4511 |
Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA
| set | Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA |
| setSize | 6 |
| pANOVA | 0.00964 |
| s.dist | -0.61 |
| p.adjustANOVA | 0.0504 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| H19 | -11004 |
| IGF2BP3 | -10911 |
| CD44 | -10680 |
| ACTB | -7382 |
| MYC | -4670 |
| IGF2BP2 | 3333 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| H19 | -11004 |
| IGF2BP3 | -10911 |
| CD44 | -10680 |
| ACTB | -7382 |
| MYC | -4670 |
| IGF2BP2 | 3333 |
ROBO receptors bind AKAP5
| set | ROBO receptors bind AKAP5 |
| setSize | 7 |
| pANOVA | 0.00619 |
| s.dist | -0.597 |
| p.adjustANOVA | 0.0355 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PRKCA | -10914 |
| PPP3CB | -10541 |
| AKAP5 | -10345 |
| PRKAR2A | -10246 |
| PRKACB | -6889 |
| PRKACA | -714 |
| ROBO3 | 2402 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PRKCA | -10914 |
| PPP3CB | -10541 |
| AKAP5 | -10345 |
| PRKAR2A | -10246 |
| PRKACB | -6889 |
| PRKACA | -714 |
| ROBO3 | 2402 |
Interleukin-6 signaling
| set | Interleukin-6 signaling |
| setSize | 10 |
| pANOVA | 0.00108 |
| s.dist | -0.597 |
| p.adjustANOVA | 0.00845 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| STAT1 | -10928 |
| SOCS3 | -10421 |
| IL6ST | -10319 |
| STAT3 | -9901 |
| JAK1 | -9176 |
| PTPN11 | -8706 |
| CBL | -6596 |
| IL6R | -5911 |
| JAK2 | -4114 |
| TYK2 | 8655 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| STAT1 | -10928 |
| SOCS3 | -10421 |
| IL6ST | -10319 |
| STAT3 | -9901 |
| JAK1 | -9176 |
| PTPN11 | -8706 |
| CBL | -6596 |
| IL6R | -5911 |
| JAK2 | -4114 |
| TYK2 | 8655 |
Regulation of TP53 Activity through Association with Co-factors
| set | Regulation of TP53 Activity through Association with Co-factors |
| setSize | 11 |
| pANOVA | 0.000661 |
| s.dist | 0.593 |
| p.adjustANOVA | 0.00562 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| AKT1 | 9900 |
| ZNF385A | 9893 |
| TP53 | 9052 |
| AKT2 | 8400 |
| BANP | 8351 |
| PPP1R13B | 7301 |
| TP73 | 6490 |
| PPP1R13L | 6378 |
| AKT3 | 5678 |
| TP53BP2 | -185 |
| PHF20 | -6422 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| AKT1 | 9900 |
| ZNF385A | 9893 |
| TP53 | 9052 |
| AKT2 | 8400 |
| BANP | 8351 |
| PPP1R13B | 7301 |
| TP73 | 6490 |
| PPP1R13L | 6378 |
| AKT3 | 5678 |
| TP53BP2 | -185 |
| PHF20 | -6422 |
Type I hemidesmosome assembly
| set | Type I hemidesmosome assembly |
| setSize | 8 |
| pANOVA | 0.00492 |
| s.dist | -0.574 |
| p.adjustANOVA | 0.0296 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| KRT5 | -11029 |
| LAMB3 | -10945 |
| ITGA6 | -9695 |
| COL17A1 | -9228 |
| ITGB4 | -5191 |
| DST | -4269 |
| CD151 | -1131 |
| PLEC | -529 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| KRT5 | -11029 |
| LAMB3 | -10945 |
| ITGA6 | -9695 |
| COL17A1 | -9228 |
| ITGB4 | -5191 |
| DST | -4269 |
| CD151 | -1131 |
| PLEC | -529 |
RUNX3 regulates CDKN1A transcription
| set | RUNX3 regulates CDKN1A transcription |
| setSize | 7 |
| pANOVA | 0.0093 |
| s.dist | 0.568 |
| p.adjustANOVA | 0.0491 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| SMAD3 | 9753 |
| TP53 | 9052 |
| ZFHX3 | 8883 |
| CDKN1A | 8619 |
| TGFB1 | 7345 |
| RUNX3 | 1164 |
| SMAD4 | -5430 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| SMAD3 | 9753 |
| TP53 | 9052 |
| ZFHX3 | 8883 |
| CDKN1A | 8619 |
| TGFB1 | 7345 |
| RUNX3 | 1164 |
| SMAD4 | -5430 |
Condensation of Prometaphase Chromosomes
| set | Condensation of Prometaphase Chromosomes |
| setSize | 11 |
| pANOVA | 0.00116 |
| s.dist | -0.566 |
| p.adjustANOVA | 0.00888 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CDK1 | -10879 |
| CCNB1 | -10137 |
| NCAPG | -9729 |
| NCAPH | -9672 |
| CCNB2 | -9036 |
| NCAPD2 | -8779 |
| CSNK2A1 | -7886 |
| SMC4 | -6338 |
| CSNK2A2 | -3472 |
| SMC2 | 798 |
| CSNK2B | 4619 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CDK1 | -10879 |
| CCNB1 | -10137 |
| NCAPG | -9729 |
| NCAPH | -9672 |
| CCNB2 | -9036 |
| NCAPD2 | -8779 |
| CSNK2A1 | -7886 |
| SMC4 | -6338 |
| CSNK2A2 | -3472 |
| SMC2 | 798 |
| CSNK2B | 4619 |
Mitotic Telophase/Cytokinesis
| set | Mitotic Telophase/Cytokinesis |
| setSize | 13 |
| pANOVA | 0.000421 |
| s.dist | -0.565 |
| p.adjustANOVA | 0.00378 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| KIF20A | -10170 |
| PDS5A | -9186 |
| STAG2 | -8933 |
| SMC3 | -8596 |
| NIPBL | -8207 |
| STAG1 | -7923 |
| WAPL | -7805 |
| PLK1 | -6724 |
| RAD21 | -6485 |
| KIF23 | -5801 |
| SMC1A | -4346 |
| PDS5B | -2072 |
| MAU2 | 3035 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| KIF20A | -10170 |
| PDS5A | -9186 |
| STAG2 | -8933 |
| SMC3 | -8596 |
| NIPBL | -8207 |
| STAG1 | -7923 |
| WAPL | -7805 |
| PLK1 | -6724 |
| RAD21 | -6485 |
| KIF23 | -5801 |
| SMC1A | -4346 |
| PDS5B | -2072 |
| MAU2 | 3035 |
Diseases of Mismatch Repair (MMR)
| set | Diseases of Mismatch Repair (MMR) |
| setSize | 5 |
| pANOVA | 0.0319 |
| s.dist | -0.554 |
| p.adjustANOVA | 0.123 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MSH6 | -8034 |
| MSH2 | -7338 |
| MSH3 | -7216 |
| MLH1 | -6489 |
| PMS2 | -2374 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MSH6 | -8034 |
| MSH2 | -7338 |
| MSH3 | -7216 |
| MLH1 | -6489 |
| PMS2 | -2374 |
CREB1 phosphorylation through the activation of Adenylate Cyclase
| set | CREB1 phosphorylation through the activation of Adenylate Cyclase |
| setSize | 9 |
| pANOVA | 0.00403 |
| s.dist | -0.554 |
| p.adjustANOVA | 0.0252 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CALM1 | -10853 |
| PRKAR1A | -10586 |
| PRKAR2A | -10246 |
| PRKAR1B | -8692 |
| PRKACB | -6889 |
| PRKAR2B | -4222 |
| CREB1 | -4119 |
| PRKACA | -714 |
| PRKX | -223 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CALM1 | -10853 |
| PRKAR1A | -10586 |
| PRKAR2A | -10246 |
| PRKAR1B | -8692 |
| PRKACB | -6889 |
| PRKAR2B | -4222 |
| CREB1 | -4119 |
| PRKACA | -714 |
| PRKX | -223 |
Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus
| set | Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus |
| setSize | 5 |
| pANOVA | 0.0345 |
| s.dist | -0.546 |
| p.adjustANOVA | 0.13 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PROC | -10372 |
| GAS6 | -10292 |
| PROS1 | -9524 |
| PROZ | -940 |
| BGLAP | 115 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PROC | -10372 |
| GAS6 | -10292 |
| PROS1 | -9524 |
| PROZ | -940 |
| BGLAP | 115 |
OAS antiviral response
| set | OAS antiviral response |
| setSize | 8 |
| pANOVA | 0.00802 |
| s.dist | -0.541 |
| p.adjustANOVA | 0.0439 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| OAS2 | -10640 |
| RNASEL | -10526 |
| OAS1 | -10498 |
| OASL | -9669 |
| OAS3 | -9337 |
| PDE12 | -413 |
| ABCE1 | 676 |
| FLNA | 1187 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| OAS2 | -10640 |
| RNASEL | -10526 |
| OAS1 | -10498 |
| OASL | -9669 |
| OAS3 | -9337 |
| PDE12 | -413 |
| ABCE1 | 676 |
| FLNA | 1187 |
Metabolism of ingested SeMet, Sec, MeSec into H2Se
| set | Metabolism of ingested SeMet, Sec, MeSec into H2Se |
| setSize | 7 |
| pANOVA | 0.0133 |
| s.dist | 0.54 |
| p.adjustANOVA | 0.0639 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CBS | 9624 |
| AHCY | 9418 |
| GNMT | 7945 |
| SCLY | 7321 |
| HNMT | 4369 |
| CTH | 2516 |
| NNMT | -3855 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CBS | 9624 |
| AHCY | 9418 |
| GNMT | 7945 |
| SCLY | 7321 |
| HNMT | 4369 |
| CTH | 2516 |
| NNMT | -3855 |
Cohesin Loading onto Chromatin
| set | Cohesin Loading onto Chromatin |
| setSize | 10 |
| pANOVA | 0.00359 |
| s.dist | -0.532 |
| p.adjustANOVA | 0.0228 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PDS5A | -9186 |
| STAG2 | -8933 |
| SMC3 | -8596 |
| NIPBL | -8207 |
| STAG1 | -7923 |
| WAPL | -7805 |
| RAD21 | -6485 |
| SMC1A | -4346 |
| PDS5B | -2072 |
| MAU2 | 3035 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PDS5A | -9186 |
| STAG2 | -8933 |
| SMC3 | -8596 |
| NIPBL | -8207 |
| STAG1 | -7923 |
| WAPL | -7805 |
| RAD21 | -6485 |
| SMC1A | -4346 |
| PDS5B | -2072 |
| MAU2 | 3035 |
Negative regulation of TCF-dependent signaling by WNT ligand antagonists
| set | Negative regulation of TCF-dependent signaling by WNT ligand antagonists |
| setSize | 6 |
| pANOVA | 0.025 |
| s.dist | -0.528 |
| p.adjustANOVA | 0.102 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| LRP5 | -10264 |
| LRP6 | -9506 |
| KREMEN1 | -8316 |
| WNT4 | -7440 |
| KREMEN2 | -1541 |
| WNT9A | 971 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| LRP5 | -10264 |
| LRP6 | -9506 |
| KREMEN1 | -8316 |
| WNT4 | -7440 |
| KREMEN2 | -1541 |
| WNT9A | 971 |
Platelet sensitization by LDL
| set | Platelet sensitization by LDL |
| setSize | 16 |
| pANOVA | 0.000259 |
| s.dist | -0.527 |
| p.adjustANOVA | 0.0025 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MAPK14 | -10642 |
| FGR | -10342 |
| PECAM1 | -9655 |
| PTPN11 | -8706 |
| LRP8 | -7521 |
| PPP2CA | -7332 |
| PPP2R5A | -7028 |
| PPP2R5C | -6556 |
| PPP2R1B | -6069 |
| PPP2R5E | -5368 |
| PTPN6 | -4480 |
| PPP2R5D | -3700 |
| PPP2CB | -3552 |
| PLA2G4A | -2553 |
| PPP2R5B | -1596 |
| PPP2R1A | -962 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MAPK14 | -10642 |
| FGR | -10342 |
| PECAM1 | -9655 |
| PTPN11 | -8706 |
| LRP8 | -7521 |
| PPP2CA | -7332 |
| PPP2R5A | -7028 |
| PPP2R5C | -6556 |
| PPP2R1B | -6069 |
| PPP2R5E | -5368 |
| PTPN6 | -4480 |
| PPP2R5D | -3700 |
| PPP2CB | -3552 |
| PLA2G4A | -2553 |
| PPP2R5B | -1596 |
| PPP2R1A | -962 |
Ca2+ activated K+ channels
| set | Ca2+ activated K+ channels |
| setSize | 6 |
| pANOVA | 0.0267 |
| s.dist | 0.522 |
| p.adjustANOVA | 0.108 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| KCNMB4 | 10126 |
| KCNMB1 | 9713 |
| KCNN4 | 8165 |
| KCNMA1 | 7853 |
| KCNMB3 | -2106 |
| KCNN3 | -2875 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| KCNMB4 | 10126 |
| KCNMB1 | 9713 |
| KCNN4 | 8165 |
| KCNMA1 | 7853 |
| KCNMB3 | -2106 |
| KCNN3 | -2875 |
Cytosolic iron-sulfur cluster assembly
| set | Cytosolic iron-sulfur cluster assembly |
| setSize | 13 |
| pANOVA | 0.00131 |
| s.dist | 0.515 |
| p.adjustANOVA | 0.00986 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MMS19 | 10035 |
| ERCC2 | 9997 |
| NUBP1 | 8984 |
| ABCB7 | 8574 |
| NDOR1 | 8504 |
| POLD1 | 6946 |
| NUBP2 | 6795 |
| CIAO3 | 6355 |
| CIAO1 | 5184 |
| RTEL1 | 3174 |
| CIAO2B | 1161 |
| CIAPIN1 | -4754 |
| BRIP1 | -5151 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MMS19 | 10035 |
| ERCC2 | 9997 |
| NUBP1 | 8984 |
| ABCB7 | 8574 |
| NDOR1 | 8504 |
| POLD1 | 6946 |
| NUBP2 | 6795 |
| CIAO3 | 6355 |
| CIAO1 | 5184 |
| RTEL1 | 3174 |
| CIAO2B | 1161 |
| CIAPIN1 | -4754 |
| BRIP1 | -5151 |
Cobalamin (Cbl) metabolism
| set | Cobalamin (Cbl) metabolism |
| setSize | 7 |
| pANOVA | 0.0191 |
| s.dist | -0.511 |
| p.adjustANOVA | 0.0834 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MMADHC | -10718 |
| MMUT | -9966 |
| MMACHC | -9158 |
| MTRR | -8489 |
| MMAA | -5582 |
| MMAB | -2847 |
| MTR | 5917 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MMADHC | -10718 |
| MMUT | -9966 |
| MMACHC | -9158 |
| MTRR | -8489 |
| MMAA | -5582 |
| MMAB | -2847 |
| MTR | 5917 |
Regulation of NPAS4 gene expression
| set | Regulation of NPAS4 gene expression |
| setSize | 11 |
| pANOVA | 0.00431 |
| s.dist | -0.497 |
| p.adjustANOVA | 0.0265 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| REST | -10392 |
| TNRC6C | -8777 |
| AGO4 | -8357 |
| NR3C1 | -7576 |
| SRF | -7220 |
| AGO3 | -6163 |
| TNRC6B | -4806 |
| MOV10 | -3273 |
| TNRC6A | -3186 |
| AGO2 | -2850 |
| AGO1 | 98 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| REST | -10392 |
| TNRC6C | -8777 |
| AGO4 | -8357 |
| NR3C1 | -7576 |
| SRF | -7220 |
| AGO3 | -6163 |
| TNRC6B | -4806 |
| MOV10 | -3273 |
| TNRC6A | -3186 |
| AGO2 | -2850 |
| AGO1 | 98 |
Regulation of RUNX1 Expression and Activity
| set | Regulation of RUNX1 Expression and Activity |
| setSize | 18 |
| pANOVA | 0.000279 |
| s.dist | -0.495 |
| p.adjustANOVA | 0.00268 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| H19 | -11004 |
| RUNX1 | -10752 |
| CCND3 | -10658 |
| CBFB | -9467 |
| TNRC6C | -8777 |
| PTPN11 | -8706 |
| AGO4 | -8357 |
| AGO3 | -6163 |
| CCND1 | -6141 |
| CCND2 | -4872 |
| TNRC6B | -4806 |
| PML | -4376 |
| MOV10 | -3273 |
| TNRC6A | -3186 |
| AGO2 | -2850 |
| CDK6 | -316 |
| AGO1 | 98 |
| SRC | 1810 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| H19 | -11004 |
| RUNX1 | -10752 |
| CCND3 | -10658 |
| CBFB | -9467 |
| TNRC6C | -8777 |
| PTPN11 | -8706 |
| AGO4 | -8357 |
| AGO3 | -6163 |
| CCND1 | -6141 |
| CCND2 | -4872 |
| TNRC6B | -4806 |
| PML | -4376 |
| MOV10 | -3273 |
| TNRC6A | -3186 |
| AGO2 | -2850 |
| CDK6 | -316 |
| AGO1 | 98 |
| SRC | 1810 |
Regulation of IFNG signaling
| set | Regulation of IFNG signaling |
| setSize | 14 |
| pANOVA | 0.00141 |
| s.dist | -0.493 |
| p.adjustANOVA | 0.0105 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| STAT1 | -10928 |
| SOCS3 | -10421 |
| PTPN1 | -10313 |
| SUMO1 | -10101 |
| JAK1 | -9176 |
| SOCS1 | -9115 |
| PTPN11 | -8706 |
| PTPN6 | -4480 |
| IFNGR2 | -4270 |
| JAK2 | -4114 |
| IFNG | -3589 |
| PTPN2 | -3309 |
| IFNGR1 | 2989 |
| PIAS1 | 6646 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| STAT1 | -10928 |
| SOCS3 | -10421 |
| PTPN1 | -10313 |
| SUMO1 | -10101 |
| JAK1 | -9176 |
| SOCS1 | -9115 |
| PTPN11 | -8706 |
| PTPN6 | -4480 |
| IFNGR2 | -4270 |
| JAK2 | -4114 |
| IFNG | -3589 |
| PTPN2 | -3309 |
| IFNGR1 | 2989 |
| PIAS1 | 6646 |
Transcriptional regulation of testis differentiation
| set | Transcriptional regulation of testis differentiation |
| setSize | 5 |
| pANOVA | 0.0565 |
| s.dist | 0.492 |
| p.adjustANOVA | 0.188 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| FGF9 | 9732 |
| PTGDS | 9430 |
| ZFPM2 | 7080 |
| AMH | 5343 |
| WNT4 | -7440 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| FGF9 | 9732 |
| PTGDS | 9430 |
| ZFPM2 | 7080 |
| AMH | 5343 |
| WNT4 | -7440 |
NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose
| set | NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose |
| setSize | 5 |
| pANOVA | 0.0568 |
| s.dist | 0.492 |
| p.adjustANOVA | 0.189 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| NR1H3 | 9468 |
| RXRA | 4552 |
| RXRB | 4529 |
| PLIN1 | 3008 |
| NR1H2 | 2553 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| NR1H3 | 9468 |
| RXRA | 4552 |
| RXRB | 4529 |
| PLIN1 | 3008 |
| NR1H2 | 2553 |
Interleukin-20 family signaling
| set | Interleukin-20 family signaling |
| setSize | 17 |
| pANOVA | 0.000475 |
| s.dist | -0.489 |
| p.adjustANOVA | 0.00422 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| STAT1 | -10928 |
| JAK3 | -10659 |
| IL10RB | -10571 |
| SOCS3 | -10421 |
| STAT3 | -9901 |
| JAK1 | -9176 |
| PTPN11 | -8706 |
| STAT2 | -7381 |
| IFNLR1 | -7113 |
| STAT4 | -6553 |
| IL19 | -4984 |
| JAK2 | -4114 |
| STAT5B | -3345 |
| IL24 | -1545 |
| IL20RB | -919 |
| STAT5A | 2457 |
| TYK2 | 8655 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| STAT1 | -10928 |
| JAK3 | -10659 |
| IL10RB | -10571 |
| SOCS3 | -10421 |
| STAT3 | -9901 |
| JAK1 | -9176 |
| PTPN11 | -8706 |
| STAT2 | -7381 |
| IFNLR1 | -7113 |
| STAT4 | -6553 |
| IL19 | -4984 |
| JAK2 | -4114 |
| STAT5B | -3345 |
| IL24 | -1545 |
| IL20RB | -919 |
| STAT5A | 2457 |
| TYK2 | 8655 |
Signaling by PDGFRA extracellular domain mutants
| set | Signaling by PDGFRA extracellular domain mutants |
| setSize | 12 |
| pANOVA | 0.00341 |
| s.dist | -0.488 |
| p.adjustANOVA | 0.0218 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| STAT1 | -10928 |
| PIK3CB | -10024 |
| STAT3 | -9901 |
| KRAS | -9391 |
| PIK3CA | -8890 |
| NRAS | -7707 |
| SOS1 | -6963 |
| PDGFRA | -6739 |
| PIK3R1 | -5606 |
| GRB2 | -4488 |
| PIK3R2 | 6044 |
| HRAS | 7548 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| STAT1 | -10928 |
| PIK3CB | -10024 |
| STAT3 | -9901 |
| KRAS | -9391 |
| PIK3CA | -8890 |
| NRAS | -7707 |
| SOS1 | -6963 |
| PDGFRA | -6739 |
| PIK3R1 | -5606 |
| GRB2 | -4488 |
| PIK3R2 | 6044 |
| HRAS | 7548 |
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
| set | Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants |
| setSize | 12 |
| pANOVA | 0.00341 |
| s.dist | -0.488 |
| p.adjustANOVA | 0.0218 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| STAT1 | -10928 |
| PIK3CB | -10024 |
| STAT3 | -9901 |
| KRAS | -9391 |
| PIK3CA | -8890 |
| NRAS | -7707 |
| SOS1 | -6963 |
| PDGFRA | -6739 |
| PIK3R1 | -5606 |
| GRB2 | -4488 |
| PIK3R2 | 6044 |
| HRAS | 7548 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| STAT1 | -10928 |
| PIK3CB | -10024 |
| STAT3 | -9901 |
| KRAS | -9391 |
| PIK3CA | -8890 |
| NRAS | -7707 |
| SOS1 | -6963 |
| PDGFRA | -6739 |
| PIK3R1 | -5606 |
| GRB2 | -4488 |
| PIK3R2 | 6044 |
| HRAS | 7548 |
MASTL Facilitates Mitotic Progression
| set | MASTL Facilitates Mitotic Progression |
| setSize | 10 |
| pANOVA | 0.00786 |
| s.dist | -0.485 |
| p.adjustANOVA | 0.0435 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CDK1 | -10879 |
| CCNB1 | -10137 |
| ENSA | -8123 |
| PPP2CA | -7332 |
| MASTL | -7001 |
| PPP2R1B | -6069 |
| ARPP19 | -5078 |
| PPP2CB | -3552 |
| PPP2R1A | -962 |
| PPP2R2D | 3550 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CDK1 | -10879 |
| CCNB1 | -10137 |
| ENSA | -8123 |
| PPP2CA | -7332 |
| MASTL | -7001 |
| PPP2R1B | -6069 |
| ARPP19 | -5078 |
| PPP2CB | -3552 |
| PPP2R1A | -962 |
| PPP2R2D | 3550 |
Competing endogenous RNAs (ceRNAs) regulate PTEN translation
| set | Competing endogenous RNAs (ceRNAs) regulate PTEN translation |
| setSize | 10 |
| pANOVA | 0.00798 |
| s.dist | -0.484 |
| p.adjustANOVA | 0.0438 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| VAPA | -9537 |
| TNRC6C | -8777 |
| CNOT6L | -8632 |
| AGO4 | -8357 |
| AGO3 | -6163 |
| TNRC6B | -4806 |
| MOV10 | -3273 |
| TNRC6A | -3186 |
| AGO2 | -2850 |
| AGO1 | 98 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| VAPA | -9537 |
| TNRC6C | -8777 |
| CNOT6L | -8632 |
| AGO4 | -8357 |
| AGO3 | -6163 |
| TNRC6B | -4806 |
| MOV10 | -3273 |
| TNRC6A | -3186 |
| AGO2 | -2850 |
| AGO1 | 98 |
RUNX1 regulates transcription of genes involved in differentiation of keratinocytes
| set | RUNX1 regulates transcription of genes involved in differentiation of keratinocytes |
| setSize | 7 |
| pANOVA | 0.0268 |
| s.dist | -0.483 |
| p.adjustANOVA | 0.108 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RUNX1 | -10752 |
| SOCS3 | -10421 |
| CTSL | -10029 |
| CBFB | -9467 |
| SOCS4 | -5224 |
| CTSV | -433 |
| CTSK | 7562 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| RUNX1 | -10752 |
| SOCS3 | -10421 |
| CTSL | -10029 |
| CBFB | -9467 |
| SOCS4 | -5224 |
| CTSV | -433 |
| CTSK | 7562 |
Network diagram
Only used for one-dimensional analysis.
Here, the network diagram is used to depict the similarity between
some of the top ranked gene sets. It makes separate charts for up and
downregulated sets. It works best when prioritisation is done by effect
size during the mitch_calc() step. By default, we only show
the top 20 genes, but you can use the networkplot() command
yourself with other options. See ?networkplot for more
detail. There is an element of stochasticity with regard to the network
projection, so if you see a lot of overlapping labels or labels getting
cut off, you could repeat the chart generation until you get a nice
layout. See ?networkplot for more detail.
Below the network diagrams, you will see lists of genes that make up the up and downregulated sets respectively. For upregulated genes the score needs to be >2 and for downregulated genes it needs to be < -2. This is to remove genes that have uninteresting differential expression and do not contribute enrichment.
if (d==1) {
networkplot(eres=res,FDR=0.05,n_sets=20)
network_genes(eres=res,FDR=0.05,n_sets=20)
} else {
message("Network charts only generated in one-dimensional analysis.")
}
## [[1]]
## [[1]]$`UP genesets.Butyrophilin (BTN) family interactions`
## [1] "BTN2A1" "BTN2A2" "BTN3A1" "BTNL8"
##
## [[1]]$`UP genesets.Cap-dependent Translation Initiation`
## [1] "EIF2B5" "EIF3B" "EIF4EBP1" "RPS4Y1"
##
## [[1]]$`UP genesets.Crosslinking of collagen fibrils`
## [1] "COL4A2" "LOXL3"
##
## [[1]]$`UP genesets.Cytosolic iron-sulfur cluster assembly`
## [1] "ERCC2" "MMS19"
##
## [[1]]$`UP genesets.Eukaryotic Translation Elongation`
## [1] "RPS4Y1"
##
## [[1]]$`UP genesets.Eukaryotic Translation Initiation`
## [1] "EIF2B5" "EIF3B" "EIF4EBP1" "RPS4Y1"
##
## [[1]]$`UP genesets.Eukaryotic Translation Termination`
## [1] "RPS4Y1"
##
## [[1]]$`UP genesets.Formation of a pool of free 40S subunits`
## [1] "EIF3B" "RPS4Y1"
##
## [[1]]$`UP genesets.Fructose metabolism`
## [1] "AKR1B1" "ALDH1A1" "KHK" "TKFC"
##
## [[1]]$`UP genesets.L13a-mediated translational silencing of Ceruloplasmin expression`
## [1] "EIF3B" "RPS4Y1"
##
## [[1]]$`UP genesets.Major pathway of rRNA processing in the nucleolus and cytosol`
## [1] "CSNK1E" "EXOSC10" "EXOSC2" "LAS1L" "NOL9" "NOP14" "RBM28"
## [8] "RPS4Y1" "RRP9" "TBL3"
##
## [[1]]$`UP genesets.Neurotransmitter clearance`
## [1] "ALDH2" "MAOA" "SLC22A1"
##
## [[1]]$`UP genesets.Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)`
## [1] "NCBP2" "RPS4Y1"
##
## [[1]]$`UP genesets.Peptide chain elongation`
## [1] "RPS4Y1"
##
## [[1]]$`UP genesets.RUNX3 regulates CDKN1A transcription`
## [1] "SMAD3"
##
## [[1]]$`UP genesets.Regulation of TP53 Activity through Association with Co-factors`
## [1] "AKT1" "ZNF385A"
##
## [[1]]$`UP genesets.SARS-CoV-1 modulates host translation machinery`
## [1] "RPS4Y1"
##
## [[1]]$`UP genesets.Selenocysteine synthesis`
## [1] "RPS4Y1"
##
## [[1]]$`UP genesets.Viral mRNA Translation`
## [1] "RPS4Y1"
##
## [[1]]$`UP genesets.rRNA processing in the nucleus and cytosol`
## [1] "CSNK1E" "EXOSC10" "EXOSC2" "LAS1L" "NOL9" "NOP14" "RBM28"
## [8] "RPS4Y1" "RRP9" "TBL3"
##
## [[1]]$`DOWN genesets.ARMS-mediated activation`
## [1] "BRAF" "CRK" "KIDINS220" "NTRK1" "RAP1A" "YWHAB"
##
## [[1]]$`DOWN genesets.Activation of NIMA Kinases NEK9, NEK6, NEK7`
## [1] "CCNB1" "CCNB2" "CDK1" "NEK6" "NEK7" "NEK9" "PLK1"
##
## [[1]]$`DOWN genesets.Activation of caspases through apoptosome-mediated cleavage`
## [1] "APAF1" "CASP3" "CASP7" "CASP9" "CYCS" "XIAP"
##
## [[1]]$`DOWN genesets.CREB1 phosphorylation through the activation of Adenylate Cyclase`
## [1] "CALM1" "CREB1" "PRKACA" "PRKACB" "PRKAR1A" "PRKAR1B" "PRKAR2A"
## [8] "PRKAR2B" "PRKX"
##
## [[1]]$`DOWN genesets.Condensation of Prometaphase Chromosomes`
## [1] "CCNB1" "CCNB2" "CDK1" "CSNK2A1" "CSNK2A2" "CSNK2B" "NCAPD2"
## [8] "NCAPG" "NCAPH" "SMC2" "SMC4"
##
## [[1]]$`DOWN genesets.Establishment of Sister Chromatid Cohesion`
## [1] "CDCA5" "ESCO1" "ESCO2" "PDS5A" "PDS5B" "RAD21" "SMC1A" "SMC3" "STAG1"
## [10] "STAG2" "WAPL"
##
## [[1]]$`DOWN genesets.G2/M DNA replication checkpoint`
## [1] "CCNB1" "CCNB2" "CDK1" "PKMYT1" "WEE1"
##
## [[1]]$`DOWN genesets.Interleukin-21 signaling`
## [1] "IL21R" "IL2RG" "JAK1" "JAK3" "STAT1" "STAT3" "STAT4" "STAT5A"
## [9] "STAT5B"
##
## [[1]]$`DOWN genesets.Interleukin-6 signaling`
## [1] "CBL" "IL6R" "IL6ST" "JAK1" "JAK2" "PTPN11" "SOCS3" "STAT1"
## [9] "STAT3" "TYK2"
##
## [[1]]$`DOWN genesets.Maturation of protein 3a_9683673`
## [1] "GALNT1" "ST3GAL1" "ST3GAL2" "ST3GAL3" "ST3GAL4"
## [6] "ST6GAL1" "ST6GALNAC2" "ST6GALNAC3" "ST6GALNAC4"
##
## [[1]]$`DOWN genesets.Maturation of protein 3a_9694719`
## [1] "GALNT1" "ST3GAL1" "ST3GAL2" "ST3GAL3" "ST3GAL4"
## [6] "ST6GAL1" "ST6GALNAC2" "ST6GALNAC3" "ST6GALNAC4"
##
## [[1]]$`DOWN genesets.Mitotic Telophase/Cytokinesis`
## [1] "KIF20A" "KIF23" "MAU2" "NIPBL" "PDS5A" "PDS5B" "PLK1" "RAD21"
## [9] "SMC1A" "SMC3" "STAG1" "STAG2" "WAPL"
##
## [[1]]$`DOWN genesets.Protein repair`
## [1] "MSRA" "MSRB1" "MSRB2" "MSRB3" "PCMT1" "TXN"
##
## [[1]]$`DOWN genesets.ROBO receptors bind AKAP5`
## [1] "AKAP5" "PPP3CB" "PRKACA" "PRKACB" "PRKAR2A" "PRKCA" "ROBO3"
##
## [[1]]$`DOWN genesets.Regulation of IFNA/IFNB signaling`
## [1] "IFNAR1" "IFNAR2" "JAK1" "PTPN1" "PTPN11" "PTPN6" "SOCS1" "SOCS3"
## [9] "STAT1" "STAT2" "TYK2" "USP18"
##
## [[1]]$`DOWN genesets.Response to metal ions`
## [1] "CSRP1" "MT1E" "MT1F" "MT1X" "MT2A" "MTF1"
##
## [[1]]$`DOWN genesets.SMAC (DIABLO) binds to IAPs`
## [1] "APAF1" "CASP3" "CASP7" "CASP9" "CYCS" "DIABLO" "XIAP"
##
## [[1]]$`DOWN genesets.SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes`
## [1] "APAF1" "CASP3" "CASP7" "CASP9" "CYCS" "DIABLO" "XIAP"
##
## [[1]]$`DOWN genesets.SMAC, XIAP-regulated apoptotic response`
## [1] "APAF1" "CASP3" "CASP7" "CASP9" "CYCS" "DIABLO" "XIAP"
##
## [[1]]$`DOWN genesets.Type I hemidesmosome assembly`
## [1] "CD151" "COL17A1" "DST" "ITGA6" "ITGB4" "KRT5" "LAMB3"
## [8] "PLEC"Session information
Here is the session info with all the versions of packages used.
sessionInfo()## R version 4.5.2 (2025-10-31)
## Platform: x86_64-pc-linux-gnu
## Running under: Ubuntu 24.04.4 LTS
##
## Matrix products: default
## BLAS: /usr/lib/x86_64-linux-gnu/openblas-pthread/libblas.so.3
## LAPACK: /usr/lib/x86_64-linux-gnu/openblas-pthread/libopenblasp-r0.3.26.so; LAPACK version 3.12.0
##
## locale:
## [1] LC_CTYPE=en_US.UTF-8 LC_NUMERIC=C
## [3] LC_TIME=en_US.UTF-8 LC_COLLATE=en_US.UTF-8
## [5] LC_MONETARY=en_US.UTF-8 LC_MESSAGES=en_US.UTF-8
## [7] LC_PAPER=en_US.UTF-8 LC_NAME=en_US.UTF-8
## [9] LC_ADDRESS=en_US.UTF-8 LC_TELEPHONE=en_US.UTF-8
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=en_US.UTF-8
##
## time zone: Etc/UTC
## tzcode source: system (glibc)
##
## attached base packages:
## [1] stats4 stats graphics grDevices utils datasets methods
## [8] base
##
## other attached packages:
## [1] RhpcBLASctl_0.23-42 gtools_3.9.5
## [3] xlsx_0.6.5 DT_0.34.0
## [5] ggplot2_4.0.3 kableExtra_1.4.0
## [7] beeswarm_0.4.0 eulerr_7.1.0
## [9] MASS_7.3-65 mitch_1.22.1
## [11] DESeq2_1.50.2 SummarizedExperiment_1.40.0
## [13] Biobase_2.70.0 MatrixGenerics_1.22.0
## [15] matrixStats_1.5.0 GenomicRanges_1.62.1
## [17] Seqinfo_1.0.0 IRanges_2.44.0
## [19] S4Vectors_0.48.1 BiocGenerics_0.56.0
## [21] generics_0.1.4 dplyr_1.2.1
## [23] WGCNA_1.74 fastcluster_1.3.0
## [25] dynamicTreeCut_1.63-1 reshape2_1.4.5
## [27] gplots_3.3.0
##
## loaded via a namespace (and not attached):
## [1] RColorBrewer_1.1-3 rstudioapi_0.17.1 jsonlite_2.0.0
## [4] magrittr_2.0.4 farver_2.1.2 rmarkdown_2.30
## [7] vctrs_0.7.3 base64enc_0.1-3 htmltools_0.5.8.1
## [10] S4Arrays_1.10.1 progress_1.2.3 SparseArray_1.10.10
## [13] Formula_1.2-5 sass_0.4.10 KernSmooth_2.23-26
## [16] bslib_0.9.0 htmlwidgets_1.6.4 plyr_1.8.9
## [19] echarts4r_0.5.0 impute_1.84.0 cachem_1.1.0
## [22] mime_0.13 lifecycle_1.0.5 iterators_1.0.14
## [25] pkgconfig_2.0.3 Matrix_1.7-4 R6_2.6.1
## [28] fastmap_1.2.0 shiny_1.11.1 digest_0.6.39
## [31] colorspace_2.1-2 GGally_2.4.0 textshaping_1.0.4
## [34] crosstalk_1.2.2 Hmisc_5.2-5 labeling_0.4.3
## [37] polyclip_1.10-7 abind_1.4-8 compiler_4.5.2
## [40] withr_3.0.2 doParallel_1.0.17 htmlTable_2.5.0
## [43] S7_0.2.2 backports_1.5.1 BiocParallel_1.44.0
## [46] ggstats_0.13.0 DelayedArray_0.36.1 caTools_1.18.3
## [49] tools_4.5.2 foreign_0.8-90 otel_0.2.0
## [52] httpuv_1.6.16 nnet_7.3-20 glue_1.8.0
## [55] promises_1.5.0 grid_4.5.2 polylabelr_1.0.0
## [58] checkmate_2.3.4 cluster_2.1.8.1 gtable_0.3.6
## [61] preprocessCore_1.72.0 tidyr_1.3.2 hms_1.1.4
## [64] data.table_1.18.2.1 xml2_1.5.1 XVector_0.50.0
## [67] foreach_1.5.2 pillar_1.11.1 stringr_1.6.0
## [70] later_1.4.4 rJava_1.0-18 splines_4.5.2
## [73] lattice_0.22-7 survival_3.8-3 tidyselect_1.2.1
## [76] locfit_1.5-9.12 knitr_1.50 gridExtra_2.3
## [79] svglite_2.2.2 xfun_0.54 stringi_1.8.7
## [82] statnet.common_4.13.0 yaml_2.3.11 evaluate_1.0.5
## [85] codetools_0.2-20 xlsxjars_0.9.0 tibble_3.3.0
## [88] cli_3.6.5 rpart_4.1.24 xtable_1.8-4
## [91] systemfonts_1.3.1 jquerylib_0.1.4 network_1.20.0
## [94] Rcpp_1.1.1-1.1 coda_0.19-4.1 parallel_4.5.2
## [97] prettyunits_1.2.0 bitops_1.0-9 viridisLite_0.4.3
## [100] scales_1.4.0 purrr_1.2.0 crayon_1.5.3
## [103] rlang_1.2.0END of report